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Abstract 
Itch (pruritus) is an unpleasant sensation of the skin, which evokes the desire to 
scratch. The condition commonly presents in clinical practice, as a symptom of 
systemic disease and various skin disorders, such as atopic dermatitis. Itch has 
tended to be closely associated with pain, and older evidence suggests that the 
sensations involve the same sensory nerves, firing at different frequencies. Partly 
because of this, and the subjective cognitive nature of the condition, itch has been 
relatively ignored as a research area and there is a general lack of effective animal 
models for studying itch. This has restricted detailed studies into putative mediators 
of itch and their mechanism(s) of action. 
The present studies were undertaken to develop and validate acute and chronic 
models of itch in mice, based on the combined use of behavioural tests in awake 
mice and in vivo electrophysiological recordings from itch afferents in anaesthetized 
animals. The hypothesis was that scratching behaviour can be evoked in mice using 
intradem1al injections of pruritogenic drugs and that this can be measured 
automatically and objectively to provide a reliable indicator of itch. A further 
hypothesis was that electrophysiological recordings made in vivo from murine 
cutaneous sensory nerves can be used to distinguish between pruritogens and 
algogens. 
The model of itch that was developed is based on injection of histamine into the back 
of the mouse neck to evoke scratching of the area by the hind paws. Histamine is a 
pruritogen in both humans and mice, although the lack of effectiveness of traditional 
H 1-receptor antihistamines in treating all clinical itch disorders suggests other 
mediators are also responsible for pruritus. The studies demonstrated that scratching 
in mice can be induced using histamine and other pruritogens (e.g. trypsin and 5-HT) 
in a reproducible dose dependent manner. Scratching was established as a response 
to itch-provoking agents, but not to painful stimuli. A novel mechanism of histamine 
evoked scratching involving H4 receptors was discovered. Chronic itching 111 
response to topical application of dinitrochlorobenzene was also established. A 
robust automated method for the detection and measurement of scratching in mice 
111 
was developed, which considerably enhances accuracy and reduces the time taken, in 
comparison with manual observation of scratching. 
In vivo electrophysiological recordings showed that pruritogens evoke a pattern of 
response in cutaneous nerves distinct in nature from that evoked by algogenic 
stimuli. However, nerves responded to both stimuli, suggesting that in mice, there are 
probably no independent 'pruritoceptors', unlike the situation in man. 
In summary, scratching in mice can be recorded automatically and used as a 
reproducible quantitative measure of itch. This model can be used for further studies 
on putative mediators of itch to establish their mechanism of action. Knowledge from 
such studies should provide understanding of the sensation of itch in man, and should 
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Chapter I: General Introduction 
Itch, clinically known as pruritus, is one of the most common symptoms presented 
clinically to dermatologists. In recent times, itch has become commonly defined as 
an unpleasant sensation of the skin that provokes the desire to scratch. Itch is a 
subjective sensation, and in the main is measured quantitatively by the amount of 
scratching that is elicited. 
The scratching reflex operates when the skin is presented with an itch inducing 
stimulus and is likely to occur for one of two main reasons; firstly, the scratching of 
the area is likely to remove any irritant present on the surface of the skin causing the 
itch (and potentially skin damage/infection/pain); secondly, it is suggested that the 
mechanical activation of sensory nerves in the skin (e.g. touch or pain nerves) can 
'shut-off the itch sensation, through a neural gating system. 
In the past, most studies into itch have been based on humans; clearly the fact that 
they can confirm the sensation being perceived provides more convincing evidence 
that itch is being studied. The same can't be said of studies using animal models; it 
can only be assumed that the scratching response is due to a sensation the animal 
feels as similar to that humans describe as 'itchy'. 
Despite possible inadequacies compared to a human model, it is scientifically 
beneficial to have a reliable animal model. An animal model provides us with the 
background to investigate a wider range of potential pruritic (itch inducing) and anti-
pruritic (itch relieving) drugs, in a much more intensive and also ethical manner. The 
general aim of the studies in this thesis is to attempt to create and validate a reliable 
and reproducible animal model of itch, using scratching as the main indicator of the 
sensation. 
1. 1 Neural Mechanisms of Itch Perception 
During the last hundred years or so there have been great developments in our 
understanding of itching and scratching. Clearly the sensation of itch was present 
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long before this time, and although commented on by people as long ago as Socrates, 
there was no physiological understanding of the condition. Itch is a sensation; 
therefore it is the brain's interpretation of the environment. This clearly relies upon 
there being higher centres involved with the sensation of itch. The focus of the 
studies in this thesis is on the peripheral sensation of itch and not central pathways, 
however, in this section I will discuss briefly what is known of both peripheral and 
central neural pathways in order to provide a more comprehensive picture of how the 
sensation is elicited and interpreted. 
The sensation of itch can be evoked either through a peripheral mechanism, known 
as 'pruritoceptive' itch, or through a central mechanism, known as 'neurogenic' itch. 
The early studies investigated pruritoceptive itch but in recent years there has also 
been an increase what is known of which areas of the brain contribute to the 
sensation. 
'Itch Receptors' 
In the 1950's the first systematic study to investigate the presence of 'itch receptors', 
or pruritoceptors, in skin, was reported. The work of Shelley and Arthur was based 
on the introduction of cowhage (Mucuna pruriens, the active ingredient of itching 
powder) spicules into the skin; they found that when these spicules were placed at 
the dermal-epidermal boundary that the sensation of itch was elicited (Shelley & 
Arthur, 1957). This work was the first to show where the sensation of itch is 
detected; the areas around the site of itch perception were termed 'itch spots'. 
'Itchy skin' 
'Itchy skin' was a phrase first used by Bickford in the 1930's and refers to a 
characteristic of itch that is very similar to that of hyperalgaesia and it's relation to 
pain (Bickford, 1938). The phrase itchy skin has now been replaced by the more 
technical term alloknesis and describes a situation in which the sensitivity of skin 
adjacent to that which has recently been exposed to an itchy stimulus, becomes more 
sensitive. That is to say when itch is induced in one area of skin, the skin around that 
3 
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area is more susceptible to the sensation of itch when rubbed. This phenomenon was 
shown to last in the surrounding skin up to 15 minutes after the initial itch stimulus, 
approximately twice as long as the duration directly caused by the itch stimulus 
itself. Bickford described the presence of itchy skin as being a result of a 'local 
nervous pathway'. This local nervous pathway can be used to explain the findings of 
Lewis in the 1920's. Lewis found that administration, into the skin, of what we now 
know to be histamine induces itching. He also identified the triple response to 
histamine (Lewis, 1927); itch, wheal and flare. This triple response elicits swelling 
and redderung of the area as well as the sensation of itch. Effectively the reaction is 
an immune associated response; the release of neuropeptides from nerves around the 
area, and the activation of local immune cells such as T-cells and mast cells, many of 
which have the potential to activate other nearby nerves. 
The 'anti-pruritic state' 
A notable characteristic of itch was described by Bickford and further investigated 
by Graham in the 1950's. The anti-pruritic state was used to define a situation where 
induction of pain in an area of skin, prevented the induction of itch in that area 
(Bickford, 1938; Graham et al., 1951). At that time the consensus of opinion was that 
itch and pain must therefore be different intensities of the same sensation; a small 
noxious stimulus would elicit itch and if increased, pain would be sensed. Rothman 
presented work suggesting tickle was the least intense sensation and that this 
progressed into itc~ and then pain (Rothman, 1941 ). 
Nociceptive nerve fibres and itch nerve fibres 
With time, the opinion that the afferent nerve pathways for pain and itch were the 
same became less popular. Support that the neural pathways for pain and itch are 
distinct came with the development of the gate-control theory (Melzack & Wall, 
1965). This theory describes how the sensations of pain and itch can use separate 
pathways, yet sti ll interact centrally. It was proposed that activation of fast 
conducting, large diameter axon, myelinated A-P nerve fibres, which are usually 
activated by touch and pressure, acts at the level of the spinal cord to reduce activity 
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in the slower conducting, thin diameter axon, myelinated A-8 and unmyelinated C-
fibres, believed to be associated with noxious stimulation and also possibly itch. The 
debate as to whether pain and itch sensations were transmitted using separate or the 
same nerve fibres continued, and even into the 1990's some authors concluded the 
two sensations used the same pathway (Greaves, 1997). 
McMahon and Koltzenburg provided a summary of the four different possibilities of 
the neural transduction of the pain and itch sensations (McMahon & Koltzenburg, 
1992). The four possibilities that were presented were the specificity theory, intensity 
theory, pattern theory and the selectivity theory and are discussed briefly below. 
The specificity theory is the least complicated and suggests that itch and pain are 
relayed via completely independent nerves. Pruritogenic stimuli activate 'itch nerves' 
and painful stimuli activate 'pain nerves'. Tins theory was commonly discounted 
because of the lack of evidence for the existence of nerve fibres that respond only to 
pruritogenic stimuli. It had been shown in nerve recordings from C-fibres in humans 
that both itch and pain-inducing drugs activated the same nerve fibres (Handwerker 
et a!. , 1991). It had also been shown that micro-stimulation of C-fibres was not 
conclusively able to elicit an itch rather than a pain sensation in human subjects, 
although it was possible in a limited number of cases (Torebjork & Ochoa, 1980). 
The intensity theory is that which was most commonly held during the middle of the 
20th century and is based on work presented by Rothman, as discussed above. In 
practice, however, this theory would appear flawed. The administration of opiates as 
an epidural reduces pain, however, itching is a common side affect (Ballantyne et al., 
1988; Harrison et al., 1988). This is very difficult to explain if the two sensations are 
carried through the same nerve fibres. Also micro-stimulation of C-fibres at different 
frequencies does not elicit separate sensations of itch and pain (Ochoa & Torebjork, 
1983). 
The pattern theory proposes that by activating the same nerve in a separate way, the 
brain can identify between two stimuli, or, that evoked by activating a subset of 
5 
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nerves in an area in a different way, the brain can differentiate between stimuli. This 
theory seems ideal for explaining the similarities between itch and pain, but has no 
conclusive evidence to support it. The first possibility can be discounted as it has 
been shown in C-fibre nerve recordings in humans that changing the pattern of 
activation does not change the sensation perceived by the subject (Torebjork & 
Ochoa, 1980). The second option is that by activating a different sub-population of 
nerves in an area, you can elicit a separate sensation. Therefore, by stimulating fewer 
nerves in an area of skin you may elicit itch, and by activating a few more this may 
transfer into pain (Handwerker, 1992). This would be almost impossible to achieve 
experimentally without knowing the 'code' and as yet no evidence has been found to 
suggest it occurs. 
The .final theory is the selectivity theory that suggests that there are no specific itch 
nerves, but a subset of pain nerves which also responds to an itch stimulus 
(Handwerker et al., 1991). When activated these nerves could be responding to an 
itch or pain stimulus, what is perceived is dependent on central 'itch processing'. If 
no other 'pain nerves' are being activated, the sensation is perceived as itch, if other 
pain nerves are activated the sensation perceived is pain, therefore, pain and itch 
cannot co-exist. The theory also goes on to describe that the spinal processing is 
opioid mediated, thus explaining why epidural, as described above, can relieve pain 
but enhance itch, it suggests disruption of the feedback system allows the itch 
sensing fibres to fire without being inhibited by the firing of other pain fibres. 
Despite the selectivity theory seeming plausible, the more recent evidence in this 
field has given weight to the specificity theory. It has been shown that there are itch-
specific C-fibres in human skin, which respond selectively to histamine (Schmelz et 
al., 1997) that were previously believed not to exist. It has also been shown that in 
cats there is a population of spinothalamic tract neurons (secondary neurons) that 
respond selectively to histamine (Andrew & Craig, 2001). There is now increasing 
evidence to support a specificity theory of itch, over the others discussed earlier. 
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Central Pathways of Itch 
Various authors have presented evidence to suggest that the itch sensation is carried 
via C-fibres (Fjellner, 1981; Graham et al., 1951; Handwerker et al., 1991; Ochoa & 
Torebjork, 1983; Schmelz et al., 1997; Shelley & Arthur, 1957; Torebjork & Ochoa, 
1980), the slowest conducting (<2ms.1) unmyelinated nerve fibres. These nerve 
fibres pass to the central nervous system via the dorsal root to the dorsal hom of the 
spinal cord. Here the primary afferent nerves synapse to secondary nerve fibres that 
pass to the brain in the contralateral spinothalamic tract (Greaves, 1997). It has 
recently been shown that these second order nerves in the spinal cord are selectively 
responsive to histamine and are proposed to be central 'itch nerves' (Andrew & 
Craig, 2001). Support for this being the neural pathway for itch is provided by the 
evidence that the itch sensation is abolished by spinothalamic tract cordotomy 
(Nathan, 1990). These second order nerves pass to the thalamus (Kam & Tan, 1996). 
Little evidence exists to describe the pathway for the itch sensation in the brain; 
however, recent evidence using positron emission topography (PET) provides a clue 
as to which brain areas become activated due to an itch stimulus. These studies have 
shown stimulation of various areas of the cortex during the sensation of itch. The 
areas of the brain identified as being stimulated include; the cingulate cortex, related 
to the identification of a noxious stimulus; the premotor and supplementary motor 
areas, related to the planning of motor activities and the inferior parietal lobule, 
related to the initiation of movement (Hsieh et al., 1994; Savin, 1998). Together this 
evidence suggests that there is not one single itch centre and also that the central 
activation due to an itch stimulus appears to be related to initiation of a scratch 
response. 
1. 2 Clinical Pruritic Conditions 
Pruritus commonly presents as a symptom not only of conditions of the skin, but can 
also be a secondary symptom of a variety of systemic disorders. It is important to 
remember that it is always preferential to treat the underlying condition causing the 
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itch and not to focus solely on the sensation of itch itself. Having said this, over 
recent years the pharmaceutical industry has invested in developing itch-relieving 
products, primarily designed to be over-the-counter 'lifestyle' drugs. 
In this section I will discuss briefly some of the various disorders for which pruritus 
is commonly the presenting symptom. In many cases the pathophysiology of the itch 
in these conditions is poorly understood and so it may be crude to define many of 
these disorders so generally. However, I have grouped the itch as being due to one of 
three underlying reasons; firstly, due to an underlying systemic disease, secondly, 
caused by a disorder of the skin, and finally, itch presenting with apparently no 
underlying clinical disorder. 
Itch Associated with Systemic Disease 
Chronic Renal Failure 
Chronic renal failure (uraemia) at onset does not generally produce itch, however, it 
seems to be the treatment that provokes the sensation. Itch can occur prior to, during 
or after dialysis. This makes determining the cause difficult. Earlier evidence showed 
up to 85% of patients suffered from itch (Stahle-Backdahl, 1992; Young et al., 
1973), whereas recent evidence would suggest that this level may now be as low as 
25%, this is most likely to be due to improvements and developments in the dialysis 
treatment provided to these patients (Pauli-Magnus et al., 2000). 
Although the dialysis process clearly plays a part in both relieving and causing itch 
in uraemic patients, due to accumulating or removing pruritogens, there are clearly 
other factors involved. There has been a wide range of suggestions as to the cause of 
the itch but as yet none have been convincingly shown to be responsible for the itch 
felt by uraemic patients. It is suggested that associated secondary hyperparathroidism 
can induce itch (Massry et al., 1968), and is treatable by parathyroidectomy 
(Hampers et al., 1968). There is also evidence that the number of mast cells present 
in the skin of uraemic patients is higher than healthy subjects (Leong et al., 1994). 
The plasma level of histamine in patients with uraemic itch is elevated, but the level 
ofhistamine would appear not to correlate with itch severity (Mettang et al., 1990). 
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The skin of uraemic patients is drier than that of non-uraemic patients (Young et al., 
1973) and this may also cause itch, however, changes of the skin such as those 
discussed could well be a result of the itch and not the cause itself. More recently a 
role for opioid receptors has been proposed due to the observation of a change in the 
relative expression of~- and K- receptors on lymphocytes (Togashi et al., 2002). The 
opioid receptor antagonist naltrexone has provided mixed evidence of itch relief 
(Pauli-Magnus et al., 2000; Peer et al., 1996) and it may be that these opioid effects 
are more significant in a central pathway and not peripherally. 
Hepatic Cholestasis 
Disorders of the liver are often associated with a severe and debilitating itch, most 
commonly seen in obstructive jaundice. The subsequent elevation in bile salt levels 
was seen as the explanation for the itch, although this may in part be true, it does not 
appear to be the sole reason. Elevated plasma bile salt levels are reported to cause 
itching (Ghent et al., 1977; Kirby et al., 1974), however, there appears to be no direct 
correlation between the level of plasma bile level and the degree of itch reported by 
the patient (Jones & Bergasa, 1990). 
Recent evidence implicates a role for endogenous opioids being involved in the itch 
caused by cholestasis. Changes in the opioidergic tone is said to affect the itch 
centres of the brain during liver disease (Bergasa & Jones, 1995; Jones & Bergasa, 
1999). This suggestion is supported by the evidence that opioid antagonists, such as 
naloxone, are effective at relieving cholestatic pruritus (Bergasa, 1995). 
Haematologica/ 
Conditions of the blood are often associated with itch. 50% of patients with 
polycythaemia vera present with itch and in patients with Hodgkin's lymphoma the 
figure is as high as 30%, other conditions include leukaemia and T-cell lymphoma 
(Botero, 1978; Rajka, 1966; Winkelman, 1964). The causes of the itch are unknown, 
although polycythaemia vera is often associated with elevated histamine levels 
(Archer et al., 1988), but treatment can only be focussed on the underlying condition. 
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Iron deficiency can present clinically as pruritus in patients with normal skin 
(Lewiecki & Rahman, 1976), however, studies have revealed it would appear not to 
be directly related to the iron levels in the blood, but another, as yet unknown factor 
(Tucker et al., 1987). 
Endocrine 
The most common endocrine disorder to be linked with itch is diabetes mellitus, 
however, this is simply not true (Greaves, 1993). It was reported in a single article in 
1927 and has been presented incorrectly since that time (Greenwood, 1927), in fact 
only 3% of diabetes patients complained of itch and the degree did not correlate with 
the severity of diabetes. 
Other endocrine disorders do, however, present as pruritus. Hyperthyroidism has 
been shown to cause itch (Carvati et al., 1969; Rothfield, 1968) and this may, at least 
in part, be due to vasodilatation and increased blood flow to the skin (Fruhstorfer et 
al., 1986). Postmenopausal women also commonly present with itch associated with 
hot flushes, thought to be reliant upon plasma levels of gonadotrophins (Greaves, 
1993). 
Malignant Tumours 
The presence of a malignant tumour can present as a generalized itch and this can be 
months or even years prior to the discovery of the tumour itself (Connia, 1965) 
(Andreev, 1978; Lober, 1993). Generalized itch normally occurs due to the presence 
of a visceral tumour, however, a localised itch can also occur, most commonly due to 
the presence of a tumour in the brain (Andreev & Petkov, 1975). 
HIV/AIDS 
Itch occurs in patients with HIV and AIDS, both with and without associated skin 
abnormalities (Shapiro et al., 1987). In many cases the itch is due to a wide range of 
secondary conditions including skin infections or other systemic disease. However, 
some patients complain of itch without any obvious skin or systemic disorder 
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(Hoover & Lang, 1991). Recently it has been shown that HN/AIDS patients have an 
increased incidence of a condition known as eosinophilic folliculitis, this is a pruritic 
condition in which papules or plaques form on the skin and appears to be linked with 
increased IgE serum levels (Rodwell & Berger, 2000). 
Neuropathic 
It is reported that abnormalities of the nervous system can lead to itch. One condition 
in which this is common is multiple sclerosis (Yamamoto et a/., 1981 ). It is 
suggested that in instances such as this the cause of the itch is due to abnormal 
synaptic transmission rather than damage to the nerve axon through demyelination 
(Sandyk, 1994). 
Itch Associated with Disorders of the Skin 
Atopic Eczema 
Eczema is a condition associated with drying and lichenification of the skin and is 
intensely itchy in all patients. Changes in the skin of eczema patients provides an 
indication as to the cause of the itch although treatment for the condition focuses on 
treating the dryness of the skin using emollients and reducing inflammation with 
corticosteroidal cream. Changes in the skin have been shown to include an increase 
in the number of mast cells (Mihm et al. , 1976). It is also believed there may a 
prominent role for a central as well as peripheral mechanism in the itch of eczema 
patients. This suggestion is based on the finding that low sedation antihistamines are 
less effective than the older sedatory antihistamines (Krause & Shuster, 1983). The 
effectiveness of opioid antagonists in relieving the itch in some patients also supports 
the suggestion that a central role may be important in the itch of atopic eczema 
(Monroe, 1989). 
Psoriasis 
Up to 80% of patients with psoriasis suffer from itch (Krueger et a!., 2001 ), however, 
the itch is not necessarily localised to the affected areas of skin. Inflammation of the 
skin occurs and this is most likely to be the cause of the itch, but there is also an 
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increase in sensory nerve innervation to the skin that could explain the pruritus 
(Naukkarinen eta/., 1989). 
Urticaria 
Urticaria is the itch associated with a release of histamine and other endogenous 
compounds from mast cells as an immune response, such as insect sting or bite. 
Urticaria is one of the most easily treated forms of pruritus and can be alleviated 
using a traditional antihistamine. The itch associated with urticaria is localised to the 
affected area of skin. 
Superficial Parasitosis 
When skin is physically damaged due to a parasitic infection it can often present as a 
feeling of itch. The classic example is that of scabies, the associated inflammatory 
response is the most likely cause of the itch although which mediator is responsible 
is unknown. 
Miscellaneous Itch Conditions 
Aquagenic Pruritus 
Aquagenic pruritus is a disorder characterised by intense itch with no apparent 
changes in skin condition. The itch appears on any area of skin wetted by water, of 
any temperature, and lasts for up to one hour (Greaves et al. , 1981). It has been 
reported that anywhere up to 3.3% of the population may suffer from such a 
condition (Potasman et al., 1990), however there are no 'reported systemic effects. 
Senile Pruritus 
It is reported that up to 50% of people aged 70 or above suffer from this condition 
(Twycross et al., 2003). Often there may be underlying causes of the itch, such as 
dryness of the skin, lack of moisture of the skin, or an underlying disorder, however, 
true senile pruritus presents with no apparent skin abnom1alities. 
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1.3 Mediators of Itch 
Evidence as to which endogenous compounds evoke the sensation of itch have been 
derived from both experimentally-induced itch in healthy subjects as well as studies 
into patients with clinical disorders of which itch is a symptom. In the following 
section I will focus on what is known of the various mediators of itch in humans. In 
many cases the evidence to date may appear incomplete and hypothetical and the 
exact mechanism of how the compound evokes itch is not clear. In some cases the 
examples used are not endogenous to human skin, however, the tools used provide an 
indication as to a possible in vivo action of related compounds. 
Histamine 
Some of the earliest research into itch found the compound now known as histamine 
to be present in increased quantities in the skin of' itchy patients'. The substance was 
at that time referred to as 'H-substances' . It was shown to induce itch when injected 
superficially, but to cause a burning pain when administered less superficially 
(Lewis, 1927). Since these early times histamine has been widely regarded as the 
stereotypic itch inducer in humans and normally forms the benchmark against which 
experiments are performed, in both human and animal models. Work in the 1960's 
by Keele and Armstrong was the first comprehensive research of experimentally 
induced itch using histamine in humans. This work provided the first details of dose 
required to evoke itch, volume in which the histamine should be administered to 
maximise the itch response and how the histamine should be administered 
(intradermal injection was found to be the most effective) (Keele & Armstrong, 
1964). 
Endogenous histamine is stored in mast cells located in the dermis, activation of the 
mast cells (for example as part of an inflammatory response) causes degranulation 
and histamine release. Histamine acts upon one of four receptors; H1, H2, H3 and R<t 
(Leurs et al., 2001). The role histamine H1 and H2 receptors in itch have been well 
characterised (see below), however, until now there has been no evidence in the 
literature to support a role for involvement of either the H3 or H4 receptor in itch. 
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Chapter 5 of this thesis investigates the role of the different histamine receptors in 
itch in more detail. Histamine induced itch has been shown to operate through the 
histamine H1, but not the histamine Hz receptor (Davies & Greaves, 1980; 
Hagermark et al., 1979). However, although traditional antihistamines (H1 receptor 
antagonists) can reduce experimentally induced itch they are not effective in all itch 
conditions, most typically, the itch associated with atopic eczema (Berth-Jones & 
Graham-Brown, 1989; Wahlgren et al., 1990). Despite the lack of strong evidence to 
support a direct role of the histamine Hz receptor in itch, Hz receptor antagonists are 
used clinically in some conditions. A combined H 1 and Hz receptor antagonist 
therapy is used in the treatment of urticaria (Monroe et al., 1981 ). The effectiveness 
of the combined drugs may be due to the possible role the Hz receptor plays in the 
vasodilation of the blood vessels in the skin, more than its direct effect on relieving 
itch (Marks & Greaves, 1977). 
Although recognised as a pruritogen, histamine does not appear to play an integral 
role in many clinical itch conditions. It has been suggested that traditional 
antihistamines may have central sedatory actions in itch relief, more important than 
direct peripheral actions, at least in conditions such as eczema, where the major 
mediator is not believed to be histamine (Krause & Shuster, 1983; Savin et a/., 
1986). 
One final piece of evidence suggests that histamine is not a major mediator of itch in 
chronic skin conditions; repeated histamine administration results in a gradual loss of 
itch response, this is referred to as tachyphylaxis (Stahle-Backdahl et al., 1988). If 
histamine induces tachyphylaxis, it is fair to assume that histamine could not induce 
chronic itch conditions, as the sensory nerves would be desensitised and no longer 
relay the itch sensation. 
Despite the ambiguity of histamine as a major mediator of itch in clinical conditions, 
it has nevertheless been shown to play a role in mediating itch and is to this point the 
most widely investigated pruritogen and the most common target in therapeutic 
treatment. 
14 
Chapter I: General Introduction 
Mast Cell Degranulation 
As discussed previously, the effects of histamine in vivo occur through the release of 
histamine from mast cells. Various endogenous compounds induce this effect (see 
below) but one useful tool in this field is the compound 48/80. This drug when 
administered intradermally causes mast cell degranulation and elevated histamine 
levels, with an associated itch (Ruckwied et al, 2002; Fjellner & Hagermark, 1981). 
Compound 48/80 is of use in two ways; firstly it induces a mast cell-like itch, useful 
in evoking acute models of itch and secondly it can be used to degranulate mast cells 
prior to the administration of another pruritogen, providing an indication as to 
whether these other pruritogens evoke their effects through the activation of mast 
cells or through a separate mechanism. 
Neuropeptides 
Neuropeptides are a group of peptides synthesized and released by nerves. Among 
these compounds identified from peripheral nerves in the skin are substance P, 
vasoactive intestinal peptide (VIP), calcitonin gene-related peptide (CGRP), secretin, 
somatostatin, neurotensin, neurokinin A and neuropeptide Y. These peptides are 
released to act as neurotransmitters or modulators acting on nearby cells, such as 
mast cells (Hokfelt et a!., 1980). 
The most widely studied neuropeptide with regards to the induction of itch is 
substance P. Substance Pis synthesized in the dorsal root ganglion and transported to 
the periphery down the nerve axon, where it is co-localized with the other 
neuropeptides CGRP and VIP in the nerve terminals (Bloom et al., 1988). 
Administration of substance P intradermally induces itch in healthy subjects (Ward et 
al, 2004; Fjellner & Hagermark, 1981; Hagermark et al., 1978), it is suggested that 
this acts through the release of histamine from mast cells (Ebertz et al., 1987; Jorizzo 
et al., 1983) and is associated with the same triple response seen with a histamine 
response. 
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Many neuropeptides have yet to be studied as potential mediators of itch, however, 
secretin, neurotensin and VIP have been reported to be pruritogenics (Misery et al, 
2003). The actions of these compounds have been shown to act through mast cells 
and subsequent histamine release as their actions are reduced by prior administration 
of the H1 antagonist, mepyramine or the mast cell degranulator, compound 48/80 
(Fjellner, 1981). Another of the neuropeptides, CORP, has been shown to have no 
itch inducing properties (Brain & W-illiams, 1985). A later study confirmed this 
finding and also contradicted the earlier report that VIP was pruritogenic, by stating 
that neither compound could evoke itch in man (Greaves & Wall, 1996). Despite this 
evidence there is a reduction in the number of CORP immunoreactive sensory nerves 
following phototherapy in humans, which is recognised clinically to be effective in 
reducing itch (Wallengren & Sundler, 2004). Whether CORP is involved directly 
with the itch sensation will require further investigation. 
Proteases/kinins 
Proteases were first shown to play a role in mediating itch through work using 
spicules of the plant cowhage, Mucuna pruriens, inserted into the dermis of the skin 
(Shelley & Arthur, 1955). They reported that the active ingredient of the spicules was 
a protease enzyme, mucunain, based on evidence that spicules that had been boiled 
prior to being inserted into the dermis evoked no itch, due to denaturing of the 
enzyme. 
A search for endogenous proteases, and the substrates from proteolysis, was 
undertaken by Monash and Woessner. They presented evidence for itch evoking 
properties of ficin, papain, pancreatin and chymotrypsin (Monash & Woessner, 
1958). The mechanism by which these proteases induce itch would appear to be 
different. The itch evoked by trypsin and chymase is associated with a triple response 
similar to that induced by histamine and the itch is relieved by administration of 
antihistamines (Hagermark et al., 1972). However, the itch evoked by two other 
proteases, papain and kallikrein, was not reduced by antihistamines and there was no 
triple response (Hagerrnark, 1974). 
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Bradykinin is a peptide substrate formed by the breakdown of kininogen by 
kallikrein that has been studied as a possible mediator of itch (Stander et al, 2003). It 
has been shown that intradermal administration of bradykinin produces a sensation of 
pain and not itch (Greaves & Shuster, 1967), however, it has also been reported that 
bradykinin can potentiate the itch evoked by histamine (Schmelz et al, 2003; 
Hagermark, 1974). The mechanism of potentiation is still unknown, however, and 
has the potential to provide an interesting insight into the mechanisms of itch in 
clinical disease. 
The evidence suggests that proteases can evoke itch through both a histamine and a 
non-histamine pathway. Proteases also act directly on protease-activated receptors 
(PARs). There are four PARs discovered to date, PAR-1, PAR-2, PAR-3 and PAR-4 
(Macfarlane et al., 2001; Vergnolle et al., 2001b). They are implicated as playing a 
role in inflammation responses. One of these receptors, PAR-2, is also suggested to 
be involved in mediating the sensation of itch (Steinhoff et al, 2003). The receptor is 
found on C-fibre nerve terminals and is activated by tryptase released from mast cells 
(Steinhoff et al., 2000; Compton et al, 2000). As yet the exact functional role of 
PARs is unclear, however, further investigation may reveal they are involved in itch. 
Opioids 
The endogenous opioids are a family ofpeptides with morphine-like activity referred 
to as endorphins or enkephalins (Hughes et al., 1975). They are a specific group of 
neuropeptides located in both central and peripheral nerves, commonly recognised to 
play a role in the perception of pain (Beaumont & Hughes, 1979). Due to the wide 
distribution of the opioids throughout the nervous system it is proposed that they play 
a role in mediating itch both centrally and also peripherally. 
Peripherally administered morphine results in mast cell degranulation and itching, 
characteristic of histamine release, i.e. the triple response of itch, weal and flare 
(Feldberg & Paton, 1951). Morphine and beta-endorphin, injected intradermally, also 
potentiates the itch response induced by histamine injection (Fjellner & Hagerrnark, 
1982), however the potentiation effect is not elimjnated by prior mast cell 
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degranulation using compound 48/80 (Fjellner & Hagermark, 1982). The 
potentiation of histamine induced itch by morphine and beta-endorphin is also 
unaffected by the morphine antagonist, naloxone (Fjellner & Hagermark, 1984). It 
would therefore appear that opiates are capable of potentiating itch through a 
pathway that is non-opiate and non-histaminergic, as yet the mechanism of this 
potentiation is still unknown. 
There would also appear to be role for opiates in mediating itch through central 
mechanisms. Morphine has been shown to cause itch in up to half of the patients 
receiving an epidural injection (Ballantyne eta!., 1988; Harrison et al., 1988). The 
itchy areas of skin are not affected by the triple response associated with histamine 
and so the effect is probably not mast cell related, but may be the effect of 
potentiating the pruritogenic effect of another compound (Scott & Fischer, 1982). 
The itch inducing effects of spinally administered opiates are removed by the opiate 
antagonist naloxone (Vedrenne eta!., 1991), however, the evidence to date does not 
conclusively suggest there is a role for naloxone in relieving clinical itch conditions 
(Bernstein & Swift, 1979; Summerfield, 1981). There are reports to suggest another 
opioid antagonist, nalmefene, is effective at reducing the itch associated with liver 
disease (Thornton & Losowsky, 1988), and that of atopic eczema (Monroe, 1989). 
Interestingly, more recent reports have indicated that the itch induced by spinally 
administered opiates is reduced by the 5-HT3 receptor antagonist, ondansetron 
(Borgeat & Stirnemann, 1999; Kyriakides et a!., 1999). This evidence provides the 
first insight that the itch inducing properties of opiates may involve the 5-HT 
pathway. 
5-Hydroxytryptamine (5-HT, Serotonin) 
5-HT evokes itch when injected intradermally into human skin. It is considered a 
weak pruritogen and the degree of itch, even at high concentrations is not considered 
as strong as that induced by histamine (Fjellner & Hagermark, 1979). However, it 
has been shown to induce a more intense itch when co-injected with prostaglandin 
Ez, PGE2 (Fjellner & Hagermark, 1979). 5-HT is not stored in human mast cells, 
although it is in the mast cells of rodents, and the primary source of 5-HT in the skin 
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is from platelets (thrombocytes), from where it is released during platelet aggregation 
(Hagermark, 1992). Although 5-HT is not stored in mast cells it has been reported 
that 5-HT induced itch is mast cell dependent, operating through the histamjne 
pathway, with no itch occurring following prior mast cell degranulation with 
compound 48/80 (Weisshaar et al., 1999). In polycythaemia vera, it is believed that 
the itch is caused by the simultaneous release of 5-HT and prostaglandins, this has 
been confirmed by the finding that 5-HT antagonists are effective at relieving the itch 
ofthis condition (Tefferi & Fonseca, 2002; Fitzsimons et al., 1981). 
The 5-HT3 receptor antagonist, ondansetron, is effective at relieving the itch induced 
by spinally administered opiates (see above). The same drug is used in the treatment 
of itch in patients with cholestasis (Schworer & Ramadori, 1993) and itch during 
pregnancy (Schumann & Hudcova, 2004), however, as there are no reports of the 5-
HT3 receptor being expressed in the human skin it is proposed that these effects are 
centrally operating (Jones & Bergasa, 1999). This hypothesis fits with the evidence 
that suggests the opiates also operate at a central level. 
Platelet activating factor (PAF) 
P AF is a phospholipid, released by proinflammatory cells due to the activity of 
phospholipase A2. It has been shown to be pruritic in humans, with its activity being 
reduced by antihistamines or prior mast cell degranulation using compound 48/80 
(Kato et al, 2003; Thomson et al, 2002; Archer et al., 1988; Fjellner & Hagermark, 
1985). 
Eicosanoids 
Eicosanoid is the collective term for the derivatives of arachadonic acid. These 
substances are commonly associated with inflamed skin and include the 
prostaglandins and leukotrienes and are releas~d from a host of proinflammatory 
cells (Greaves et al., 1971; Voorhees, 1983). Prostaglandins E 1, ~ and H2 are 
reported as having little or no pruritic activity when injected intradermally into 
human skin, i.e. itch is not reported in all subjects and the itch sensation is described 
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as weak (Greaves & McDonald-Gibson, 1973; Hagermark & Strandberg, 1977). 
However, it has been reported that these prostaglandins act to lower the threshold 
itch response to a subsequent injection of histamine (Neisius et al, 2002; Hagennark 
& Strandberg, 1977). This lowering of threshold by prostaglandins is also seen in 
relation to pain responses (Ferreira, 1972). Prostaglandin E1 also lowers the threshold 
response to intradermal injection of the protease papain (Lovell et al., 1976). 
Prostaglandin D2 does not lower the threshold response to histamine (Maurice et al., 
1987). It would appear the role of the prostaglandins is modulatory and not as 
primary mediators. This suggestion is supported by the evidence that aspirin, which 
blocks the activity of the enzyme cyclooxygenase in the prostaglandin synthesis 
pathway, and other non-steroidal anti-inflammatory drugs (NSAIDs) have no effect 
in relieving clinical itch conditions (Daly & Shuster, 1986; Hagerrnark, 1973), 
indeed aspirin appears to make skin more sensitive to histamine induced itch 
(Hagermark, 1973). Recently this .finding has been disputed with evidence 
suggesting topically applied aspirin can act to reduce histamine induced itch 
(Yosipovitch et al., 1997). 
The other major member of the eicosanoid family, the leukotrienes, have yet to be 
investigated in the same depth as the prostaglandins in this field. Recent evidence 
points to an antipruritic effect of leukotrine B4 (Storms, 2003), however, the evidence 
to date suggests they play no role in directly mediating itch in human skin because 
intradermal injections of leukotrienes B4, C4 and D4 did not cause itch (Camp et al., 
1983). 
Cytokines 
Cytokines are a family of proteins produced by the action of antigens on a variety of 
immune response cells, most commonly lymphocytes, but also keratinocytes, 
fibroblasts and mast cells (Greaves & Wall, 1996; Hagermark, 1992). There are 
accumulations of cytokines in many clinical pruritic conditions, such as eczema, 
found in the epidermis and upper dermis (Katayama et al, 2001; Hagermark, 1992). 
Research into itch has so far focussed on two cytokines, interleukin-1 and 
interleukin-2. Interleukin-1 does not induce itch when injected intradermally (Dowd 
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et al., 1988). However, interleukin-1 does appear to play a role in the mediation of 
itch associated with carcinoma (Chi et al, 2001; Woodlock et al, 1999) and HIV 
(Breuer-McHam et al, 2000). Administration of interleukin-2 either intravenously 
(Gaspari et al., 1987) or intradermally induces itch (Darsow et al., 1997; Wahlgren et 
al., 1995). The itch inducing properties of interleukin-2 is present in the skin of 
healthy subjects and patients suffering atopic eczema (Wahlgren, 1995). A possible 
role for interleukin-2 in clinical itch conditions is supported by the evidence that 
cyclosporin A, which reduces interleukin-2 production from lymphocytes, reduces 
the itch associated with eczema (Hagermark & Wahlgren, 1992; Wahlgren, 1995). A 
role has also recently been identified for IL-18 as a pruritogenics compound in a 
spontaneous itch similar to that of atopic dermatitis (Konishi et al, 2003). Another 
cytokine implicated by recent research is interferon gamma, a compound released by 
T-cells, which are immune response cells localised in the skin, this compound may 
play a role in the spontaneous itch of transgenic mice (Ny & Egelrud, 2003). To date 
there have been no investigations into the itch inducing properties of other cytokines. 
Acetylcholine (ACh) 
Acetylcholine is commonly recognised as a neurotransmitter in peripheral nerves, 
however, is not only produced in nervous tissue but also synthesized and stored in 
keratinocytes located in the skin (Grando et al., 1993) and may have a role in the 
elictation of itch (Heyer et al, 2002). Levels of acetylcholine have been shown to be 
elevated in the skin of patients suffering from atopic dermatitis compared to healthy 
subjects (Reinheimer et al., 1998). Interestingly, intradermal injection of 
acetylcholine into the skin of patients with dermatitis induces a sensation of itch, 
whereas in healthy subjects the perceived sensation is pain (Heyer et al., 1997; Heyer 
& Hornstein, 1999). Conversely it has been found that patients with dermatitis are 
less sensitive that healthy subjects to intradermal injections of histamine (Rukwied et 
al., 2000). These findings raise the possibility that clinical itch conditions could be 
due to a change in sensitivity to acetylcholine. The mechanism of action of 
acetylcholine induced itch is not clear, however, it is apparently not through 
histamine release from mast cells as administration of histamine H1 receptor 
antihistamines are ineffective at reducing the itch (Rukwied & Heyer, 1998). 
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Alternative pruritogens 
It is important to remember that the list of possible mediators of itch mentioned in 
the previous sections is not comprehensive. The evidence presented in the literature 
to date has been discussed but it is clear that there are a great number of potential 
mediators and associated receptors still to be investigated. In particular, the 
eicosanoids and cytokines have yet to be investigated in detail, with many 
compounds in these groups not studied with regards to itch. The major problem 
investigators have is that any endogenous compound present in the skin is a potential 
candidate, whether it directly activates peripheral nerves or acts via an indirect 
mechanism, such as mast cells and subsequent histamine release. The field is further 
complicated by the interactions between compounds leading to sensitisation of 
peripheral nerves to other pruritogens or potentiation of response due to interaction 
between compounds, such as that seen by some of the prostaglandins. Only further 
research will further clarify these questions. 
1.4 Animal Studies 
In this section the evidence for different mediators of itch, and the mechanisms by 
which they are believed to act, from animal studies, will be reviewed. The focus is 
mainly on studies in mice, as these formed the basis of the studies undertaken for this 
thesis. However, relevant findings from other species are also included. 
There is a need to develop robust animal models of itch for a variety of reasons. 
Animal models are the most effective method of testing a range of compounds in a 
more intensive manner than is possible using small numbers of human volunteers or 
patients. Testing of novel compounds is also easier for ethical reasons prior to drugs 
receiving safety clearance for human investigation. There are also more mundane yet 
no less crucial benefits of animal models, such as economic cost. 
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The studies in this thesis are focussed on the development of a mouse model of itch. 
The main benefit of studies in mice as opposed to studies in other animals is the 
development in genetic manipulation. The recent growth in the fie ld of transgenics 
has opened up new possibilities for discovering how endogenous compounds or 
receptors function in vivo. The ability to over or under-express specific targets gives 
us a new insight into the exact function of the target in question. In a field where we 
are examining a complex interaction between mediators and receptors, this may be 
the most effective method of establishing the specific role of these compounds, in the 
long term. 
Different model types 
The aim of any animal model is to provide an eventual end point which can be of 
direct relevance to human research and consequently to benefit the human 
populati.on. With this in mind the most suitable models to develop and study would 
be animal skin conditions that are directly comparable to human clinical conditions. 
Unfortunately, such conditions do not occur naturally in mice. However, there are a 
couple of examples ofmice with 'skin conditions'. An inbred strain ofmouse, known 
as the NC mouse has been bred that would appear, to histological examination, to 
have an atopic dermatitis-like condition ofthe skin (Suto eta!., 1999; Vestergaard et 
al., 2000). These mice show spontaneous scratching behaviour. The problem with a 
model such as this is that they are developed without knowing the exact cause of the 
condition and so still does not tell us the cause of the related human condition. 
Having said this, it is an animal model that can be investigated more rigorously than 
can the condition in human subjects and is potentially of great use in the future. 
Another such model exists that has used transgenic technology. Mice have been bred 
which express the cytokine, interleukin-4 in the epidermis (Chan et al., 2001). These 
mice scratch spontaneously and have a skin condition similar to that of atopic 
dermatitis. The expression and itch inducing powers of interleukin-4 in the epidermis 
is not one currently presented in the literature. Again, the problem of this form of 
model is that we cannot be sure that the condition although similar to a clinical 
condition is identical in its pathophysiology. Despite their drawbacks, these disease 
models are of use for investigating skin abnormalities and it seems certain many 
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more such models will be developed in the coming years. More detail of chronically 
induced models of itch will be discussed in chapter 7 ofthis thesis. 
Acutely induced scratching models 
Human studies have not only been carried out in patients with skin disease but also 
using the administration of drugs into healthy subjects to evoke itch. The same can 
be attempted in animal studies. Problems with such models are based on the 
interpretation of the induction of itch. Animals clearly are tmable to report a 
sensation of itch. In such studies scratching is assumed to equate to the sensation of 
itch. This assumption is not without its critics (McMahon & Koltzenburg, 1992), 
with some suggesting that pain elicits a scratch response in rodents. For example, 
scratching induced in arthritic rats is assumed to be due to chronic pain (De Castro-
Costa et a!., 1987). Despite its critics, acutely induced scratching behaviour is the 
most common form of animal model of itch. It has been shown that in mice 
scratching is evoked by pruritogenic, compound 48/80 and substance P, not 
algogenic, capsaicin and formalin, drugs (Kuraishi et al., 1995). 
Another problem in developing murine models of scratching is reproducibility. If the 
model does not consistently present the same evidence it is of limited use. Such 
problems can arise due to variables not being controlled, most commonly these 
would be strain differences and age-related differences. It has been reported that 
different strains of mouse vary in their responses to different itch inducing drugs. For 
example the BalbC strain of mouse is significantly less responsive to histamine that 
the ICR strain, yet, both these commonly used strains respond similarly to another 
pruritogen, 5-HT (Inagaki et al., 2001). It is also reported that there are strain related 
differences in the release of histamine from mast cells (Toda et al., 1989). It is 
important these differences are appreciated before results interpreted and conclusions 
drawn. Significant differences can also exist between individual mice dependent on 
age. BalbC mice have been shown to have a variable number of mast cells between 
the ages of six and ten weeks (Hart et al., 1999), therefore changes in scratching 
response over this time period would be expected, if we were to be studying mast 
cell degranulating compounds, independent of the drug itself. 
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Another problem of using acutely induced scratching as a model for itch is that the 
animals must be observed. This is a labour intensive procedure and highly 
inefficient. A limited number of mice can be observed at any once and if scratching 
is recorded and observed at a later date or observed at the time, a great deal of time is 
spent on a mundane task. Ideally, mouse scratching would be recorded automatically. 
Such a system has recently been developed whereby mice have a wire ring around 
the ankle and activity recorded due to the presence of a magnetic field, generated by 
copper wire and ferrite rods, in the cage in which the mouse sits. Movement of the 
metal rings, of a frequency related to that of scratching is identified (Elliott et al., 
2000). Of course the problem with such systems is that they are often likely to be 
costly and more invasive that simple observation. Further discussion and studies into 
this area can be found in chapter 4. 
Drug induced scratching in animal models 
The results gathered from experimentally induced scratching in animals is so far less 
complete than that which has been gained from human studies. This is primarily due 
to the fact that the research has not been carried out in the same depth, because of the 
problems I have discussed above. There have, however, been interesting findings that 
in some cases support, and in other cases contradict, what has been discovered in 
human studies. 
Histamine has been shown to induce scratching in mice, as is known in humans. It is 
believed this is H1 receptor, but also possibly H2 receptor mediated (Inagaki et al., 
1999). The role of H2 receptors in human itch is still very much inconclusive. As 
mentioned above, murine responses to histamine would appear to be strain related. 
More detailed discussion of histamine induced scratching in mice can be found in 
chapter 5 of this thesis. The mast cell degranulator, compound 48/80, also induces 
scratching in various strains of mice (Kuraishi et al., 1995). As the human literature 
also suggests, this is H1 receptor mediated and blocked using traditional 
antihistamines (Sugimoto eta!., 1998). Studies in guinea pigs also suggest histamine 
is pruritogenic when administered intradermally (Woodward et al., 1995), however, 
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work in Sprague-dawley rats suggested scratching was not induced by histamine or 
compound 48/80 (Thomsen et al., 2001). 
As described previously substance P is pruritogenic in humans and this is assumed to 
operate through a histamine/mast cell mechanism. Work in mice has revealed a 
potentially separate mechanism. Substance P has been shown to evoke scratching in 
mice (Kuraishi et al., 1995). Substance P has also been shown to induce scratching in 
mast cell deficient mice and can be blocked using an NKI receptor antagonist; this is 
the substance P receptor that this evidence suggests may be located on the peripheral 
nerve transmitting the itch sensation (Andoh et al., 1998). It has also been proposed 
that the NKl receptor activity may not be peripheral but may be at the level of the 
spinal cord (Sakurada et al., 1999), no such evidence exists to support this suggestion 
in humans. The possible role of the NK1 receptor is a novel one in the field of itch 
and although it may be a mouse specific mechanism it could be worth investigating 
in human studies. 
Eicosanoids have also been studied in animal models of itch. Prostaglandin E2 and 
leukotriene B4 are pruritogenic in mice when administered intradermally (Andoh & 
Kuraishi, 2000). Prostaglandins E2 and 12 are pruritogenic when administered into 
the ocular surface of the guinea pig eye (Woodward et al., 1996). Both these findings 
are contradictory to the evidence that exists in humans. Again the question is raised 
as to whether we should consider this to be species differences or a novel insight into 
a potential new mechanism of itch in humans, only with further research will we 
discover the answer. 
Evidence has been published supporting the human literature for a pruritogenic 
evoking action of 5-HT in mice. Further to the human studies it was shown that 5-HT 
induced scratching was inhibited by 5-HT2 but not 5-HT1N 3 receptor antagonists 
(Yamaguchi et al., 1999). 
Animal studies also support the human literature with regards to the central actions 
of opioids in inducing itch. Intracisternal administration of morphine or endogenous 
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endomorphins evokes scratching in mice (Kuraishi et al., 2000; Tohda et al., 1997; 
Yamaguchi et al., 1998), similar to the effect of patients receiving an epidural 
injection. Intradermal injection of morphine does not elicit scratching (Kuraishi et 
al., 2000). 
Work using guinea pigs has suggested that PAF also induces itch in animals as well 
as humans. The work indicates that P AF may operate directly on sensory nerves and 
that the pruritic activity of P AF is not reduced by traditional histamine H1 receptor 
antihistamines (Woodward et al., 1995). A direct action of PAF on sensory nerves 
has not been described in the literature in humans. 
Although the work in animal models is less comprehensive to date than that carried 
out in humans there is broad cross over in the drugs studied. The key to future work 
is to identify the differences between the two fields and establish simple species 
differences from potential drug targets for human studies. 
Electrophysiological studies 
In previous sections I have described studies in which recordings have been made 
from peripheral and spinal nerves. A small number of similar studies have been 
performed in rodents, but the problem with such studies is that evoking a neural 
signal does not tell us whether the animal would interpret that sensation as pain or 
itch? Nevertheless this technique can be useful in telling us whether a given drug 
activates peripheral nerves, and if it does, what other drugs activate the same afferent 
nerve fibres. 
Peripheral C-fibres have been shown to increase firing directly to interleukin-2, a 
pruritogen in humans, in rats (Martin & Murphy, 1995). Histamine has been shown 
to activate spinal dorsal hom neurons in rats, although these nerves also appear to be 
sensitive to a range of other stimuli, including capsaicin (Carstens, 1997). The only 
work to date in mice indicates peripheral cutaneous nerves respond to 5-HT with a 
firing response of the same duration as the scratch response to 5-HT (Maekawa et al., 
2000). No evidence yet exists in rodents that there are specific nerves that respond to 
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pruritogenic, not algogenic drugs. If such nerves could be identified we could use 
electrophysiological studies in rodents to learn more about itch inducing, or itch-. 
alleviating drugs, confident in the knowledge we were not inadvertently observing a 
pain associated response. 
1.5 Aims of PhD Research Project 
The aims of the studies in this thesis were designed to test the hypothesis that: 
• Induction of scratching behaviour in mice is a usefu l and robust model for 
studying itch, which can be used to provide a guide to pruritic and antipruritic 
drugs relevant to man. 
The techniques used in this thesis include both behavioural and in v1vo 
electrophysiological procedures to examine drug-induced actions. Inducement of 
acute and chronic scratching in mice has been employed to study the actions of 
scratch inducing, and potential scratch alleviating, compounds. 
The specific aims of this project are: 
• To develop and validate a reliable and reproducible model of itch based on 
the induction of acute scratching in mice. 
• Test putative mediators of scratching in this model. 
• Use in vivo electrophysiological recordings from cutaneous nerves of mice to 
study neural responses to pruritogenic and algogenic drugs. 
• Devise and develop an automated mechanism for the detection of scratching 
mm1ce. 
• Examine the effect of novel itch-inducing drugs, established from murine 
studies, in human volunteers. 
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The experiments desctibed in this thesis were carried out in accordance with current 
Home Office regulations and guidelines as specified in the Scientific Procedures Act 
(1986). All experiments were performed under Project Licence number PPL: 
60/2750 (Prof. D. McQueen) and, unless otherwise stated, my Personal Licence 
number PIL: 60/8073. The animals used for experiments described in this thesis were 
housed in licenced animal facilities within the School of Biomedical Clinical and 
Laboratory Sciences, in the Division ofNeuroscience, University ofEdinburgh, and 
experiments perfom1ed in licenced premises. 
A total of 603 BalbC mice, 83 C57BL6 mice and 72 ICR mice were used. Animals 
were purchased from Charles River (UK) or Harlan (UK). Animals were housed 
under controlled light (07:00-19:00hrs) and temperature (22°C) with food and water 
available ad libitum. Animals were used for only one experiment, unless otherwise 
stated. 
2.1 Acute Behavioural Studies 
Scratch-Inducing Procedure 
Scratching was induced in mice using an intra-dermal (i.d., 1 00).!.1) injection of 
pruritogen at the back of the neck, between the ears, using a 26G needle and standard 
lml syringe (BD P1astipak). During the injection procedure mice were restrained by 
scruffing by the neck. 
The site at the back of the neck was chosen as it can only be reached by the hind 
limbs of the mouse and therefore scratching of the area can be easily distinguished 
from grooming behaviour, which utilises the forelimbs. 
Measurement of Scratching 
Mice were observed for a period of up to one hour post-injection, this period of time 
was reduced once the duration of a response was established. Animals were observed 
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and also filmed with a video camera (Vista, NCD 132) and their behaviour recorded 
using a VCR (Panasonic, NV -HD640). 
The evoked scratching behaviour was measured and recorded. Scratching was 
defined as movements of the hind limbs to the injection site (back of the neck). Due 
to the speed of the scratching it was not possible by observation to count the number 
of individual scratch motions. For this reason, scratching was expressed as the 
number of 'bouts of scratching' evoked. A 'bout of scratching' was defined as three 
or more individual scratch movements of the hind paw to the area around the 
injection site. This separated the repetitive high frequency beating movement of a 
bout of scratching, from the 'pawing' ofthe area that was also sometimes observed. 
At all times mice were also observed for any overt changes in behaviour that may 
have indicated discomfort or sickness caused by the injection. 
2.2 Chronic Behavioural Studies 
DNCB Model of Chronically Induced Scratching 
In order to develop a model of scratching that is more akin to a clinical condition, 
chronic scratching was induced using the contact sensitising agent 2,4-Dinitro-
chlorobenzene (DNCB, Sigma, Poole, UK). 
Mice in these experiments were shaved using clippers (Oster, small animal clipper, 
model A5-00) on day -1, on the back of the neck, and tail-marked. They were 
replaced into their cages, housed in groups of 3. DNCB was administered (I% in 
ethanol, topically) on days 0 and 3. DNCB was applied to the shaved area at the back 
of the neck, using a cotton bud that had been immersed in the DNCB solution. The 
cotton bud was rubbed over the skin for 5 seconds, and the mouse returned to the 
cage. 
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Mice were observed either once or twice daily until any skin reaction or scratching 
behaviour had subsided. Mice were observed for a period of ten minutes each time, 
and the level of scratching evoked was measured as described above. Written 
comments were recorded as to the condition of the skin (redness, swelling, bleeding 
etc.) on the back of the neck and the general behaviour of the mice. 
Mice were treated with antipruritic drugs at the peak (days 6-11) of chronic 
~cratching, either topically or intra-dermally. Further details of these protocols are 
described in chapter 7 .2. 
2.3 In Vivo Electrophysiological Recording from Cutaneous 
Afferent Nerves 
Anaesthesia and Surgical Procedures 
Mice were anaesthetised with urethane (1ml per 100g body weight, 20% w/v) intra-
peritoneally, i.p. The depth of anaesthesia was tested using the toe-pinch withdrawal 
reflex, no experimentation occurred until this reflex was abolished. 
Once anaesthetised, mice were shaved with clippers (Oster, small animal clipper, 
model AS-00), from the level between the ears to about one centimetre above the 
base of the tail, with the shaved area being about two centimetres wide. 
Experiments were performed throughout on an automated heating blanket (Harvard 
Apparatus Limited, UK) to maintain body temperature at 37°C. Mice were placed on 
their front with their limbs secured to the operating table with tape. A midline 
incision was made in the shaved area, from between the ears, about 3 centimetres in 
length. The skin was dissected away from the underlying tissue, peeled back and held 
in place by stitching the skin to a small brass loop (see figure 2.1 ). This formed a 
pouch that was filled with heavy liquid paraffm oil (HLP) to ensure an electrically 
isolated recording system. A cutaneous nerve, running from the back of the mouse to 
the skin around the back of the neck, was then separated from the surrounding tissue 
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and split using fme forceps to produce as small a nerve filament as was possible. 
Typically this filament contained 1-3 afferent fibres. The nerve was crushed centrally 
using forceps to prevent efferent neural activity being detected by the distal 
recording electrodes. 
Recording from a cutaneous nerve 
Afferent neural activity was recorded by laying the dissected cutaneous nerve over 
bipolar platinum-iridium wire electrodes (see figure 2.2). The raw signal passed 
through a pre-amplifier (Neurolog, NL 103) and an amplifier (Neurolog, NL 105), 
producing a signal amplified by 10 000 times. The amplified signal was shown on an 
oscilloscope (Gould 1604) and digitised (Sony, Digital Audio Processor PCM-
701ES). The digitised signal was filtered (Neurolog, NL 115) at 1OOHz (low pass) 
and 1OOOHz (high pass), before being passed through a voltage discriminator 
(Digitimer D.130) connected to a loud speaker. The filtered and voltage 
discriminated signal were passed through a Micro1401 interface (Cambridge 
Electronic Design, UK) and into a personal computer (Research Machines, Pentiwn 
III/500Hz) running Spike2 software (Cambridge Electronic Design, UK, v3.20). 
Action potentials were recorded on-line using both positive and negative trigger 
filters, keyboard markers were written into the file during recording in order to 
identify the exact time of injection. Files were saved as Spike2 data files for 
subsequent off-line analysis. 
Identification of Receptor Field 
Because a major objective of this thesis was the inyestigation of chemical mediators 
of pruritus, it was necessary to show that drugs were actually being injected into an 
area of skin innervated by the nerve from which recording was taking place. In order 
to prove this the skin around where the nerve passed into the skin was tested for 
mechanosensitivity using a hand held plastic probe. Firing of the units would show 
that the correct receptor field had correctly been identified; subsequent injections of 
drugs would be made at a site within this receptor field. 
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Drug Administration 
Drugs were administered by an intra-dermal injection, into the area of skin held 
securely in place by the brass ring, into the area identified as in the receptor field of 
the nerve being recorded. Injections were in a volume of lOOj..d, administered using a 
lml syringe and a 26G needle. 
Data Analysis 
Data files were subsequently analysed usmg Spike2 software. The recorded 
waveform signal was scanned to identify action potential templates, representing 
individual nerve units. The signal was then rescanned and each unit shown on a 
separate channel. The signal was also displayed as a histogram, showing the total 
number of impulses of that unit in consecutive 1-second bins (see chapter 8 for 
examples ofresponses). 
Data on individual units were expressed as the total number of impulses generated 
and as the frequency, in impulses per second. The 15-second period immediately 
preceding injection of the drug was analysed to provide a control. Responses to each 
injection are presented as the increase in the total number of impulses post injection 
relative to the pre-injection level, and likewise with the increase in frequency of 
impulses. The duration of onset of response and the total duration of response were 
also recorded. 
2.4 Statistical Analysis 
Data were analysed usmg Microsoft Excel 2000, GraphPad Prism (v3.02) and 
GraphPad Instat (v3.01) software. 
Due to the natw-e of the work in this thesis (often relatively small sample sizes and 
large variability), non-parametric analysis parameters have been used. For 
comparison of two groups of means or medians a Mann-Whitney test was performed. 
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For paired results a Wilcoxon matched pairs test was used. For the comparison of 
three or more groups of means or medians, a Kruskal-Wallis (with Dunn's multiple 
comparison post-hoc analysis) was used. Where parametric analysis was deemed 
suitable, and distribution within groups appeared normal, a Student's paired (or 
unpaired) t-test was performed and for comparison of three or more groups a one-
way analysis of variance (ANOVA) with Tukey's post-hoc analysis was used. 
In each case the null hypothesis (that difference between group means could arise 
due to natural variability) was rejected at the probability level of 0.05. Therefore, if 
the P value was less than 0.05 the null hypothesis was rejected and difference 
between groups were considered to be statistically significant. 
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Figure 2.1 Image taken from a digital camera illustrating the surgical 
technique used for the electrophysiological studies. The diagram shows 
the skin of the back of the neck held by a brass ring to reveal the 
cutaneous nerves of the back. 
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Figure 2.2 Image taken from a digital camera to illustrate the 
peripheral cutaneous nerve laying over the platinum-iridium electrodes 
for recording of action potentials. 
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3. 1 Introduction 
The sensation of itch is a subjective one, and as such, even in humans, it is difficult 
to defme clearly and concisely (Savin, 1998). We can never be certain that the same 
substance, in two different individuals, is evoking the same degree of sensation, or 
indeed the same sensation at all. For this reason, there are many methods used to try 
to quantify itch, with widely differing complexities. Methods used to measure itch in 
humans range from asking a subject to rate the intensity of the sensation using a 
visual analogue scale (Heyer et al., 1998; Rees & Laidlaw, 1999), to recording 
activity of certain brain areas after an itchy stimulus (Hsieh et al., 1994), to recording 
directly from what are thought to be 'itch nerves' (Schmelz et al., 1997). These 
problems of measuring itch are substantial in humans, who have the ability to 
communicate the sensation and to understand what is being asked of them. Clearly, 
the problems of quantifying itch and being confident that the sensation being evoked 
is itch, are much greater in animal models, where oral communication is not possible. 
Having said this, animal models may be the most ethical and cost effective method of 
studying potential itch inducing or itch relieving drugs and there development is 
important. 
Itch in human studies is commonly induced using one of two techniques, 
iontophoresis or intradermal injection of a pruritogenic substance. The more basic 
method of injecting pruritogen into the skin is widely used (Hagermark et al., 1978) 
(Wahlgren et al., 1995), however, there is an argument against using this method in 
itch studies. It is proposed that inducing a needle into the skin evokes a pain response 
that reduces the subsequent itch sensation (Keele & Armstrong, 1964). This 
suggestion is dependent on the gate-theory, which proposes that a painful stimulus 
acts centrally to reduce the activity of itch responsive nerves in that area of skin 
(Melzack & Wall, 1965). The second common method of inducing itch is 
iontophoresis (Heyer et al., 1989; Weisshaar et al., 1998), which involves passing a 
small electrical current between two electrodes placed on the skin, any ion-charged 
solution can be placed in a well in one of the electrodes and pass through the skin, 
into the dermis. Clearly this technique is more complex and it is difficult to ascertain 
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the exact dose of drug passing through to the skin, however, it is relatively pain free, 
non-invasive and ensures the drug is delivered as superficially as is possible. Both 
methods for inducing itch have been used in murine studies with no apparent adverse 
results detected with either technique (Kuraishi et al., 1995; Laidlaw et al., 2002). 
Various elements of the experimental protocol used in animal studies into itch could 
potentially affect the results produced, each of these elements must be investigated if 
we are to be sure a model is robust and reproducible. It is essential to be confident 
that the procedures themselves are not capable of inducing scratching in mice, before 
we begin introducing drugs into the skin. 
The basis of most models of itch involves the use of histamine, the first and still most 
commonly used pruritogen in research studies. The mechanism by which histamine 
evokes scratching in mice is further investigated in chapter 5 of this thesis. 
Histamine, since it was first described in the 1920's (Lewis, 1927) has been the most 
common experimental tool for inducing itch in human (Hagermark et al., 1979; 
Keele & Armstrong, 1964) and in animal studies (Kuraishi et al., 1995; Laidlaw et 
al. , 2002). 
It has been proposed that, although histamine evokes scratching, there are other 
experimental variables to be considered. If the volume in which the drug is 
administered is too great there may be activation of pain sensing nerves, as described 
above, this could reduce the itch sensation due to the gate theory (Keele & 
Armstrong, 1964). Another possible variable of injecting pruritogens is the vehicle in 
which the drug is administered. Using distilled water could promote an ion 
imbalance, whereas using saline could create a change in pH (depending on the drug 
being investigated). It has been suggested that slight pH changes may evoke a 
sensation of itch in man (Keele & Armstrong, 1964). 
If histamine is to be used as a standard pruritogen for studying itch, we must be 
aware of any unexpected responses following histamine administration. In humans, 
histamine has been shown to give a reduced itch response after repeated 
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administration; this is referred to as tachyphylaxis (Stahle-Backdahl et a!., 1988). 
Potentially, a lack of response to histamine may not simply be a consequence of that 
animal not being sensitive to histamine, but may be due to the protocol being used in 
the experiments. 
Animal models need not necessarily always respond as in human models, however, 
aside from species differences we must also be aware of potential strain differences 
that may exist to various pmritogens (Inagaki et al., 1999). Again, inconsistency in 
histamine responses may not be due to variability but may be due to the strain being 
used and may be an indication of distinct mechanisms operating. For example, 
release of histamine from mast cells has been shown to vary between different strains 
of mouse (Toda et al., 1989). Strain differences in itch response need not be seen as a 
problem, but also an opportunity to learn more about separate mechanisms, which 
may relate favourably to those operating in man. 
The response to a pruritogen in humans is scratching the afflicted area. Without the 
ability to communicate with animals we can't be sure that they feel the same 
sensation or respond to that sensation in the same way. It has been reported that 
arthritic rats scratch, yet this sensation would be expected to be pain, not itch (De 
Castro-Costa et al., 1987). Animals may not only scratch when they feel itchy, this 
has caused some authors to question whether the study of itch based on scratching 
induced in animals is a sound basis for quantifying itch (McMahon & Koltzenburg, 
1992). Evidence exists to support the argument that animals scratch only in response 
to itch. Mice have been shown to scratch to the pruritogens (in humans) compound 
48/80 and substance P, but not to the algogenic compounds capsaicin and formalin 
(Kuraishi et al., 1995). It is important to be aware of any changes in animal 
behaviour when developing such models as we can't assume what behavioural 
response an individual animal will give to any particular drug. 
The purpose of the studies in this section of the thesis is to develop and validate a 
murine model of itch. The experiments in this chapter were performed in order to 
determine the ability to evoke scratching in mice, and whether or not we can suggest 
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that this behavioural response correlates with itch in man. Whether or not the 
experimental procedures used to generate this scratching behaviour provide a robust 
and reproducible model for similar studies into murine scratching was also 
investigated. 
3.2 Materials and Methods 
The itch-inducing procedure and measurement of scratching in this chapter are as 
previously described in chapter 2.1, unless otherwise stated. Experiments in this 
chapter were conducted in a total of 156 mice: 125 female BalbC mice, 8 male 
BalbC mice, 17 female ICR mice and 6 female C57/Bl6 mice. 
3.3 Results 
Scratching evoked by the itch-inducing procedure 
The scratch inducing abilities of various experimental procedures were investigated 
in a total of30 female BalbC nuce (see figure 3.1). Scratching was measured, over a 
20-minute period, following; no experimental procedure; scruffing of the mice; 
insertion of needle into the skin; injection of distilled water into the skin (O.lml, i.d.); 
injection of saline (O.lml, i.d.) and injection of phosphate buffered saline (PBS, 
O.lml, i.d.). A low level of scratching was observed in each experimental group, but 
there was no statistically significant difference between the means of any of the 
individual groups (Kruskal-Wallis test with Dunn's multiple comparison post-test, 
P>0.05 between all groups). 
Histamine evoked scratching 
Histamine-evoked scratching was dose-dependent in all eight BalbC mice studied, as 
summarised in figure 3.2. Scratchlng was not obtained at lower doses (up to 
0.8J..Lmol), but was consistently observed with higher doses, reaching a maximum at 
26J..Lmol rustamine. Above this dose there was no further increas.e, and often a 
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Figure 3.1 Scratching evoked by the experimental protocol used in the 
development of a murine model of scratching in female BalbC mice. 
There was no significant variation in mean response between 
unhand led mice ('nothing', n=5), scruffed mice (n=1 0), mice inserted 
with a needle (n=1 0), mice receiving water (0.1 ml, i.d. n=5), mice 
receiving saline (0.1 ml, i.d. n=8) and mice receiving PBS (0.1 ml, i.d. 
n=12, P>0.05, Kruskai-Wallis test with Dunn's multiple comparison 
post-test). 
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Figure 3.2 Pooled data for histamine-induced scratching in female 
BalbC mice during the 20-minute post injection period (n=4-8). 
Histamine caused dose-dependent scratching. Dashed line represents 
the mean level of scratching induced by PBS, which served as a control 
(5±1 bouts of scratching, n=12). 
44 
Chapter 3: Development and validation of a model of scratching in mice 
decrease, in scratching. Histamine-induced scratching reached a maximum response 
of 73±12 bouts (mean±sem, median=70), with a mean apparent EDso of 5.8~-tmol. 
Effect of various vehicle solvents on histamine evoked scratching 
Histamine-induced scratching (8J.t.mol, i.d.) was shown to be reproducible and 
independent of the vehicle used (see figure 3.3). Mean scratching was not 
significantly different whether PBS (pH 6.8) or distilled water (pH 5.6) vehicle was 
used (Mann Whitney test, P>0.05). Saline vehicle, which had a pH between the two 
values for PBS and water (pH 6.1 ), also showed no significant difference in 
scratching. 
Effect of injection volume on histamine evoked scratching 
The effects of a sub-threshold dose of histamine (0.8~-tmol, i.d.), when injected in a 
volume of 1 00~-tl, were compared to the same dose of histamine, administered in a 
volume of 1 OJ.i.l. Significant levels of scratching were not observed in either group 
( 1 00~-tl; 0±0 bouts of scratching, (roedian=O), 1 0~-tl; 1± 1 bouts of scratching 
(median=O), mean±sem, n=3 in each group). The same pattern was observed with a 
dose of 3~-tmol histamine (a dose at the base of the dose response curve); 100~-tl­
scratching response was 4±4 bouts (median=O), 1 OJ.t.l-scratching response was 1±0 
bouts (median=l, n=3 in each group). 
Effect of mouse gender on histamine evoked scratching 
Scratching was induced using histamine in eight male BalbC mice and compared to 
the responses of female mice, described above. Histamine caused dose-dependent 
scratching in male mice as previously observed in female mice (see figure 3.4). In 
male mice, histamine-induced scratching reached a maximum of 65±5 bouts 
(mean±sem, median=63), with a mean apparent ED5o of 5 . 7~-tmol. These values are 
very similar to those measured from the female mice (73±12 bouts; mean apparent 
EDso of 5.8~-tmol), indicating no gender differences in histamine induced scratching 
response in BalbC mice. 
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Figure 3.3 PBS versus distilled water vehicle does not affect histamine 
(81-Jmol, i.d) evoked scratching in female BalbC mice (P>0.05, Mann-
Whitney test, n=7 in each group). 
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Figure 3.4 Pooled data for histamine-induced scratching in male BalbC 
mice (n=8) compared with female BalbC mice (data as in figure 3.2). 
Histamine caused dose-dependent scratching in both male and female 
mice. Dashed line represents the mean level of scratching induced by 
PBS, which seNed as a control (5±1 bouts of scratching , n=12). 
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Characteristics of histamine evoked scratching 
Time course of scratching response 
The level of scratching evoked by three doses of histamine (8-80)lmol, i.d) was 
measured over the course of 40 minutes. Scratching primarily occurs in the first 10 
minutes following injection of histamine, regardless of dose administered (see figure 
3.5a). Histamine (8Jlmol) induced a total of 42±8 bouts of scratching, 38±4 of which 
occurred during the first 10 minute period (n=8). Histamine (30)lmol) evoked a total 
of 70±12 bouts of scratching, 50±7 bouts of which occurred in the first 10 minute 
period. Finally, histamine (80J..Lmol) induced a total of 67±12 bouts of scratching, 
44± 10 bouts of which occurred in the first 10 minutes. Very little scratching occurs 
after 20 minutes after any of the histamine doses, although to the higher two doses 
there was a prolonged scratching response from the first 10 minutes into the second 
1 0-minute period. More detailed studies indicated that scratching occurred 
throughout the first 1 0-minute period following histamine injection (8Jlmol, n=6, see 
figure 3.5b). Most scratching occurred in the period 4-6 minutes post injection. 
Sensitising and desensitising effects of histamine 
The effects of moderate and high doses of histamine on subsequent histamine 
responses were investigated in order to evaluate whether these doses were causing 
sensitisation or desensitisation. A high dose of histamine (30)lmol, i.d) elicited a 
scratching response of 70±12 bouts of scratching, median=66, in the earlier dose 
response studies, when this dose was administered at the end of the experimental 
procedure. If a similar dose of histamine was administered before any other 
procedure the scratching response was significantly reduced, 37±5 bouts of 
scratching (n=6 in each group, P<0.05, unpaired t-test, median=43.5), indicating that 
the earlier lower histamine doses imposed a slight sensitising effect on later 
injections. Inversely, a high dose of histamine (30)lmol, i.d) administered prior to a 
lower dose of histamine (8Jlmol, i.d) reduced scratching responses, indicating that the 
higher doses of histamine imposed a desensitising effect on later injections. Control 
scratching responses to histamine (8Jlmol), prior to any other experimental 
procedure, were 49±5 bouts (n=6 in each group, median=50). Scratching responses 
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to histamine (8j..tmol) in mice, one hour after a high dose of histamine (30j..tmol) was 
significantly lower, 12±4 bouts (n=6, P<0.05, unpaired t-test, median=IO). 
Further studies into the desensitising effects of histamine on subsequent doses of 
histamine were carried out in 12 ICR mice. Female ICR mice were used in repeat 
experiments at weekly intervals and their responses to histamine studied. ICR mice 
showed reduced histamine responses, to a range of doses, over successive weeks. 
Histamine (30nmol, i.d) evoked 23±4 bouts of scratching in week one, this fell to 
22±11 bouts in week two and 2±1 bouts in week three (n=4). Similar patterns of 
diminishing scratching response histamine over successive weeks were identified in 
a range of doses from 8-800nmol. 
Strain dependent differences to histamine evoked scratching 
Scratching evoked by histamine was studied in female BalbC (as previously 
described above), ICR and C57/Bl6 mice. In each strain histamine was shown to 
induce dose dependent scratching. As discussed earlier BalbC mice respond to 
histamine with a mean apparent ED50 of 5.8j..tmol (n=8). ICR mice respond to a 
significantly lower dose of histamine than BalbC mice, with a mean apparent ED 50 of 
0.2j.lmol (P<0.05, Kruskal-Wallis test with Dunn' s multiple comparison post test, 
n=5, see figure 3.6). Interestingly, this dose (0.2j..tmol) was shown to be unable to 
evoke scratching in any female BalbC mice studied (as can be seen in figure 3.2). 
Female C57/Bl6 mice also responded dose dependently to histamine with a mean 
apparent EDso of 1.3j..tmol (n=6, see figure 3.6). The mean apparent ED5o of C57/Bl6 
mice was not significantly different from either the BalbC or ICR strains, however, 
the trend suggests they respond to histamine in an intermediate dose range to that 
identified in the other two strains investigated (P>0.05, Kruskal-Wallis test with 
Dunn's multiple comparison post test). 
The maximum scratching evoked by histamine was significantly greater in C57/B16 
mice than in the other two strains investigated. Scratching reached a maximum level 
of 131±8 (mean±sem) bouts, over 20 minutes post-injection, in C57/B16 mice (n=6). 
This was significantly higher than that seen in BalbC mice (73±12, n=8) or ICR mice 
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Figure 3.5 Time course of histamine (i.d .) evoked scratching in female 
BalbC mice over A, a 40-minute period and B, a ten-minute period. A; 
scratching occurs primarily in the first ten-minute period at doses of 
8J.Jmol (n=8), 30j.Jmol (n=6) and 80J.Jmol (n=4 ). B; scratching peaks in 
the time period 4-6 minutes post injection (8J.Jmol , n=6). 
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Figure 3.6 Apparent ED50s for histamine in female BalbC (n=8), ICR 
(n=5) and C57/816 mice (n=6). Mean apparent ED50 was significantly 
lower in BalbC than in ICR mice (*P<0.05, Kruskai-Wallis test with 
Dunn's multiple comparison post test). Mean apparent ED50 in C57/816 
mice appeared to be intermediate between the other two strains, but 
this was not statistically significant (P>0.05, Kruskai-Wallis test with 
Dunn's multiple comparison post test). Bars show mean value. 
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(66±16, n=5, P<0.05, Kruskal-Wallis test with Dunn's multiple comparison post 
test). 
Scratch inducing properties of 'algogenic' substances 
A variety of drugs assumed to evoke a sensation of pain, was investigated for their 
scratch-inducing capabilities. Hydrochloric acid (HCl, 32%), fom1alin (2-1 0%), 
bradykinin (0.3-33nmol) and capsaicin (1-33nmol) were studied. The scratch 
evoking properties of these drugs are shown in figure 3.7a, which shows the doses of 
bradykinin and capsaicin that evoked the greatest level of scratching. HCl and 
formalin (10%) did not cause scratching in female BalbC mice. Formalin (2%) and 
bradykinin (9nmol) evoked a small scratching response, which did not differ 
significantly from that evoked by PBS. Capsaicin (33nmol) evoked a scratching 
response significantly greater than that evoked by PBS (P<0.05, Mann-Whitney test). 
Time course of capsaicin-induced scratching 
Histamine evokes scratching that occurs mainly in the frrst 10 minutes post injection, 
as described above. The pattern of the scratching response to capsaicin was also 
investigated (see figure 3.7b): very little of the scratching occurred during the first 10 
minutes. Total scratching evoked was 57±14 (mean±sem, n=4), of which only 3±3 
occurred within the frrst 10 minutes post injection. Unlike histamine induced 
scratching, capsaicin induced scratching persisted for 40 minutes. 
Behavioural responses 
Intradermal administration of HCl and formalin (10%) evoked a behavioural 
response that was quite distinct from that after histamine. The only obvious 
behavioural change following histamine injection was the onset of scratching. 
However, injection ofHCl and formalin was associated with vocalisation in all mice. 
Following injection of these agents the mice exhibited prolonged 'crouching' and 
'cowering'. This behavioural response persisted in each case until the animals were 
killed. Following injection of HCl and formalin (1 0%) mice were killed after 10 
minutes to prevent undue discomfort and pain that was adjudged to be occuning. 
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Figure 3.7 A; Scratching evoked by the algogens HCI (n=4), formalin 
(2%, n=3), formalin (10%, n=4) and bradykinin (n=4) was not 
significantly greater than that evoked by PBS in female BalbC mice 
(P>0.05, Kruskai-Wallis test with Dunn's multiple comparison post test). 
Scratching evoked by capsaicin (n=4) was significantly greater than that 
evoked by PBS (*P<0.05, Mann-Whitney test). (Dashed line illustrates 
scratching induced by PBS). B; time course of capsaicin induced 
scratching over a forty-minute period. Scratching began after the first 
1 0-minutes after injection and lasted for 40 minutes. 
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3.4 Discussion 
The results from this section of the study show that scratching can be evoked in mice 
in a reliable and reproducible manner. The data also indicate that quantifying the 
scratching behaviour evoked can be used as a method of studying itch objectively in 
these animals. 
The initial experiments of this study were focussed on establishing whether the 
devised protocol for inducing scratching was suitable as a method for studying itch. 
Scratching in mice was not evoked by any of the experimental control procedures 
used. Mice were shown not to scratch prior to handling, while neither scruffing the 
animal or insertion of a needle evoked scratching response. Water, saline and PBS 
induced a small scratching response, but these responses were negligible when 
compared to responses generated by the pruritogen, histamine, as described below. 
These simple control experiments ensure that the induction of scratching was a 
response to agents being administered to the skin and not due to the model itself. 
The method used for inducing scratching in these studies involved intradermal 
injections of pruritogen. The use of iontophoresis in itch research is common in both 
human and animal models (Hagem1ark et al., 1978; Laidlaw et al., 2002; Wahlgren 
et al., 1995). Iontophoresis has many advantages, mainly that it does not usually 
evoke a pain response and that the drug is delivered superficially. Despite the 
benefits of iontophoresis it was not used in these studies due to two main reasons. 
Iontophoresis in humans is made easy due to the lack of movement of the subject. 
· The use of animals, which are in many cases only slightly bigger than the equipment 
itself, provides problems of restraining the animal to ensure the drug can pass 
through to the skin without the electrodes moving away from the desired point. The 
second reason iontophoresis not being used was that estimating the dose of drug 
being administered is less precise. The ·studies in this thesis include a dose response 
element, which is easier to estimate using the intradermal injection method. 
54 
Chapter 3: Development and validation of a model of scratching in mice 
Mainly due to its historical role and wider reporting in the literature, the basis of the 
scratching model developed was using histamine. Histamine is recognised as an 
inducer of itch in humans (Hagermark eta/., 1979; Keele & Armstrong, 1964; Lewis, 
1927). The strain of mouse selected for the development of the model was made for 
various reasons. The BalbC mouse was recognised as a standard laboratory strain 
that had been used in research into itch that had been previously presented in the 
literature (Inagaki eta/., 2001; Inagaki eta/., 2000; Laidlaw et al., 2002; Sugimoto et 
at., 1998). This strain was relatively cheap and readily available, with the known 
ability to scratch following drug application. Results from this study show histamine 
evokes a dose dependent scratching response in mice, as previously described in the 
literature (Inagaki et al., 2001; Laidlaw et at., 2002), but contrary to some evidence 
(Kuraishi et al., 1995). The results of this study also show that the scratching 
response is independent of mouse sex. Female mice were used in these studies, 
primarily for ease of housing, but it would appear a model could also be based on 
male mice. 
The evidence from these studies indicate that for a given dose of histamine, the 
scratching is independent of the vehicle used; water, PBS or saline. This evidence 
shows that changes in ion balance or pH changes do not significantly affect the 
scratching response, as was previously suggested (Keele & Armstrong, 1964) 
Despite this finding, PBS was used as a standard vehicle for all intradern1al 
injections where possible. 
Changes in the volume of vehicle in which the drug was injected might also affect 
scratching response (Keele & Armstrong, 1964). This evidence proposes that the itch 
sensation may be reduced if the volume of injection is too great, due to the activation 
of pain nerves, reducing the activity of itch nerves via the _' gate-theory' (Melzack & 
Wall, 1965). In order to test this suggestion a dose found to be sub-threshold, and 
another dose at the base of the histamine dose response curve were administered in a 
lower volume (1 0 versus 1 OOfl.l). The results indicate that there is no increase in 
scratching response if the histamine is administered in a smaller volume. 
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The temporal characteristics of scratching in response to histamine were examined in 
greater detail. Histamine evoked scratching lasted a maximum of forty minutes. 
However, the majority of scratching occurred within the first ten-minute period. The 
peak of scratching occurred 4-6 minutes after the injection of histamine. The pattern 
of scratching in the first ten-minute period was true of all doses, although with higher 
doses, where more total scratching occurred, there was still scratching in the second 
ten-minute period. These findings support the literature in both human and animal 
models that histamine induced itch lasts for 10 to 20 minutes (Hagermark et al., 
1979; Inagaki et al., 1999; Keele & Armstrong, 1964; Laidlaw et al., 2002). 
The results of this study show high doses of histamine cause a desensitisation to 
future histamine injections. These results support the evidence that in humans, 
histamine causes tachyphylaxis after repeat administration (Stahle-Backdahl et al., 
1988). Doses of histamine at the lower end of the dose response curve did not cause 
desensitisation, and in fact seem to sensitise the mice to subsequent histamine 
application. Studies in which mice were used for multiple experiments at weekly 
intervals showed that histamine response was reduced after administration over 
successive weeks. For this reason, all future experiments used mice for one 
experiment only. Repeat use of animals would have proved beneficial for not only 
economic reasons but also would have enabled each animal to act as its own control 
over a period of time. Unfortunately, the evidence from these experiments indicated 
that this would not be possible. 
The effect the particular strain of mouse has on histamine evoked scratching 
response was investigated in two other common laboratory strains; ICR and C57/B16 
mice. Both strains had previously been described in the literature in itch studies 
(Andoh et al., 1998; Kuraishi et al., 1995). The results from this study supports 
previous evidence that there are significant strain dependent differences in histamine 
evoked scratching responses. The dose of histamine that induced half the maximum 
scratching response (mean apparent ED50) was significantly lower in the ICR strain 
in comparison with the BalbC strain (approximately 30 times). The C57/Bl6 strain 
appeared to have histamine sensitivity between the other two strains studied. The 
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reason for these differing sensitivities is not clear, but could be due to separate 
histamine receptor subtypes being present, or different behavioural responses to the 
same sensation. Further studies continued using the BalbC strain. Although more 
sensitive, the ICR and C57/Bl6 strains provided more variable responses, not ideally 
suited to behavioural studies in which variability was already a significant obstacle. 
It is also important to note that histamine dose sensitivity in BalbC mice from this 
study is approximately 100 times lower than in humans (Hagermark et al., 1979). 
This illustrates that species differences should not be forgotten when interpreting the 
importance of animal models. The reason for the difference between species is 
unknown. The mechanism of histamine mediated scratchjng is further described in 
chapter 5 ofthis thesis. 
It has been suggested that scratching in mice may not provide a sound basis for 
estimating itch (McMahon & Koltzenburg, 1992). This is partly based on the 
observation that arthritic rats appear to scratch more than non-arthritic rats, and that 
this would be expected to be a pain response, not itch (De Castro-Costa et al., 1987). 
The results from this study indicate that compounds thought to evoke pain (HCl, 
formalin and bradykinin) do not evoke scratching at a level greater than that induced 
by PBS. This evidence supports earlier findings in mice that pruritogenic, not 
algogenic drugs evoke scratching in mice (Kuraishi et al., 1995). An exception to 
this evidence would appear to be that capsaicin evoked scratching in mice in this 
study. One explanation would be that mice scratch to some but not all pain stimuli, 
although this would seem unlikely. Another explanation is that capsaicin is capable 
of evoking the sensation of itch, possibly as well as that of pain, a suggestion that 
previously been made in the literature (Lynn, 1992). One major argument against this 
explanation would be the gate theory described above, that a pain response has the 
ability to reduce an itch response centrally, therefore eliminating the need to scratch. 
The results of this study provide a clue that this may not necessarily be the case. 
Unlike histamine-evoked scratching, capsaicin induced scratching does not occur in 
the first ten minutes post injection; in fact the scratching begins after this time. This 
provides the possibility that pain does reduce the itch response in the early stages, but 
as the pain response declines, the itch response becomes prevalent and scratching 
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occurs. A second possibility would be that capsaicin evokes only pain, and no itch, 
but that 'pain-induced scratching' occurs over a time course distinct from that of 
itch-induced scratching. Either of these explanations does not conceal the fact that 
the model developed in this study can differentiate between a pain response and an 
itch response. 
In summary, the results from this study indicate that the murine model developed can 
be effectively used to induce and quantify the level of itch. The model, based on the 
use of intradermally injected histamine and recording of the scratching evoked, 
provides a robust and reproducible model, on which a range of other putative 
mediators of itch could be investigated. 
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Chapter 4 
Development of an Automated Scratch Detector 
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4. 1 Introduction 
The subjective nature of the itch leads to inevitable problems in quantification of the 
sensation. In humans, these problems are overcome primarily by the patient 
expressing the degree of itch using an arbitrary scale, such as a visual analogue scale 
(Greaves & Wall, 1996; Heyer et al. , 1989; Rees & Laidlaw, 1999; Wahlgren et al., 
1989). In animal models the quantification of itch cannot be reported in such a way. 
As described in Chapter 3, animal models rely on the recording of scratching 
behaviour as a measure of itch. 
Manual measurement of scratching in mice involves video recording of animals and 
watcrung of the video at a later date, or observation of the animals at the time of 
investigation. Either of these approaches involves an individual investigator 
watching the animals in 'real time', counting the number of scratches. Tills approach 
is extremely time consuming and an unproductive use of research time. Other 
drawbacks of such an approach are that few animals can be observed. Pilot studies 
established that it was simply not possible to measure the scratching of any more 
than four individual animals at any one time. Clearly this is a restriction on the 
productivity of the research. Another disadvantage of manual observation of 
scratching is that in real-time only 'bouts of scratching' can be identified (see chapter 
2.1 ). Without the use of slow motion videoing it is not possible visually to discern 
the individual number of scratch movements made by the animal. However, to watch 
each individual animal in slow motion over the course of the study would simply add 
to the labour intensity and lack of productivity. 
In order to reduce the labour intensity and increase efficiency it would be preferable 
to automate the detection of scratching in individual animals. Similar developments 
have been attempted in human studies. Detectors of limb movement have been 
placed on the arms and legs of pruritic patients that record the total movement of 
each limb over the course of a night (Summerfield & Welch, 1980). This system, 
although not a direct measure of scratching, provides an objective valuation of itch 
when compared to the level of movement in non-pruritic subjects. Two automated 
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detectors of scratching in mice have previously been described in the literature. The 
first system attached aluminium wire rings to the hind legs of mice and placed the 
animals in cages that were surrounded by ferrite rods and copper coils. Movement of 
the hind limb, and therefore the wire ring, evoked an electrical current in the rod and 
coil. This electrical current was computer analysed and electrical pattern similar in 
intensity to that of scratching could be identified (Elliott et al., 2000). A second 
system involved the insertion of small magnets into the hind paws of mice and the 
animals were placed in a cage surrounded by a coil. Again, the movement of the hind 
paw, and magnet, evoked an electrical current that was identified by computer to 
search for patterns related to that of scratching, based on the intensity and frequency 
of the movement (Inagaki et al., 2003). 
The purpose the present study was to develop and valjdate a relatively simple, 
inexpensive and non-invasive automated detector of scratching in mice based on the 
repetitive movements that occur as a mouse scratches the back of the neck using a 
hind paw. 
4.2 Materials and Methods 
Force Platform 
An inexpensive force platform was constructed using two parallel aluminium plates 
(20cm x 30cm) joined by plastic hinges at one end and separated at the other end by 
a force transducer (see Figure 4.1C). This simple design of force platform exhibits 
varying sensitivity to movement forces depending on distance of the animal from the 
hinge but in practice that has little effect, as the activities being monitored are 
restricted to a narrow area of the upper plate distal from the hinge. Other factors, 
such as the direction of the repetitive movement being monitored, also affect the 
forces measured by the platform. More complex designs of force platform were 
considered during the early stages of development. For example, using three force 
transducers it is possible to obtain an accurate measure of the vertical force and also 
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the position of the animal in the cage. In practice, the much simpler design described 
here provides appropriate data for use in the present studies. 
The transducer output is amplified by a bridge amplifier (see Figure 4.2). The offset 
and gain of this stage may be altered by front panel controls on the repetitive detector 
unit. The output of the bridge amplifier is filtered by a 20Hz gth order switched 
capacitor low pass filter. The buffered analogue output from these stages is available 
externally. 
Low weight compressed polystyrene cages were placed on top of the platform, held 
in place by small steel pins. The mouse cages were designed to be as low weight as 
possible in order for the movement signal generated by the mouse to be as large as 
possible, relative to the background signal evoked. 
For routine testing, a simple test 'mouse' phantom was constructed using a small 
electric motor with an eccentric weight of a few grams mounted on its shaft. The 
phantom was self-contained with its own battery and its speed could be adjusted to 
confirm the correct triggering of the repetitive event detector. 
Theory 
In designing the system we considered the forces that would be generated by a 
repetitive movement of a small mass such as the hind limb of a mouse. Consider a 
mass (m) of lg moving vertically sinusoidally with a frequency (f) of 12Hz and 
amplitude (D) of 5mm. 
Displacement x = D sin(2nft) where tis the elapsed time (sec) 
Acceleration a = - 4Dn2f sin(2nft) 
The corresponding force (F) measured by the force platform would be 
F=ma 
The amplitude ofthis force would be 
IFI = 4 rnD n2f = 4 X 10-3 X 5 X 10-3 X 144 X n2 = 28.4 mN = 2.9gf 
This would be observed as 5.8gfpeak to peak. 
If the sinusoidal movement was not vertical but at an angle of 8 to the vertical then 
the force exerted on the platform would be reduced by the factor cos(8). 
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8 c 
Figure 4.1 A: Overall view of apparatus showing the supporting 
framework (a) for the anti-vibration table (b), the four force platforms 
with animal boxes (b), the associated repetitive movement detector 
electronics (c) and the overhead video camera (d). 8 : Aerial view of the 
four force platforms with one animal box removed. Studies could be 
conducted on four mice simultaneously. C: Force platform with hinged 
plates separated to show the force transducer. 
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Repetitive Event Detector 
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Figure 4.2 Flow diagram illustrating the data collection system used in 
the automated scratch detector. 
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Repetitive Event Detector 
The filtered output signal from the force platform is also applied to two comparators 
(figure 4.2). One comparator was set at 8V volts above zero and the other at 8V volts 
below zero. 8V may be adjusted, by a front panel control, over the range of Om V to 
400mV. The comparator outputs are applied to a bistable logic circuit such that its 
output switches to a logic '1' when the signal exceeds the upper threshold and 
switches to a logic '0' when the signal goes below the lower threshold. The bistable 
output is applied to a data input of a PIC16F84 micro-controller. 
The micro-controller was programmed to identify periodic intervals in the bistable 
output signal that corresponded to repetitive frequencies in the range 8Hz to 20Hz. 
The program does not acknowledge a single acceptable interval but requires a 
minimum of two such intervals, after which it accumulates the intervals until two 
incorrect intervals are detected (the total number of acceptable intervals received 
relates directly to the number of scratch movements identified by the micro-
controller). The lowest acceptable frequency may be selected from either 8Hz, 9Hz, 
10Hz or 11Hz by a front panel control. This variation in the frequency filters allows 
us to identify movement of varying frequency of scratch movement, which may be 
seen between individual mice. To assist in the analysis, the repetitive count is fed 
through a 4 bit digital to analogue converter (DAC) the output of which was recorded 
with the filtered analogue data on a PowerLab system. The number of intervals 
detected is readily determined later by examining the staircase waveform from the 
DAC. An external white light, situated beside the cage, was provided for marking 
any detected events onto video recordings that were made of the studies, to assist in 
the locating of the scratching behaviour when observing the videotape at a later date. 
Anti-vibration Table 
The force platform proved to be extremely sensitive and it detected vibrations from 
the steel frame building in which it was used. In addition, vibration caused by staff 
moving around the laboratory, lifts and air conditioning systems also contributed 
considerable levels of unwanted 'noise' to the platform signal, confounding 
measurements. After some tests, an anti-vibration table was constructed. This 
consisted of a 20kg rectangular steel plate supported within a tubular steel frame by 
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steel springs at 45° to the horizontal, attached to each comer of the plate. The anti-
vibration table and springs had a natural undamped resonance of 1.5Hz and the table 
was large enough to hold four force platforms (Figures 4.1A and 4.1B). The 1.5Hz 
resonance was damped out by plastic foam placed between the platform and the 
laboratory bench. Great care was taken to prevent unwanted vibrations travelling up 
connecting cables. In practice, this anti-vibration table removed all significant 
unwanted vibrations. As a result, while a stationary mouse was being monitored, its 
ventilatory frequency could be clearly observed in the force platform signal (Figure 
4.4B). The whole system, set up for monitoring four individual cages, is shown in 
Figures 4.1A and 4.1B. 
Procedure 
Scratching was evoked using a range of known doses of pruritogens from previous 
studies; histamine (0.03-9.8JLmol), HTMT (0.16JLmol), imetit (3JLmol) or 
clobenpropit (0.002-2.l2JLmol), by injecting the drugs intra-dermally (i.d.) into the 
back of the neck via a 26G needle. All drugs were dissolved in PBS (pH 7 .4). 
Individual mice received up to four injections and scratching was recorded both 
manually and by the automated detector on each occasion, to enable correlation and 
validation of the automated system being developed. Mice were placed one of the 
lightweight cages for 10 minutes conditioning prior to experimentation. 
Scratching was recorded manually as described in chapter 2.1. In order to identify the 
individual number of scratch movements, mice were filmed for five-minute periods 
using a Sony digital video camera (model DCR-PClOOE), and observed under slow 
motion. 
Statistical Analysis 
All data was analysed using GraphPad Prism (v3 .02) software. Data are shown as a 
scatter plot and the goodness of fit is given as Pearson r-value. 
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4.3 Results 
Response of Force Platform 
In order to test that the force platfonn responded consistently in the frequency range 
we were interested in studying the frequency response of the force platfonn was 
examined by means of magnetic forces applied to a small pennanent magnet fixed to 
the top of the platfonn. Opposing this magnet and secured to the bench was a coil 
which was driven from a constant current sine wave source. This generated a force 
proportional to the instantaneous current and allowed the frequency characteristics of 
the force platform to be investigated. The magnet and coil were calibrated against a 
digital balance to establish the relationship between a steady DC coil current and the 
resulting force on the magnet. At 15Hz the maximum sensitivity ofthe platfonn was 
about 500mV/gfbut the system was normally used at a lower gain corresponding to 
about 150mV/gf. 
The normalised frequency response of the force platform is shown in Figure 4.3. The 
platfom1 responds consistently between the range of approximately 5 and 18Hz. Pilot 
studies had indicated that mice scratched at a frequency of 12 and 15Hz. Grooming 
behaviour, associated with the fore limbs generally occurs in the region of 8Hz. 
Although the platfonn responded in the frequency range related to scratchjng, to 
prevent the identification of grooming behaviour the repetitive event detector filters 
could be set at 8, 9, 10 or 11Hz (Low filter) to eliminate the grooming signal, with 
the upper filter limit being fixed at 20Hz. 
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Figure 4.3 Normalised frequency response of force platform showing 
consistent responses around the 11-15 Hz frequency range which is 
associated with scratch movements. The labelled bars indicate the 
range of frequencies associated with scratching and with grooming. 
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Automated Measurement of Itch 
Scratching was recorded as a Chart file (v4.22, ADinstruments); a sample trace is 
shown in figure 4.4A. The detector was set to record all repetitive activity of 
frequency greater than 11Hz (pilot studies had showed that below this level 
grooming behaviour was also recorded) and of amplitude greater than ±125mV. 
When such behaviour occurred, a staircase signal was produced, with each step in the 
output representing one scratch movement. This enabled us to measure both the 
'bouts' of scratching evoked (3 or more scratch movements in one staircase) together 
with the total number of scratch movements per bout. Pilot studies indicated that the 
average number of scratch movements per bout was 5± 1. At a frequency of 
approximately 12Hz, that indicated a bout of scratching lasts in the region of 0.4 
seconds. 
Correlation between 'bouts' of scratching detected manually and 
by automated system 
The correlation between the numbers of bouts of scratching induced by histamine 
receptor agonjsts, as measured manually and by the automated detection system, is 
shown in Figure 4.5. The correlation was 0.91 (95% CI 0.88 - 0.93; Pearson r), 
showing that the automated detector consistently identified 91% of the bouts of 
scratching. 
Correlation between total number of scratch movements detected 
manually and by automated system 
The correlation between the total numbers of individual scratch movements induced 
by histamine receptor agonists, as assessed manually and by the automated detection 
system, is shown in Figure 4.6. There was a close relationship between the 
automated and manual counts, the Pearson r-value being 0.95 (95% CI 0.91 - 0.97), 
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Figure 4.4 Sample trace from Macl ab for two of the detection units. A: 
Two traces from one detection unit: lower part of the recording is the 
raw signal from the movement detector during scratching and the upper 
staircase is the processed signal representing a cumulative record of 
individual scratch movements evoked by injection of histamine (3.3,umol 
i.d.). The number of scratches in each of the three bouts in the panel is 
shown by the three ramps in the upper trace of the figure representing 
5, 4 and 4 scratches consecutively. B: Output from a second detection 
unit following injection of 0.1 ml PBS: no activity was observed, either 
visually (from videotape) or in the output from the movement detector. 
Since the mouse did not move or scratch, there was no output from the 
scratch monitor channel (upper trace). The animal 's breathing was 
detected as oscillations in the detector trace (frequency 180 breaths per 
minute), illustrating the high sensitivity of the detector system. 
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Figure 4.5 Plot showing the relationship between the numbers of bouts 
of scratching as recorded manually and by the automated detection 
system. The graph consists of 241 recordings made from 155 individual 
mice. The dashed line illustrates the line of equality. 
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Figure 4.6 Graph showing relationship between the total number of 
scratch movements per bout as recorded manually from visual analysis 
during slow playback of videotaped recording, and by the automated 
detection system. The graph consists of 40 recordings made from 16 
individual mice. The dashed line illustrates the line of equality. 
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4.4 Discussion 
The frndings from the present study provide evidence that the amount of scratching 
in a mouse can be measured automatically, based on characteristic repetitive 
movement of the hind paw. The system also reliably measures the total number of 
individual scratch movements of the hind paw over a given period of time. 
Initial pilot studies using a simple strain gauge indicated that the pattern associated 
with scratching was distinct from general movement of the animal within the cage 
and also from other specific behaviours such as grooming. The pattern identified was 
the rhythmical beating activity seen during a bout of scratching, further investigation 
established the frequency of movement to be in the region of 12-15Hz. General 
movement created no regular frequency but there was a similar rhythmical pattern 
response to grooming behaviour. The majority of grooming behaviour could be 
eliminated using a filtering system as most grooming has a frequency lower than that 
of scratching at 8-1OHz. 
The development of an effective automated detector of scratching is of potentially 
great benefit to researchers in the field of itch. Previously, scratching in mice had 
been identified by labour intensive manual observation and counting, either at the 
time, or at a later date through the use of a video camera and recorder. This is time 
consuming and highly unproductive, as few animals can be studied at any one time, 
not to mention highly tedious. This system allows the study of a number of mice at 
any one time as the rate-limiting step (aside from the number of detection systems in 
place), is the speed at which the investigator can place mice in the cages. 
The final design of the detection system encompasses: a force platform that both 
holds the cage and encloses the strain gauge; a repetitive event detection unit 
containing the filtering system and a micro-controller to identify and record scratch 
movements; an anti-vibration table to remove unwanted background noise from the 
system and finally a PowerLab and PC to record and store the signals generated by 
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the system. The system currently consists of four force platforms and event detectors 
enabling the study of four mice at any one time. 
Objective indicators of scratching in humans have also been developed. These 
systems generally rely on gross movement of the limbs rather than specific detectors 
of scratching (Felix & Shuster, 1975; Summerfield & Welch, 1980). 
Two systems have previously been described in the literature to measure and record 
scratching in mice. Both systems use the repeated beating pattern of the hind limb as 
the indicator for scratching. The earlier system uses aluminium wire rings around the 
hind paw to elicit an electrical current in a ferrite rod and copper coil, surrounding 
the cage (Elliott et al., 2000). Movement of the hind paw during scratching was 
reported to evoke a characteristic pattern of electrical current. The frequency of the 
scratching peaked at 15Hz, a figure similar to that identified during the present 
studies. The detector of scratching developed by Elliott et al identifies 80-85% of the 
scratching observed manually. However, the detector developed in this study is non-
invasive to the mouse and does not require an aluminium ring around the hind limb, 
which would cause a loss of signal if the mouse managed to remove it. The most 
recently reported detector of scratching is very similar to that developed by Elliott et 
al. Again, the basis of the system relies on the generation of an electrical current 
identified by a metallic coil outside the cage, in this case the current is evoked by a 
magnet surgically inserted into the hind paw (Inagaki et al., 2003). As with the 
detector developed in this study and that by Elliott et al, the system described by 
lnagaki et al identifies scratching based on frequency. Inagaki et al record activity of 
a frequency of 5-20Hz and can identify 90-95% of the scratching observed manually. 
This high correlation rate is achieved due to the wide range of frequencies measured. 
As the system only records activity from the hind paw, there is no signal overlap 
with the grooming behaviour (which primarily occurs using the fore paws). The 
obvious drawback with the system developed by Inagaki et al, is that despite the high 
correlation rate, the mice require prior surgery to insert the magnet into the hind paw. 
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The advantage the system described in the present studies has over both those 
previously presented in the literature, aside from the non-invasive nature, is that this 
detector is not simply a detector of hind limb activity but is a detector of, potentially, 
all activity, with the added capability of filtering out all other non-scratching 
behaviour. Therefore, leaving the ability, if required, to look at more than purely 
scratching. 
The detection system enables users to learn more about the scratching behaviour of 
the mice than is possible from manual observation. As well as identifying bouts of 
scratching and the total number of scratch movements, the trace generated also gives 
an indication as to general activity, for example the trace can be analysed for the 
amount of time the mouse is active but not scratching. This may be of particular 
interest if drugs are being investigated with potential sedatory effects. 
It would be feasible using a system very similar to that described to identify other 
repetitive behaviours in mice (such as grooming), or to expand the system for use in 
other small animal studies for which repetitive movements are a characteristic. 
Studies in rats or guinea pigs would be possible, however, the current system is 
designed to maximise the response generated in a 20-30g animal. A larger strain 
gauge would be required and it would be assumed that the frequency of scratching in 
a larger animal would be reduced compared to that in a mouse; pilot studies to 
determine the exact frequency of the behaviour would establish this. 
The studies described in this section of the thesis have focused on the recording of 
acutely induced scratching. This system would be ideal for the recording of 
scratching in a chronically induced pruritic state. The labour intensity associated with 
manual observation of scratching over a longer period than 20 minutes would clearly 
be increased, whereas, this system could record scratching over periods of several 
hours/days. 
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In conclusion, the automated detector is a non-invasive and objective device for 
detecting scratching and could be used on a significantly larger scale in the study of 
pruritic and anti-pruritic drugs. 
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Chapter 5 
Histamine-mediated Scratching in Mice 
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5.1 Introduction 
Histamine is an endogenous amine, most commonly located in the brain, lungs, gut 
and skin of humans (Hill, 1990). Histamine is synthesised, stored and released 
peripherally from mast cells and to a lesser extent basophils. When released 
histamine acts on a family of receptors, known as histamine receptors. There are now 
recognised to be four histamine receptors; H~, H2, H3 and H4 (Leurs et al., 2001). 
Each receptor subtype consists of a seven transmembrane domain protein, which is 
coupled to a G-protein secondary messenger system. Activation of each receptor by 
histamine activates a separate G-protein, which in turn activates a secondary 
messenger and evokes an intracellular cascade reaction, eliciting a cellular response 
(for example, nerve cell depolarization). H1 receptor activation couples to a Gq 
protein that activates a secondary messenger known as phospho-inositol (PI). The 
other three histamine receptors all use cAMP as a secondary messenger, in the case 
of H2 receptors there is up-regulation of this messenger, in the case of H3 and H4 
receptors there is down-regulation (Haaksma eta/., 1990; Hill eta/., 1997). 
Histamine has long been recognised as a mediator of itch in humans (Lewis, 1927). 
Intradermal administration of histamine can elicit itch in doses as low as 0.7nmol 
(Hagennark, 1973). Although traditional H 1 receptor antagonists are effective at 
reducing histamine-induced itch (Hagermark et al., 1979) and are widely used 
clinically for treating pruritus (Greaves, 1997), they are not in fact effective 
antipnuitics in clinical conditions such as atopic eczema (Yosipovitch et al., 2003). It 
has been claimed that the effectiveness of H 1 receptor antagonists at relieving itch 
results from central sedation rather than peripheral actions on sensory nerves, in 
conditions where histamine is not seen as the primary mediator (Krause & Shuster, 
1983; Savin, 1980; Savin et al., 1986). Histamine H2 receptor antagonists are also 
used clinically for treating itch (Monroe et al., 1981; Ring & Thomas, 1989), but 
their ability to inhibit itching is not conclusive (Davies & Greaves, 1980; Hagermark 
et a!., 1979). Overall the evidence suggests that mechanisms other than those 
involving H 1/H2 receptors are involved in itch. 
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Until recently it was commonly believed that histamine-induced itch was well 
understood and that, although an important mediator in some conditions, histamine 
could not be responsible for all clinical pruritic states, due to the lack of effectiveness 
of H 1 and H2 receptor antagonists in treating these conditions. The discovery of two 
new histamine receptors has, however, opened up the possibility that histamine may 
be operating through a previously unidentified receptor mechanism, to evoke itch. 
Histamine could elicit itch through an action on either the H3 receptor or the R! 
receptor. The H3 receptor is localized to nervous tissue, mainly in the brain (Arrang 
et al., 1983; Haaksma et at., 1990; Levenberg et al., 1999). It has been postulated 
that there are several potential isoforms of the H3 receptor (Coge et al. , 2001), which 
are believed to respond differently to agonists and antagonists, thus making the 
characterization of these receptors very difficult. Mouse and rat H3 receptors have 
been identified, but, whether different isoforms exist in these species is at present 
unknown (Leurs et al., 2001; Levenberg et al., 2000). The most recently described 
histamine receptor is the H4 receptor (Liu et al., 2001a; Nakamura et al., 2000; 
Nguyen et al., 2001; Oda et al., 2000; Zhu et at., 2001). Unlike the H3 receptor, the 
H4 receptor has not been identified in the brain but appears to be associated with 
tissues involved in the immune response. The R! receptor is commonly localized to 
bone marrow and eosinophils/leukocytes (Liu et al., 2001a; Oda et al., 2000). The H4 
receptor has also been shown to play a role in mast cell chemotaxis, indicating its 
potential as a mediator of inflammatory and possibly pruritic responses (Hofstra et 
at., 2003; O'Reilly et al., 2002). 
In murine studies itch is estimated by measuring the scratching elicited by itch-
provoking agents (Kuraishi et al., 1995), as described in Chapter 3. Although some 
reports have questioned the potential role of histamine as a pruritogen in mice 
(Kuraishi et al., 1995), others have shown that histamine H1 antagonists are effective 
at reducing histamine-induced scratching in this species (Inagaki et al., 1999; 
Sugimoto et al., 1998). When examining histamine-mediated scratching in mice (and 
other animal models) it is necessary to be aware of both strain differences (Inagaki et 
al., 2001) and also possible species differences between humans and mice. 
Differences between strains of mice have previously been discussed in chapter 3, 
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however, species differences also exist. Recent evidence suggests that H4 receptors in 
different species have differing affinities for histamine; it is reported that histamine 
has an eight fold lower affinity for murine H4 receptors than for human or guinea pig 
~ receptors (Liu et al., 2001b). The H1 receptor has also been shown to have 
species-dependent differences; some agonists and antagonists have different 
affinities for human and guinea pig H1 receptors (Seifert et al., 2003). 
The use of receptor selective agonists and antagonists as tools for characterizing 
receptor mechanisms is useful, but can be flawed if incorrect assumptions are made 
about the activity of these drugs at different receptors. As has been described above, 
there appear to be several isoforms of the human H3 receptor, which respond 
differently to various agonists and antagonists (Coge et al., 2001). No evidence exists 
in mice to support this finding; however, until a complete characterization of these 
receptors and the drugs that act upon them has been established it is important not to 
misinterpret results. The action of drugs known to act at the well characterized H1 
and H2 receptors may also have actions at the newly discovered H3 and H4 receptors. 
For example the commonly used H 1 receptor antagonist, mepyramine, has the same 
affinity for the human H4 receptor as does histamine (Nguyen et al., 2001). 
This study was undertaken to investigate the role of H1, H2, H3 and H4 receptors in 
histamine-induced itch, primarily in BalbC mice, based on the quantification of 
acutely induced scratching. 
5.2 Materials & Methods 
Procedure 
Details on the induction of itch and the measurement of scratching are described in 
chapter 2.l .Experiments were conducted in a total of 265 female BalbC mice. 
In experiments involving antagonists, scratching was induced by a mid-range dose of 
histamine, which was repeated 30 and again 90 minutes after treatment with either an 
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H 1, H2 or H3/H4 antagonist (20mgkg-
1 i.p.). This dose of antagonist was selected on 
the basis of its effectiveness in reducing the scratching evoked by receptor selective 
H,, H2 or H3 agonists. 
The effect of antagonists on receptor-selective agonist-induced scratching were 
studied in separate groups of mice, as desensitization to the agonists precluded 
repeated dosing. The responses to agonist was recorded 30 minutes after antagonist 
treatment and compared to responses obtained from vehicle (PBS) treated mice. The 
dose of agonist was selected on the ability of that dose to elicit scratching in each 
mouse studied, with the aim of eliciting approximately 50% of the maximum 
scratching response. 
As described in Chapter 2.4 non-parametric statistical analyses were used. The mean 
'apparent' ED 50 was calculated from pooled data and was the dose required to elicit 
half the apparent maximal response. 
5.3 Results 
Histamine-induced scratching in BalbC mice 
Histamine caused dose-dependent scratching in all the BalbC mrce studied, as 
previously described in Chapter 3.3. Scratching was not evoked at lower doses 
(below 0.8J..lmol), but was consistently observed with higher doses, reaching a 
maximum at 26J..lmol histamine. Above this dose there was no further increase, and 
often a decrease, in scratching. Histamine-induced scratching reached a maximum of 
73±12 bouts (mean±sem, n=8), with a mean apparent ED50 of 5.8J..lmol. 
Scratching induced by phosphate buffered saline served as a control (5±1 bouts of 
scratching, n=12), as previously summarised in Chapter 3.3. 
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Itch inducing effects of an intradermally administered H1 receptor 
antagonist, mepyramine, in BalbC mice 
During pilot studies mepyramine was administered intradermally, to the area around 
the back of the neck. Mepyramine (0.1-lrngkg-1) did not reduce histamine evoked 
scratching: histamine (8!-lmol, i.d.) evoked 42±3 bouts of scratching (median=41, 
n=8); 30 minutes following mepyramine treatment (0.1mgkg-1, i.d.), histamine 
(8!-lmol, i.d.) evoked 49±8 bouts of scratching (median=52, n=6); 30 minutes 
following a higher dose of mepyramine (1mgkg"1, i.d.), histamine (8!-lmol, i.d.) 
evoked 55±6 bouts of scratching (rnedian=54, n=6). 
Higher doses of mepyramine, administered intradermally evoked a scratching 
response independent of histamine injection. Mepyramine (10mgkg"1 i.d.) induced 
35±11 bouts of scratching (n=4). Due to the unexpected itch inducing properties of 
mepyrarnine, future experiments. focused on the systemic administration of 
antagonists, which did ~ot themselves evoke a scratching response. 
Itch inducing effects of intradermally administered H2 and H314 
receptor antagonists in BalbC mice 
Unlike mepyramine, cimetidine (H2 receptor antagonist) and thioperamide (HJ and 
H4 receptor antagonist), were relatively ineffective at inducing scratching. 
Cimetidine (lOmgkg-1, i.d. n=ll) evoked 6±2 bouts of scratching (rnedian=4), 
whereas thioperarnide (1 Omgkg-1, i.d. n=6) evoked 14±5 bouts of scratching 
(median=12). Neither of these responses differs significantly from scratching evoked 
by PBS (P>0.05, Mann Whitney test). Despite these drugs not eliciting scratching 
when administered intradermally, further experiments using these compounds were 
conducted using systemic administration in order to allow direct comparison with 
studies using mepyramine, which did elicit a scratching response when administered 
intradermally (see above). 
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Role of histamine H1 receptors in histamine-induced scratching in 
BalbC mice 
The selective histamine H1 receptor agonist, HTMT, evoked dose dependent 
scratching in all six mice studied (Figure 5.1 A). Maximal scratching was 133± 17 
bouts, with a mean apparent ED 5o for HTMT of 0.1 J.lmol. 
Histamine-induced (8J.lmol, i.d.) scratching was significantly reduced following 
mepyramine (20mgkg-1, i.p. P<0.05, n=6, Figure 5.2Ai). PBS, used as a control for 
the antagonist, did not significantly reduce histamine-induced scratching (P>0.05, 
n=5, Figure 5.2Aii). 
HTMT-induced scratching (0.2).lmol, i.d.) was significantly reduced in mice pre-
treated with mepyramine (20mgkg-1, i.p.) in comparison with vehicle treated mice 
(P<0.05, Figure 5.2B). Lower doses of mepyramine (1-10mg/kg-1) did not 
significantly reduce HTMT -induced scratching. 
HTMT -induced scratching (0.2j.lmol, i.d.) was also significantly reduced by pre-
treatment with the non-sedating histamine H 1 receptor antagonist, terfenadine 
(20mgkg-1, i.p.) as compared with vehicle treated mice (P<0.05, Figure 5.2C). Lower 
doses of terfenadine (1-10mgkg-1) did not significantly reduce HTMT-induced 
scratching (P>0.05) but there was variabil ity with responses, and the trend indicated 
that the anti-scratch effect ofterfenadine was dose related. 
Role of histamine H2 receptors in histamine-induced scratching in 
BalbC mice 
Dimaprit, histamine H2 receptor agonist, did not induce dose dependent scratching in 
mice (0.04-40).lmol, i.d. n=3, Figure 5.1D). 
The H2 receptor antagonist cimetidine (20mgkg-1, i.p.) did not significantly reduce 
histamine-induced scratching (P>0.05, n=6, Figure 5.3). 
Role of histamine H3 receptors in histamine-induced scratching in 
BalbC mice 
Imetit, histamine H3 and H4 receptor agonist, induced dose-dependent scratching in 
all six mice studied (Figure 5.1 C). The maximal level of scratching was 69±23 bouts, 
with a mean apparent ED 5o for imetit of 0.9).lmol. 
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Figure 5.1 Pooled data illustrating scratching induced by (A) HTMT (H1 
receptor agonist, n=6), (B) clobenpropit (H4 agonist, n=1 0), (C) imetit 
(H3/H4 agonist, n=6) and (D) dimaprit (H2 agonist, n=3) in BalbC mice. 
HTMT, clobenpropit, and to a lesser extent imetit, caused dose related 
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Figure 5.2 (Ai) Mepyramine (20mgkg"1, i.p.) significantly reduced 
scratching induced by histamine (8pmol, i.d.) in female BalbC mice, 30 
minutes after treatment with the antagonist versus pre-treatment value 
(*P<0.05, Wilcoxon matched pairs test, n=6). (Aii) Saline vehicle did not 
significantly reduce scratching induced by histamine \P>0.05, Wilcoxon 
matched pairs test, n=5). (B) Mepyramine (20mgkg· , i.p.) pre-treated 
mice showed a significantly lower scratching response to HTMT 
(0.2pmol, i.d.) in comparison with vehicle treated animals (*P<0.05, 
Mann Whitney test, n=6 in each group). Mepyramine at lower doses 
(1 mgkg·\ 3mgkg·1 or 1 Omgkg-1) did not significantly reduce HTMT-
induced scratching (P>0.05, Mann Whitney test, n=6 in each group). 
(C) Terfenadine significantly reduced scratching induced by HTMT 
(0.2pmol, i.d.) in a dose dependent manner (terfenadine 20mgkg-1 
versus control, *P<0.05, Mann Whitney test, n=6 in each group). 
(Dashed line illustrates PBS induced scratching). 
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Figure 5.3 Cimetidine (20mgkg"1, i.p.) did not reduce histamine-induced 
scratching in BalbC mice (8J1mOI, i.d. P>0.05, W ilcoxon matched pairs 
test, n=6). (Dashed line illustrates PBS induced scratching). 
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Scratching induced by histamine (3J..Lmol, i.d.) was significantly reduced following 
treatment with the dual H3 and H4 receptor antagonist thioperamide (20mgkg·
1
, i.p. 
P<0.05, n=6, Figure 5.4Ai). PBS vehicle (i.p.) did not significantly reduce histamine-
induced scratching (P>0.05, n=6, Figure 5.4Aii). 
Imetit-induced scratching (3J,.Lmol, i.d.) was significantly reduced in mice pre-treated 
with thioperamide (20mgkg·1, i.p.) in comparison with vehicle treated animals 
(P<0.05, Figure 5.4B). Lower doses ofthioperamide (1-10mgkg"1) reduced the mean 
level of imetit-induced scratching, but due to variability in responses, the difference 
between means (versus PBS) was not statistically significant (P>0.05). 
Studies conducted using a different H3 receptor antagonist (RWJ-662733, RW 
Johnson), confirmed histamine evoked scratching was significantly reduced by an H3 
receptor antagonist. Histamine (8J..Lmol, i.d.) evoked of 33±2 bouts of scratching prior 
to antagonist treatment, this was reduced to 7±3 bouts 30 minutes following 
antagonist treatment (P<0.05, Paired t-test, n=4). 
Role of histamine H4 receptors in histamine-induced scratching in 
BalbC mice 
Clobenpropit, a histamine H4 receptor agonist and H3 receptor antagonist, induced 
dose-dependent scratching in all ten mice studied (Figure 5.1B). The maximal level 
of scratching was 144±20 bouts, with a mean apparent ED50 for clobenpropit of 
0.05J,.Lmol. 
Clobenpropit-induced scratching (0.06J,.Lmol, i.d.) was significantly lower in mice 
pre-treated with the highest two doses of thioperamide used (1 Omgkg"1 and 20mgkg· 
1
, i.p.) in comparison with vehicle treated mice (P<0.05, Figure 5.5). 
H1 versus H3/H4 receptor involvement in itch in BalbC mice 
Ht agonist, HTMT (0.2J,.Lmol, i.d.), induced scratching was not significantly reduced 
by the H3/H4 receptor antagonist, thioperamide (20mgkg"1, Figure 5.6A, P>0.05 
versus vehicle), whereas it was by the H 1 receptor antagonists, terfenadine and 
mepyramine (as described above). 
The H4 agonist, clobenpropit (0.06J,.Lmol, i.d.) induced scratching was not 
significantly reduced by mepyramine (sedatory), or terfenadine (non-sedatory), H1 
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receptor antagonists (20mgkg"1, Figure 5.6B, P>0.05 versus vehicle), whereas it was 
by the H3/H4 receptor antagonist thioperamide (see above). 
Effects of histamine receptor antagonism in other strains of mice 
The effects of mepyramine, H1 antagonist, and thioperamide, H3/H4 antagonist, on 
histamine-induced scratching were investigated in ICR and C57/Bl6 strains of mice. 
These strains, as previously described in chapter 3.3, are responsive to lower doses of 
histamine than the BalbC strain. Studies into the antagonistic effects of mepyramine 
and thioperan1ide in these strains did not provide clear evidence due to large 
variability in the responses to histamine. There was no particular dose of histamine 
that consistently evoked a scratching response, and repeated doses of histamine 
evoked largely variable responses. For this reason, studies into the anti-pruritic 
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Figure 5.4 (A) Thioperamide (20mgkg·1, i.p.) significantly reduced 
scratching induced by histamine in BalbC mice (3t~mol, *P<0.05, 
Wilcoxon matched pairs test, n=6). (Aii) Saline vehicle did not 
significantly reduce scratching induced by histamine (P>0.05, Wilcoxon 
matched pairs test, n=6). (B) Thioperamide (20mgkg·1, i.p.) pre-treated 
mice showed a significantly lower scratching response to imetit (3t~mol , 
i.d.) in comparison with vehicle treated animals (*P<0.05, Mann 
Whitney test, n=5 in each group). Thioperamide at lower doses 
(1 mgkg-1, 3mgkg·1 or 1 Omgkg-1) did not significantly reduce imetit-
induced scratching (P>0.05, Mann Whitney test, n=4 in each group). 
(Dashed line illustrates PBS induced scratching). 
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Figure 5.5 Thioperamide (20mgkg·1 and 1 Omgkg·\ i.p.) pre-treated 
BalbC mice showed a significantly lower scratching response to 
clobenpropit (0.06pmol, i.d) in comparison with vehicle treated animals 
(*P<0.05, Mann Whitney test, n=6 in each group). Thioperamide at 
lower doses (1 mgkg·1 or 3mgkg'1) did not significantly reduce imetit-
induced scratching (P>0.05, Mann Whitney test, n=6 in each group). 
(Dashed line illustrates PBS induced scratching). 
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Figure 5.6 (A) Thioperamide (20mgkg·1, i.p.) did not significantly reduce 
HTMT-induced scratching (0.2pmol, i.d.) in comparison with vehicle 
treated mice (P>0.05, Mann Whitney test, n=6 in each group), whereas 
the H1 antagonist, terfenadine (20mgkg·1, i.p.) reduced HTMT-induced 
scratching (*P<0.05, Mann Whitney test, n=6 in each group). (B) 
Mepyramine and terfenadine, sedatory and non-sedatory H1 receptor 
antagonists respectively (20mgkg·1, i.p.) did not significantly reduce 
clobenpropit induced scratching (0.06pmol, i.d.) in comparison to 
vehicle treated mice (P>0.05, Mann Whitney test, n=6 in each group), 
whereas the H3,4 antagonist, thioperamide (20mgkg·1, i.p.) did reduce 
clobenpropit-induced scratching (*P<0.05, Mann Whitney test, n=6 in 
each qroup). (Dashed line illustrates PBS induced scratchinq). 
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5.4 Discussion 
Results from studies in this section of the project provide evidence for the 
involvement of histamine H4 receptors in the scratching (itch) evoked by histamine, 
in mice. The lack of effectiveness of classical H 1-receptor antihistamines in 
alleviating many chronic pruritic conditions (Greaves, 1997) led to the focus of 
research for anti-pruritic drugs being shifted from histamine to other putative 
mediators. This study suggests that histamine can generate itching in BalbC mice via 
the recently discovered & and (possibly) H3 receptors. 
It was confirmed that acutely administered histamine induces dose-dependent 
scratching when injected intradermally in BalbC mice (Inagaki et al., 2001), as it 
does in humans (Keele & Armstrong, 1964). It has previously been shown in mice 
that the dose of histamine required to induce scratching in this species is substantially 
higher (approximately 100 times) than that which evokes itch in humans (Inagaki et 
al., 2001; Kuraishi eta/., 1995; Maekawa et al., 2000). This may reflect differences 
in the sensitivity of histamine receptors to agonists, in mice and man; such evidence 
has been shown to exist between human and guinea pig Ht receptors (Liu et al. , 
2001b) and also between H4 receptors of humans and mice (Seifert eta/., 2003). But 
also illustrates that comparisons of findings made in mouse and man need to be 
interpreted cautiously. 
Early pilot studies provided an unanticipated problem with the peripherally 
administered H 1 receptor antagonist, mepyramine. The antagonist itself was capable 
of evoking scratching when injected i.d., and although the other antagonists used did 
not evoke scratching it was decided to administer antagonists systemically in all 
cases to avoid further similar complications. A suggestion as to why this scratching 
response to mepyramine may have occurred is described below. 
The Ht antagonist, mepyramine reduced histamine-induced scratching, as previously 
established in mice (Sugimoto et al., 1998) and humans (Hagermark et a/., 1979). 
Some authors have suggested this may, at least in part, be due to the sedating 
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properties of H 1 antagonists rather than any peripheral action at pruritoceptors 
(Krause & Shuster, 1983). We have shown that injection of the histamine H, receptor 
agonist HTMT induces acute scratching in mice, strongly suggesting the involvement 
of peripheral H 1 receptors in itch. This action of HTMT was shown to be mediated 
via H 1 receptors because mepyramine reduced agonist-induced scratching. 
Mepyramine is a traditional H1 receptor antihistamine, with an affinity 1000 times 
greater at the H 1 receptor than at the H2 or H3 receptor, see below for actions of 
mepyramine at H4 receptor, however, mepyramine also has central sedating actions 
(Rang et al., 1996). In order to prove the role of an H1 mechanism we used a second 
H1 receptor antagonist, which lacked central actions. This study showed that the non-
sedating H1 receptor antagonist, terfenadine, significantly reduced HTMT-induced 
scratching, thus proving that a sedatory effect is not the sole action of H, receptor 
antihistamines. 
This study has found no evidence for involvement of H2 receptors in the scratching 
evoked by histamine in mice. The H2 receptor agonist, dimaprit, did not evoke 
scratching, and the H2 receptor antagonist, cimetidine, had no significant effect on 
histamine-induced scratching. This finding is consistent with evidence in the 
literature: although a combination of H 1 and H2 receptor antagonists is sometimes 
used clinically for treating itch (Drake et al., 1994; Ring et al., 1999), H2 receptors 
are not thought to be crucial in histamine-evoked itch (Davies & Greaves, 1980; 
Hagermark et at., 1979). 
The discovery ofhistamine H3 (Levenberg et al., 1999) and, more recently, H4 (Oda 
et al., 2000) receptors, has implications for the involvement of histamine as a 
mediator of itch (Repka-Ramirez, 2003). The tissue distribution of both receptors 
indicates a potential role for them in the periphery: the H3 receptor affects histamine-
mediated axonal transport in mouse dorsal root ganglia (Amano et al., 2001) and is 
localized to nervous tissue (Levenberg et a!., 1999), whereas the H4 receptor is 
associated with immune responses, is preferentially expressed on leukocytes (Oda et 
al., 2000), and plays a role in mast cell chemotaxis (Hofstra et al., 2003). The present 
study found that the dual H3 and H4 receptor antagonist thioperamide (greater than 
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1000 times more selective for the H3 and H4 receptors than H1 or H2 receptors) 
significantly reduced histamine-induced scratching in mice. A second H3 receptor 
antagonist, RWJ-662733 from RW Johnson, also reduced histamine evoked 
scratching, although this cannot discount any action this compound may also have on 
H4 receptors. The H3 and ~ receptor agonist, imetit, evoked scratching that was 
reduced by thioperarnide. In order to try and differentiate histamine H3 from H4 
mechanisms the compound clobenpropit was used, which is an H3 antagonist, but an 
H4 agonist (Oda et al., 2000). Clobenpropit induced dose-dependent scratching in 
mice, which was antagonised by thioperamide. This finding implicates a peripheral 
H4 receptor in scratching induced by intradermal histamine. 
It can be concluded that distinct H 1 and H4 receptor mechanisms are responsible for 
itching evoked by exogenous histamine, and this is supported by the data that shows 
H1-agonist induced scratching was not significantly reduced by the H3/H4 antagonist. 
Also, scratching evoked by an H4 agonist was not significantly reduced by either the 
sedatory or non-sedatory H1 receptor antagonists. 
Although this data strongly suggests a role for H1 and H4 receptors in histamine 
mediated scratching, it is not possible to determine whether H3 receptors play a role. 
The difficulty is that imetit, thioperamide and clobenpropit act at multiple histamine 
receptor subtypes. The H3/~ receptor agonist imetit induced less scratching than the 
Ht and H4 agonists, which could be because imetit has a low affinity for the murine 
H4 receptor, or it may be due to a combination of H3 and H4 actions. It has recently 
been reported that mepyramine binds to the ~ receptor with a similar affinity to 
histamine; this may explain why H1 anti-histamines relieve some clinical itch 
conditions, even if H 1 receptors are not involved (Nguyen et al., 2001 ). This may 
also explain the possible itch evoking properties of intradermally administered 
mepyramine, as described earlier. Further studies using drugs with greater selectivity 
for histamine receptor subtypes, particularly selective H4 receptor agonists and 
antagonists, are required to distinguish between an H3 and/or an H4 mechanism, but 
based on the use of currently available drugs, it is possible to conclude that H4 as 
well as H1 receptors contribute to itch evoked by histamine in BalbC mice. Based on 
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the tissue distribution of histamine H4 receptors in immune response tissue (Liu et 
a/., 2001a; Oda et al., 2000) it is realistic to propose that H4 mediated itch may be 
elicited through a pathway involving eosinophil infiltration to inflamed or damaged 
areas of skin. Further research would be rewiured to determine whether there is a 
scientific basis to this suggestion. 
Pilot studies into the mechanism of action of histamine-evoked scratching in ICR and 
C57/Bl6 mice proved inconclusive. These strains are more sensitive to histamine, as 
described in chapter 3, by approximately 30 times. This sensitivity lead to very 
variable responses, unlike those seen in the BalbC strain. This variability of 
responses meant that we were unable to produce clear evidence concerning the 
effects of agonists and antagonists selective for the different types of histamine 
receptor. It would be fascinating to determine whether this increased sensitivity to 
histamine is due to different receptor subtypes being present, different isoforms 
being expressed that respond to drugs in a distinct manner or simply that different 
behavioural responses to drugs are evoked between strains. Establishing a greater 
understanding of the reasons for the differences in histamine response between 
strains may also provide us with clues as to differences in histamin.e responses 
between humans and mice. 
This evidence is unable to provide defmitive evidence as to whether the responses to 
histamine that was being studied result from direct actions on pruritoceptors (the 
most likely explanation), or indirect actions via mast cells, basophils etc (Poli eta/., 
1994; Ring & Thomas, 1989). Nevertheless, the results from these functional studies 
provide sufficient evidence to warrant further investigation on the involvement of H4 
receptors in the physiology and pathophysiology of itch in both mouse and man, and 
may be sufficient to target H4 receptor antagonists for developing specific anti-itch 
drugs. 
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Alternative Mediators of Scratching in mice 
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6. 1 Introduction 
Despite the role of histamine as a mediator of itch, as described in chapter 5, it is by 
no means the only itch inducing substance that requires investigation. Histamine was 
presumed to be the most significant mediator of itch in clinical human conditions 
since its discovery as a provoker of pruritus (Lewis, 1927). Two main pieces of 
evidence exist that support a role for other mediators of the sensation, aside from 
histamine. The first evidence indicating that histamine is not the only mediator of 
itch comes from the ineffectiveness of traditional histamine H, receptor 
antihistamines at relieving itch in a number of clinical conditions such as atopic 
eczema (Yosipovitch et al., 2003). Clearly, if histamine were responsible for the itch 
associated with such conditions we would expect such drugs to alleviate the itch of 
all clinically pruritic states. Secondly, experimentally induced itch, using histamine, 
indicates that responses to histamine are reduced after repeated application, 
tachyphylaxis (Stahle-Backdahl et al., 1988). If histamine alone were to mediate 
clinical itch, we would expect a gradual loss of sensation in chronic itch conditions, 
due to desensitization. This evidence suggests that the search for new, putative 
mediators of itch must be continued in order to establish a greater understanding of 
how clinical pruritic conditions may be treated. 
A general overview of many of the possible mediators of itch, as previously 
described in the literature, was given in Chapter 1.3. The studies presented in this 
chapter were focused on a few of the potential receptor targets that may be associated 
with evoking itch. Many more potential receptor targets have been, and will be in the 
future, identified, and the current study must be seen as a work in progress, in which 
there are many more possibilities to investigate. 
5-HT 
5-HT was identified as a compound capable of inducing itch in humans (Fjellner & 
Hagermark, 1979). However, the sensation generated was described as being less 
intense than that evoked by histamine. For this reason, studies into the itch-inducing 
properties of 5-HT were relatively ignored until the 1990's. 5,HT-induced itch is of a 
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greater intensity when the amine is co-injected with PGE2, as is also the case with 
histamine (Fjellner & Hagermark, 1979). Another similarity with histamine-induced 
itch is that the response is mast cell-dependent (Weisshaar et al., 1999). However, 5-
HT was taken more seriously in its own right as a mediator of itch following 
evidence showing that the 5-HT3 receptor antagonist, ondansetron, is effective at 
relieving the itch associated with cholestasis (Schworer & Ramadori, 1993), and also 
the itch induced by spinally administered opioids during epidurals (Borgeat & 
Stirnemann, 1999; Kyriakides et a!., 1999). 5-HT3 receptor antagonists were also 
shown to reduce the itch induced by experimentally administered 5-HT (Weisshaar et 
a!., 1997). 
Unlike histamine, 5-HT is not stored in human mast cells, but is released from 
platelets during platelet aggregation. However, rodent mast cells do contain 5-HT 
(Hagermark, 1992). Intradermal administration of 5-HT was shown to evoke 
scratching in mice (Andoh & Kuraishi, 2000; Inagaki eta!., 2001) and rats (Thomsen 
et al., 2001). Studies so far suggest that 5-HT induced scratching in mice is 5-HT2 
and not 5-HT3 receptor mediated, in contrast with the situation in man (Nojima & 
Carstens, 2003; Yamaguchi et al., 1999). 
SubstanceP 
Substance P is a neuropeptide synthesized and released from afferent nerves, which 
acts as a neuromodulator on mast cells (Hokfe)t et a!., 1980). Administration of 
substance P into the skin of healthy human subjects elicits the sensation of itch 
(Fjellner & Hagerrnark, 1981; Hagermark eta!., 1978), which acts though the release 
of histamine from mast cells (Ebertz eta!., 1987; Jorizzo eta!., 1983). In studies on 
mice, substance P has also been shown to induce dose related scratching (Kuraishi et 
al., 1995). However, it has been proposed that unlike in man, this action is not mast 
cell mediated but is possibly dependent on NK 1 receptors located on the peripheral 
nerves (Andoh & Kuraishi, 1998). To date, no clinical evidence exists to support the 
suggestion that NK 1 receptors are associated with the sensation of itch. 
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PAR-2 
The first work using proteases as pruritogens was performed using spicules of the 
plant cowhage, Mucuna pruriens, inserted into the dermis of man. It was proposed 
that the active ingredient was the enzyme, mucunain. This enzyme is denatured and 
the itch inducing properties lost, after boiling the spicules (Shelley & Arthur, 1955). 
The mechanism whereby proteases induce itch is still not clear. Trypsin and chymase 
elicit itch in man that is alleviated by histamine HI receptor antagonists and is 
presumed to be mast cell dependent (Hagermark et al., 1972). Two other endogenous 
proteases, papain and kallikrein, evoke itch that is not effectively reduced by HI 
receptor antagonists (Hagem1ark, 1974). 
Recent evidence provides a new possibility for the mechanism of action of pruritic 
proteases, as they have been shown to act directly on receptors, known as protease 
activated receptors (PARs). There are currently four recognised receptors, PAR-1, 
PAR-2, PAR-3 and PAR-4 (Macfarlane et al., 2001; Vergnolle et al., 2001a). These 
receptors have so far been associated with inflammatory responses; however, the 
P AR-2 has also been implicated in mediating the sensation of itch (Steinhoff et al., 
2003). The receptor is located on peripheral C-:fibre nerves and is activated by 
trypsin released from mast cells (Steinhoff et al., 2000). PAR-2 may present a novel 
mechanism by which the sensation of itch is detected by cutaneous nerves. 
Compound 48180 
Compound 48/80 is a compound that causes mast cell degranulation and subsequent 
itch in man (Fjellner & Hagermark, 1981) and mice (Kuraishi et al., 1995). The itch 
is a result of histamine release and is blocked by histamine HI receptor antagonists 
(Sugimoto et al., 1998). Compound 48/80 is a useful experimental tool used to 
determine whether a proposed itch-inducing protocol involves the mast cell and 
subsequent release of histamine pathway, or is histamine independent. By 
administering compound 48/80 to degranulate mast cells, any itching induced by 
drugs is assumed to be independent of mast cells or histamine (Andoh et al., 1998; 
Rukwied et al., 2000). 
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The experiments m this chapter were designed to confirm the scratch evoking 
properties of putative itch inducing drugs in mice, and to attempt to elucidate novel 
mechanisms of action. The studies were also designed to establish whether the 
scratch-inducing protocols, developed for use in the histamine-mediated model, 
described in chapters 3 and 5, are also suitable for studying other pruritogenic drugs. 
6.2 Materials and Methods 
The procedure for inducing itch and measurement of scratching as used in this 
chapter is as previously described in chapter 2.1, unless otherwise stated. 
Experiments in this chapter were conducted in 124 female BalbC mice, 10 female 
ICR mice and 12 female C57 /Bl6 mice. 
6.3 Results 
5-HT induced scratching in BalbC mice 
5-HT evoked scratching that was dose-dependent m all six female BalbC miCe 
studied when administered intradermally, as summarised in figure 6.1A. Scratching 
was not observed at doses below 3nmol, but was consistently observed with higher 
doses, reaching a maximum at 80nmol 5-HT. Above this dose there was no further 
increase, and often a decrease, in scratching. 5-HT-induced scratching reached a 
maximum response of 113±13 bouts (mean±sem), with a mean apparent ED50 of 
11 nmol. 
Strain differences to 5-HT induced scratching 
5-HT also evoked dose-dependent scratching in both female C57 /B16 and ICR strains 
ofmice. 5-HT evoked scratching in all six C57/Bl6 mice, with a mean apparent ED50 
to 5-HT of 4nmol (see figure 6.1B). The maximum scratching response evoked was 
142±30 bouts (mean±sem). 
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5-HT evoked scratching in all ten female ICR mice, with a mean apparent EDso to 5-
HT of 8nmol (see figure 6.IC). Maximum scratching response evoked was 93±10 
bouts (mean±sem). 
The three strains of mice showed no significant difference in mean apparent ED so to 
5-HT (P>0.05, Kruskal-Wallis test with Dunn's multiple comparison post-test). The 
mean maximal scratching responses evoked by 5-HT also showed no statistically 
significant difference between strains (P>0.05, Kruskal-Wallis test with Dunn's 
multiple comparison post test), however, the trend suggests that the C57/Bl6 mice 
scratch to a greater degree than either of the other two strains in response to 5-HT. 
Mechanism of 5-HT induced scratching in BalbC mice 
5-HT2 receptor subtype 
5-HT induced (8nmol, i.d.) scratching was significantly reduced 30 minutes 
following cinanserin hydrochloride (5-HT2 receptor antagonist, 5mgkg"
1
, i.p. P<0.05, 
repeated measures ANOV A, n=4, figure 6.2A). 5-HT induced scratching returned to 
pre-treatment levels 90 minutes following antagonist. The same procedure repeated 
in the same mice, one hour later, provided the same result, with a reduction in 
scratching after 30, but not 90 minutes post-antagonist (P<0.05, repeated measures 
ANOVA). 
5-HT induced (8nmol, i.d.) scratching was not reduced in mice treated with vehicle 
for the antagonist (distilled water, i.p. P>0.05, repeated measures ANOVA, n=4, see 
figure 6.2B). 
5-HT3 receptor subtype 
5-HT induced (8runol, i.d.) scratching was not significantly reduced 30 minutes 
following 3,tropanyllndole 3,carboxylate methiodide (a 5-HT3 receptor antagonist, 
5mgkg·1, i.p.). The same procedure repeated on two more occasions did not reduce 5-
HT evoked scratching responses (P>0.05, repeated measures ANOVA, n=4, see 
figure 6.3A). The vehicle used for the antagonist did not reduce 5-HT induced 
scratching (P>0.05, repeated measures ANOV A, n=4, see figure 6.3B). 
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Figure 6.1 5-HT induced dose-dependent scratching in female mice: A: 
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Figure 6.2 A: Pre-treatment with Cinanserin hydrochloride (5HT 2 
antagonist, 5mgkg-1, i.p) significantly reduced 5-HT (8nmol, i.d., 30m ins 
post antagonist) induced scratching compared with pre-treatment 
scratching response (*P<0.05, repeated measures AN OVA, n=4 ). 
90mins post antagonist responses returned to pre-treatment levels. A 
second dose of antagonist gave the same result when repeated in the 
same group of mice. B: 5HT induced scratching was not significantly 








01 .. e 
.E ~ 41 125 
.c: Q. ell 
.; ell t! 100 
~ ·~ i 
75 
_o_ 
0 N C 
ll ~ :B 50 s·§ ~ 
m -o :if 25 
0 
Chapter 6: Alternative mediators of scratching in mice 





I +30mins I 
t 
vehicle 













(5n'gt<g'', l p.) 
I +30mins I 
vehicle 
I +90minsl 
I +90mins l 
Figure 6.3 A: Pre-treatment with 3,tropanylindole 3,carboxylate 
methiodide (5HT 3 antagonist, 5mgkg-1, i.p) did not significantly reduced 
5-HT (8nmol, i.d.) induced scratching compared with pre-treatment 
scratching response (P>0.05, repeated measures AN OVA, n=4 ), after 
either of 3 separate antagonist injections. 8: 5HT induced scratching 
was also not significantly reduced in mice receiving vehicle for the 
antagonist (P>0.05, repeated measures ANOVA, n=4). 
104 
Chapter 6: Alternative mediators of scratching in mice 
Substance P induced scratching 
Substance P evoked scratching at all doses tested (0.7-70nmol) in female BalbC mice 
that was significantly greater than that induced by vehicle (PBS, P<0.05, Mann 
Whitney test, n=4, see figure 6.4A). The scratching was not dose-dependent 
following the doses used (maximum dose used was dependent on the solubility of the 
compound). The maximum scratching observed was 40± 18 bouts (mean±sem, 
20nmol, median=26.5) following Substance P. 
Substance P also evoked scratching, significantly greater than that induced by PBS, 
over the· same dose range in female C57/Bl6 mice (P<0.05, Mann Whitney test, n=6, 
see figure 6.4B). The trend In C57 /Bl6 suggests that the response may be dose 
related, but the evidence from these experiments was inconclusive. The maximum 
scratching response in C57/B16 mice was 51±24 bouts (mean±sem, 70nmol, 
median=32.5), indicating no significant difference from the maximal scratching 
response observed in BalbC mice (P>0.05, Mann Whitney test). 
Role of PAR-2 agonists in the induction of scratching in BalbC 
mice 
Trypsin-induced scratching 
Trypsin (1 Oj.tg-1 Omg, i.d.) induced dose-dependent scratching, in all six female 
BalbC mice studied, as shown in figure 6.5. Trypsin-induced scratching reached a 
maximum of75±6 bouts (mean±sem, n=6) with a mean apparent ED5o of3.3mg. The 
mean maximum scratching response to trypsin was not significantly different to that 
observed for histamine as previously described in Chapter 3.3 (73±12 bouts, n=6, 
P>0.05, Mann Whitney test). 
Trypsin (3mg, i.d.) induced scratching was not significantly lower in rruce pre-
treated with the histamine H 1 receptor antagonist, mepyrarnine (63±13 bouts, 
20mgkg-1, i.p., median=60), versus vehicle treated mice (54±21 bouts, median=42, 
P>0.05, Mann Whitney test, n=4 in each group). 
Trypsin (3mg, i.d.) induced scratching was also not significantly different in mice 
pre-treated with the histamine H 314 receptor antagonist, thioperamide (92±20 bouts, 
20mgkg-1, i.p. , median=82.5), versus vehicle treated mice (54±21 bouts, median=42, 
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Figure 6.4 Scratching induced by Substance P in female mice: A: 
BalbC strain (n=4) and B: C57/BI6 strain (n=6). In both strains 
substance P induced scratching that was significantly greater than that 
evoked by PBS (dashed line, P<0.05, Mann Whitney test). Scratching 
was not dose dependent. 
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Figure 6.5 Scratching induced by trypsin in female BalbC mice (n=6). 
Scratching responses were dose dependent. 
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Papain-induced scratching 
Papain (30J,Lg-3mg, i.d.) induced dose dependent scratching, in all four female BalbC 
mice studied. Papain-induced scratching reached a maximum of 85±15 bouts 
(mean±sem, n=4) with a mean apparent ED5o of 1.9mg. The maximum scratching in 
response to papain was not significantly different from that observed for histamine, 
as previously described in Chapter 3.3 (73± 12 bouts, n=6, P>0.05, Mann Whitney 
test), as was the case for trypsin, described above. 
Papain (0.3mg, i.d.) induced scratching was not significantly different in mice pre-
treated with the histamine H1 receptor antagonist, mepyramine (40±7 bouts, 
median=41, 20mgkg1, i.p.), in comparison with vehicle treated mice (55±8 bouts, 
median=58.5, P>0.05, Mann Whitney test, n=4 in each group, figure 6.6A). 
Thioperamide (20mgkg"1, i.p. histamine H314 receptor antagonist) pre-treated mice 
had a significantly reduced scratching response to papain (0.3mg, i.d.) compared to 
vehicle treated mice, 13±4 versus 52±6 bouts, median=13 versus 52 (mean±sem, 
P<0.05, Mann Whitney test, n=6 in each group, figure 6.6B). 
SLIGRL-induced scratching 
SLIGRL (PAR-2 agonist, 0.01J,Lg-3J.Lg, i.d.) induced dose dependent scratching in all 
four female BalbC mice studied. SLIGRL-induced scratching reached a maximum of 
31±3 bouts (mean±sem, n=4) with a mean apparent ED50 of 0.09J,Lg. The mean 
maximum scratching response to SLIGRL was significantly less than that observed 
for histamine, as previously described in Chapter 3.3 (73±12 bouts, n=6, P<0.05, 
Mann Whitney test). 
Mepyramine (20mgkg·1, i.p.) pre-treated mtce showed a significantly lower 
scratching response to SLIGRL (lJ.Lg, i.d.) in comparison with vehicle treated mice, 
15±5 versus 37±4 bouts, medians=lO versus 33.5 (mean±sem, P<0.05, Mann 
Whitney test, n=8 in each group, figure 6. 7 A). 
Thioperamide (20mgkg"1, i.p.) pre-treated mice also had a significantly reduced 
scratching response to SLIGRL ( l J.Lg, i.d.) compared to vehicle treated mice, 3±1 
versus 36±8 bouts, medians=2 versus 29.5(mean±sem, P<0.05, Mann Whitney test, 
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I 
post vehicle post mepyramine 
Papain (0.3mg, i.d.) 
* 
post vehicle post thioperamide 
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Figure 6.6 A: Pre-treatment with mepyramine (20mgkg-1, i.p.) did not 
significantly reduce papain (0.3mg, i.d.) induced scratching compared 
with vehicle pre-treated mice (P>0.05, Mann Whitney test, n=4 in each 
group). B: Thioperamide (20mgkg-1, i.p.) pre-treatment significantly 
reduced papain (0.3mg, i.d.) induced scratching compared with vehicle 
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* 
post vehicle post mepyramine 
SLIGRL (1 ~ g , i.d.) 
* 
I 
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SLIGRL (1 ~ g, i.d.) 
Figure 6.7 A: Mepyramine (20mgkg-1, i.p.) pre-treatment significantly 
reduced SLIGRL (PAR-2 agonist, 1,ug, i.d.) induced scratching 
compared with vehicle pre-treated mice (*P<0.05, Mann Whitney test, 
n=8 in each group). B: Thioperamide (20mgkg-1, i.p.) pre-treatment 
significantly reduced SLIGRL (1,ug, i.d.) induced scratching compared 
with vehicle pre-treated mice (*P<0.05, Mann Whitney test, n=4 in each 
group). 
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Compound 48/80 induced scratching in BalbC mice 
Compound 48/80 evoked scratching that was dose-dependent in all four female 
BalbC mice studied, when administered intradermally, as summarised in figure 6.8. 
Scratching in response to compound 48/80 reached a maximum of 180± 16 bouts 
(mean±sem, n=4), with a mean apparent ED50 of 1lp.g. The maximum scratching 
response to compound 48/80 was significantly greater than that evoked by histamine 
(73±12 bouts, P<O.OS, Mann Whitney test). 
A repeat dose of compound 48/80 (300p.g, i.d.), one hour after the initial dose, 
significantly reduced the level of scratching observed, from 180± 16 to 27± 12 
(P<O.OS, Mann Whitney test, n=4, medians=180.5 and 22.5 respectively). This 
suggests that 300p.g of compound 48/80 is sufficient to cause a loss a scratching 
response, probably as a consequence of mast cell degranulation. 
Compound 48/80 (300p.g, i.d.) pre-treatment caused a significant reduction in 
SLIGRL (lp.g, i.d.) induced scratching when compared to vehicle treated mice, as 
shown in figure 6.9. Pre-treatment with compound 48/80 (300p.g, i.d.) also caused a 
significant reduction in histamine (3p.mol, i.d.) induced scratching when compared to 
vehicle treated mice, 13±3 versus 47± 14 bouts, medians=l2 versus 38 (P<O.OS, 
Mann Whitney test, n=4 in each group). 
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Figure 6.8 Compound 48/80 induced scratching in female BalbC mice 
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* 
post vehicle post compound 48/80 
SLIGRL (1 ~-tg, i.d.) 
Figure 6.9 Pre-treatment with compound 48/80 (300pg, i.d.) 
significantly reduced SLIGRL (1pg, i.d.) induced scratching compared 
with vehicle pre-treated mice (*P<0.05, Mann Whitney test, n=8 in each 
group). 
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6.4 Discussion 
The results from the studies in this chapter confirm that substances other than 
histamine cause scratching in mice. The evidence also suggests that the model of 
scratching developed in chapters 3 and 5 is suitable for use with pruritogenic drugs, 
in addition to histamine. 
5-HT 
The results showed that 5-HT induced dose-dependent scratching in female BalbC 
mice. The doses used in this study were similar to that used in previous studies both 
in man (Fjellner & Hagermark, 1979) and mice (Inagaki eta!., 2001). This suggests 
that 5-HT is a pruritogen in both species, with little species difference, unlike the 
differences in histamine response described in Chapter 3. The results also indicate 
that there is no strain dependent difference between 5-HT induced scratching. The 
difference in mean apparent ED50s to 5-HT between the three strains used was 2-3 
fold. This contrasts with the 30-fold difference in mean apparent EDsos to histamine, 
which illustrated a difference in scratching between strains (as described in chapter 
3). This evidence implies that the 5-HT induced mechanism of scratching is 
consistent between strains, something that may not necessarily be the case with 
respect to histamine-induced scratching. 
Evidence for the ·involvement of 5-HT as a mediator of itch in clinical conditions 
came form the antipruritic effect of ondansetron, a 5-HT 3 receptor antagonist, in itch 
associated with cholestasis (Schworer & Ramadori, 1993) and also the itch induced 
by spinally administered opiates during epidural (Borgeat & Stirnemann, 1999; 
Kyriakides et al., 1999). The results of this study do not support the findings from 
clinical human studies; there was no evidence of 5-HT3 receptors being involved in 
5-HT induced scratching. The results of these studies do, h_owever, support the 
findings from previous murine studies that suggest a role for 5-HT2 receptors in the 
scratching evoked by 5-HT (Nojima & Carstens, 2003; Yamaguchi et a!. , 1999). 
Although these findings suggest a species difference between human and murine 
models of 5-HT induced scratching, much more work in the future will be required to 
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clarify whether any other 5-HT receptor subtypes are involved in the induction of 
scratching by 5-HT. The role of 5-HT in clinical itch may then become clearer. 
Substance P 
Substance P is the most widely investigated neuropeptide with respect to itch. The 
findings from the present study did not support the evidence previously presented in 
the literature. Dose-dependent scratching was not evoked in BalbC or C57/Bl6 mice 
at the doses used (maximum dose was dependent on the solubility of the drug). This 
contradicts the previous evidence in mice, in which substance P elicits dose related 
scratching responses, in doses similar to those used in this study (Kuraishi et al., 
1995). Although the present study failed to clearly elicit dose dependent scratching, 
the scratching that was evoked was of a level significantly greater than that induced 
by control. One possible explanation of the current findings would be that the itch is 
evoked via release of a secondary compound, most likely histamine from mast cells. 
This would support findings from human studies that substance P acts through mast 
cell degranulation (Ebertz et al., 1987; Jorizzo eta!., 1983), and may explain an 'on 
or off' response, depending on whether the dose of substance P was sufficient to 
result in mast cell degranulation. 
PAR-2 
Protease-activated receptors are a group of 4 receptor subtypes that operate due to the 
cleaving effect of the protease on the N-terminus of the receptor protein, this action 
'unteathers' the protein, which acts via a G-protein coupled mechanism (Vergnolle et 
al., 2001b). One of these receptors, PAR-2, is known to be activated by trypsin, on 
peripheral nerve terminals (Steinhoff et al., 2000). Trypsin itself has been shown to 
posses itch inducing properties (Hagermark et al., 1972). In the present study, trypsin 
was shown to evoke dose dependent scratching in mice, consistent with the evidence 
in humans. The scratching evoked by trypsin was shown to be independent of 
mepyramine and thioperamide (histamine H 1 and H3;4 receptor antagonists 
respectively). Another itch inducing protease, papain, not active at the P AR-2 also 
evoked dose dependent scratching, again supporting the evidence from human 
studies (Hagermark, 1974). Scratching induced by papain was shown to be mediated, 
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at least in part, via histamine H3,4 receptors, but not an H1 mechanism. This evidence 
suggests that trypsin induces scratching via a P AR-2 mechanism, distinct from 
scratching evoked by other proteases such as papain, which act through a histamine 
dependent mechanism. 
The selective P AR-2 agonist, SLIGRL, induced dose-dependent scratching. 
However, scratching induced by SLIGRL was significantly reduced by both 
mepyramine and thioperamide, suggesting that P AR-2 operates via a histamine 
dependent pathway, most likely through mast cell activation. This evidence suggests 
that the scratching induced by trypsin, may be partly due to its action on P AR-2 
receptors on mast cells, but also partly due to a non-histamine related mechanism, 
presumably through its proteolytic action other surrounding anti-inflammatory cells. 
Compound 48/80 
The mast cell degranulator compound 48/80 induced dose dependent scratching in 
female BalbC mice, consistent with the evidence in the literature in both man 
(Fjellner & Hagermark, 1981) and mouse (Kuraishi et al., 1995). As expected, a 
large dose of compound 48/80 resulted in a loss of further responses to the drug, as 
the mast cells had already been degranulated. This study also showed that subsequent 
injections of histamine and the P AR-2 agonist, SLIGRL, were significantly reduced. 
This evidence supports the earlier suggestion that SLIGRL, acts on P AR-2 on mast 
cells, and that prior degranulation results in a loss of response. SLIGRL would 
appear unable to act directly on sensory nerves via P AR-2 to elicit scratching. 
Summary 
The findings from the present studies show that scratching can be induced in mice by 
compounds, other than histamine known to be pruritogenic in humans. 5-HT, 
substance P, compound 48/80, trypsin, papain and the PAR-2 agonist, SLIGRL, were 
shown to cause scratching. 5-HT elicits a scratching response independent of 
histamine release, whereas the other compounds were histamine-dependent. P AR-2 
activation results in scratching in mice, but the present results suggest this pathway is 
also histamine dependent, and probably involves mast cell degranulation. Future 
experiments on these and other compounds will almost certainly uncover new 
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mechanisms of itch induction, both dependent and independent of histamine release. 
This may result in the discovery of novel drug approaches to the treatment of clinical 
pruritic conditions. 
117 
Chapter 7: Chronically induced scratching in mice 
Chapter 7 
Chronically Induced Scratching in mice 
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7.1 Introduction 
The experiments described in this thesis have so far focussed on the induction of 
acute scratching behaviour. Although such models are useful in determining the 
pruritic effect of various endogenous compounds they do not mimic clinical pruritic 
states in which the itch is of a considerably longer timescale than 15-20 minutes. 
Acute models of scratching do not lead to pathophysiological changes, such as those 
associated with chronic clinical itch. In order to investigate the role of putative 
antipruritic compounds it is necessary to develop chronic itchy conditions in animal 
models that are similar in pathophysiology to clinical states. 
The ideal solution to chronic itchy conditions in mice is to find strains of mice in 
which these conditions exist naturally. So far only one such model exists: the 
NC/Nga mouse is a strain that spontaneously develops an atopic dermatitis-like 
condition, unless housed in a specific pathogen free environment, and shows 
increased, spontaneous scratching behaviour (Suto et al., 1999; Vestergaard et al., 
2000). The development of gene technology may also provide the possibi lity in the 
future of creating transgenic mice with chronic itch disorders by over or under-
expressing specific receptor subtypes or ligands. There is no evidence in the 
literature to date that such mice have been specifically developed. 
Another approach to developing models of chronic itch is to evoke such skin 
responses using drugs. Evidence for long lasting pruritic actions of drugs 
administered to the skin is provided by the evidence that the contact sensitiser 2,4-
dichloronitro benzene (DNCB) induces a scratching that persists for hours or days, 
rather than minutes (Laidlaw et al., 2002). The purpose of the experiments in this 
' study was to attempt to develop a model of chronic itching using DNCB in order to 
investigate the antipruritic actions ofvarious compounds. 
Compounds other than DNCB may also have the potential to cause chronic itch. One 
possible strategy that could evoke a chronic pruritic condition is the use of pro-
inflammatories. One such pro-inflammatory is Freunds complete adjuvant (FCA), 
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heat killed micro-bacteria tuberculosis (Greenwald & Diamond, 1988), which is 
commonly used to evoke inflammation in joints to mimic arthritis (Gaul die et a/., 
2001; Grubb et al., 1991). If such a compound were administered to the skin, one can 
test the hypothesis that the subsequent inflammatory response may evoke an elevated 
scratching response. 
A second potential target for evoking chronic itch is the P AR-2 receptor (Macfarlane 
et a!., 2001 ; Vergnolle et al., 2001 a). It has been shown that pro teases, such as 
trypsin and papain, evoke acute scratching in mice, as does the P AR-2 receptor 
specific agonist SLIGRL (see chapter 6 for more details). One of the studies within 
this chapter investigates the hypothesis that repeated administration of papain or 
SLIGRL leads to the induction of a chronic pruritic condition. 
The development of chronic itchy conditions provides a background upon which 
putative antipruritic drugs can be tested. In Chapter 5 of this thesis, the antipruritic 
effects of histamine H1 and H3/H4 receptor specific antagonists were examined in 
detail. The development of a chronic itchy model would enable further investigation 
ofthe antipruritic effect of these drugs (mepyramine and thioperamide) to be studied. 
Recently, a new antipruritic drug bas been developed, tacrolimus. This compound is 
topically administered as a cream, which is effective in relieving the itch of atopic 
dermatitis in man (Cheer & Plosker, 2001) and also reduces scratching in NC/Nga 
mice (Hiroi et al., 1998). Tacrolimus acts to stabilise T-cells, which are the early 
immune response cells. Tacrolimus is believed to bind to a protein within the T -cell 
and prevent up-regulation of genes of pro-inflammatory proteins (Pustisek et al., 
2002). The antipruritic effect of tacrolimus on drug induced chronic itch conditions 
will also be investigated in this chapter. 
7. 2 Materials & Methods 
The protocols for the induction and recording of scratching using DNCB, and the 
administration of antipruritic drugs to DNCB-treated mice are described in chapter 
2.2. Antagonists used in this chapter were mepyramine maleate (H1 antagonist), 
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thioperamide maleate (H3 and H4 antagonist) and tacrolimus cream (1% and vehicle, 
Fujisawa, Osaka, Japan). 
The chronic itch model based on the administration of FCA (1mgmr1, heat killed 
Mycobacterium tuberculosis suspended in heavy paraffm oil) involved a protocol of 
2 doses of FCA (0.1ml, intradermally) on days 0 and 3. The models based on papain 
(topically, 2.1 units mrt) and SLIGRL (1~-tg, i.d., in distilled water) involved 
application on a twice-daily basis, for the period between days 0-1 0. 
Experiments in this chapter were conducted in a total of 72 female BalbC mice and 
were performed in the animal facility, 1 George Square. 
7.3 Results 
DNCB-induced chronic scratching in female BalbC mice 
DNCB evoked a chronic skin response in all six female BalbC mice studied. DNCB 
(1% in ethanol) was administered topically to the area around the back of the neck on 
days 0 and 3. The skin response consisted of hair loss from the back of the neck as 
well as dryness and blistering of the skin. The hair loss and dryness of the skin was 
apparent from day 5 and lasted until approximately day 20, at which point the hair 
around the area began to re-grow. The dryness of the skin resulted in occasional 
minor bleeding of the skin, however, the mice appeared to be in no general state of 
distress. The only behavioural change observed in the mice was the induction of 
scratching (see figure 7.1A). Scratching behaviour was not observed prior to 
treatment with DNCB on day 0. By day 5 a noticeable, but not statistically 
significant level of scratching was observed (3± 1 bouts of scratching,· mean±sem). 
The level of scratching increased steadily until day 10, reaching a peak of 7±3 
(median=5) bouts, on that day. Over the period between day 10 and day 17 the mean 
level of scratching remained consistently above 5 bouts, per 10-minute observation 
period. Beyond 17 days the mean level of scratching began to fall markedly. Due to 
the relatively small sample sizes and large degree of variability there was at no time 
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period a statistically significant level of scratching versus pre-treatment levels 
(P>0.05, one-way ANOV A, n=6). Despite this, the clear trend in scratching induced 
by DNCB indicated that this was a suitable scratch model from which to compare 
other chronic pruritogens and also investigate the effects of putative itch relieving 
compounds. 
Ethanol, the vehicle for dissolving DNCB, did not induce the same pattern of 
scratching as DNCB in female BalbC mice (see figure 7.1B, n=4). There was no 
increase in scratching between days 5 and 10 in contrast to the scratching observed in 
DNCB treated mice, scratching in the ethanol treated group reached a peak of 3±2 
bouts, on day 15. There was also no hair loss or change in condition of the skin, 
unlike that observed in the DNCB treated group. 
Effects of change in dose regimen on DNCB-induced scratching 
A three-dose regimen of DNCB treatment was also studied, with topical application 
on days 0, 3 and 6 (n=8). The skin responses observed following the three-dose 
protocol was similar to that previously described following two doses; there was total 
hair loss from the treated area, associated with dryness and blistering of the skin, 
with occasional bleeding. The skin response was also observed between days 5 and 
20, as described above. Scratching increased steadily up to day 9, reaching a peak 
level of 23±3 bouts (mean±sem, median=20), significantly greater than the level of 
scratching induced by either the two dose regimen or ethanol (see figure 7.2A, 
P<0.05, Kruskal-Wallis test with Dunn's post test). Despite peaking at a higher level, 
scratching fell away and by day 12 had decreased to 6±2 bouts. As was observed in 
the two-dose protocol, scratching remained consistently above 5 bouts up to day 17, 
after which scratching became more inconsistent. 
A study into the effects of a four-dose regimen of DNCB application (on days 0, 3, 6 
and 12) provided very similar results to that observed following the three-dose study. 
A characteristic loss of hair, and skin response was observed in all 8 mice studied. 
Scratching levels increased steadily up to day 10, peaking at 18±3 (median=20) 
bouts, statistically significantly greater than that observed in the ethanol group (see 
figure 7.2B, P<0.05), 
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Figure 7.1 Chronic scratching induced by: A, DNCB (1 %, topically, n=6, 
administered on days 0 and 3) and B, Ethanol (vehicle for DNCB, n=4). 
DNCB treated group increase scratching response up to day 10, 
followed by consistent plateau of response up to day 17. Vehicle treated 
mice do not increase scratching levels in the same pattern. Arrows 
indicate time of DNCB administration. 
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Figure 7.2 Chronic scratching induced by DNCB (1 %, topically) using 
A; 3-dose regimen (days 0, 3 and 6, n=8) and 8; 4-dose regimen (days 
0, 3, 6 and 12, n=8). Both groups show a peak scratching response on 
day 10, with a subsequent plateau of scratching response between 
days 12 and 17. Arrows indicate time of DNCB administration. 
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but not significantly different from that induced by either the 2 or 3-treatment 
protocol (P>O.OS, Kruskal-Wallis test with Dunn's post test). As was observed with 
the 2-dose group, scratching levels fell by day 11, to below 10 bouts. After this time, 
there was again a consistent scratching response over the following few days, until 
day 17 when scratching levels fell and became more variable. 
Chronic scratching induced by PAR-2 receptor agonists 
SLIRGRL (1p.g, i.d.) was administered daily to the back of the neck of six female 
BalbC mice. Scratching responses were observed and recorded on a twice-daily basis 
(see figure 7.3A). The treatment protocol took place over 11 days with mice being 
treated on days 0, 1, 2, 3, 7, 8, 9 and 10. After the treatment protocol ended mice 
were observed for scratching for the following 13 days. Directly following SLIGRL 
treatment scratching was observed, indicating SLIGRL to be mediator of itch (as 
previously described in Chapter 6). Following SLIGRL treatment scratching ranged 
from 6±2 to 21±4 bouts. The mean scratching response to SLIGRL over the 8 
treatment days did not differ significantly (P<O.OS, Kruskal-Wallis test with Dunn's 
post test), however, the trend from the data indicate that over the course of 
consecutive treatment days the mice scratch to a greater level following each 
administration; over days 0-3, scratching increased from 11 ±2 to 16±3 bouts and 
over the treatment days 7-10, scratching increased from 6±2 to 17±3 bouts. 
Scratching prior to treatment on each day was also observed, in order to determine if 
there was any chronic increase in the background level of scratching due to the 
SLIGRL administration. Background scratching peaked on day 3 at 4±2 bouts, not 
significantly greater than that of the peak response to the ethanol control discussed 
previously (P>O.OS, Mann-Whitney test) . The mice from this study showed no 
behavioural changes other than those discussed and there were no apparent changes 
in the condition ofthe skin. 
Papain (2.1 units mr1, topically) was applied daily to the back of the neck of six 
female BalbC mice. Scratching was observed and recorded on a twice-daily basis 
(see figure 7.3B). The treatment and observation protocol were as previously 
described for the study involving SLIGRL. Immediately after papain administration 
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scratching was consistently observed, indicating papain to be a mediator of itch (as 
previously described in Chapter 6). Scratching following papain treatment ranged 
from 7±2 to 35±4 bouts. The mean scratching response to papain over the eight 
treatment days did not differ significantly (P<0.05, Kruskal-Wallis test with Dmm's 
post test), however, the trend from the data indicate that over the course of 
consecutive treatment days the mice scratched to a greater level following each 
administration, as occurred with SLIGRL. Scratching prior to papain treatment on 
each day was also observed, in order to determine if there was any increase in the 
background level of scratching associated with papain administration. Background 
scratching peaked on day 10 at 9±3 bouts, not significantly greater than that of the 
peak response to the ethanol control discussed previously (P>0.05, Mann-Whitney 
test). The background responses to papain, although not statistically significant, do 
appear to show a small elevation in scratching, however, this slight increase in 
scratching response (mean scratching remained above 5 bouts over the period day 8-
11) diminished within a day or two of stopping the papain and did not provide the 
same plateau of scratching response as generated by DNCB treatment. The mice 
from this study showed no behavioural changes other than those discussed and there 
were no apparent changes in the condition of the skin. 
Chronic scratching induced by Freunds Complete Adjuvant (FCA) 
Freunds complete adjuvant (FCA, 0.05ml, i.d. on days 0 and 3) did not induce 
scratching in female BalbC mice, significantly greater than that induced by ethanol 
(see figure 7.4, P>0.05, Mann-Whitney test), scratching peaked at 4±4 bouts on day 
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Figure 7.3 A; Chronic scratching induced by SLIGRL (PAR-2 receptor 
agonist, 1Jlg, i.d. administered on days 0, 1, 2, 3, 7, 8, 9 and 10, n=6). 
Scratching was induced following administration on each day. 
Background scratching (as measured prior to treatment) did not 
increase over the treatment period. B; Chronic scratching induced by 
papain (2.1 units mr1, topically, administered on days 0, 1, 2, 3, 7, 8, 9 
and 10, n=6). Scratching was induced following administration on each 
day. Background scratching (as measured prior to treatment) did not 
increase over the treatment period. 
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Figure 7.4 Chronic scratching induced by FCA (Freunds complete 
adjuvant, 1 mgml"1, i.d. n=4 ). Maximal FCA induced scratching was not 
significantly greater than that induced by ethanol. Arrows indicate time 
of FCA administration. 
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Effect of Tacrolimus on DNCB-induced scratching 
Tacrolimus cream (1%, topically) was administered twice daily (days 6-11) to six 
DNCB treated mice. The background level of scratching (see figure 7.5A), measured 
by observing the level of scratching prior to tacrolimus administration on each day, 
increased steadily between days 3 to 12, reaching a peak of 15±2 (meclian=15) bouts; 
not significantly different from the peak level from the two-dose DNCB treated 
group not receiving tacrolimus, described previously (P>0.05, Mann-Whitney test). 
As well as scratching behaviour, there were also associated behavioural changes due 
to tacrolimus administration. The tacrolimus treated mice appeared to be hyperactive 
and uncomfortable, not only directly following treatment, but also before treatment 
on each day. This behaviour became more pronounced over the six treatment days, 
but began to subside within two days of ending the tacrolimus treatment. By the end 
of the study the behaviour was not different from mice that had not received 
tacrolimus. The trend from the data suggested that directly following tacrolimus 
administration, there was a reduction in the level of scratching (although at no time 
was this a significant reduction, P>0.05, Kruskal-Wallis test with Dunn's post test). 
This reduction may, at least in part, be due to the associated change in behaviour 
mentioned previously. It appeared that the mice were uncomfortable and distressed; 
this may explain reluctance of the mice to scratch following treatment. 
A separate group of DNCB pre-treated mice received the tacrolimus vehicle cream. 
In these mice there was no reduction in mean scratching directly following 
application of the cream, compared with background scratching levels (see figure 
7 .5B), in fact there was a slight increase on each day; tbis may be due to the presence 
of the cream on the back of the neck, and may simply be an attempt to remove the 
cream. The background scratching response followed a pattern similar to that 
observed in mice receiving no tacrolimus (or vehicle) cream, however, there is an 
indication from the data that the plateau of scratching response may be shortened. 
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Figure 7.5 A; Tacrolimus (1%, topically, administered on days 6-11, 
n=6) did not reduce background scratching induced by DNCB (1 %, 
topically, administered on days 0 and 3). Scratching directly following 
tacrolimus was reduced on the first four days of treatment but this effect 
was not seen following the last two days of treatment. B; Vehicle for 
tacrolimus (topica lly, administered on days 6-11 , n=6) appeared to 
shorten the characteristic plateau of scratching response (usually 
lasting to day 17) induced by DNCB (1 %, topically, administered on 
days 0 and 3). Scratching directly following vehicle was not reduced on 
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130 
Chapter 7: Chronically induced scratching in mice 
Effect of histamine receptor antagonists on DNCB-induced 
scratching 
Mepyramine (H1 receptor antagonist, 20mgkg"
1 ,i.p.) and thioperamide (H3/H4 
receptor antagonist, 20mgkg·1 ,i.p.) were administered twice daily on days 6-11 to 
two separate groups of mice that had been pre-treated with DNCB (on days 0 and 3). 
Background scratching responses to both drugs were not lower than those seen in 
mice receiving no antagonist. Scratching peaked at 13±3 bouts (mean±sem) in the 
mepyrarnine group (see figure 7.6A) and 19±5 bouts in the thioperamide group (see 
figure 7.6B). Both groups also showed the plateau of scratching response, which 
lasted for several days, as previously identified in the group receiving no antagonist. 
Although there was no reduction in background scratching, both groups of mice 
showed an apparent (but not statistically significant) reduction in scratching response 
directly following antagonist. 
Combined antagonist treatment (20mgkg·1 mepyrarnine and 20mgkg·1 thioperamide, 
i.p.) eliminated scratching directly following administration (see figure 7.6C). 
Combined treatment also appeared to reduce background scratching, with a peak 
mean scratching response of 4±2 bouts seen on day 14 (after the antagonist treatment 
had ended). 
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Figure 7.6 A; Mepyramine (H1 antagonist 20mgkg-
1
, i.d. administered 
on days 6-11 , n=6) and B; thioperamide (H3/H4 antagonist 20mgkg-
1
, 
i.d. administered on days 6-11, n=6) did not reduce background 
scratching induced by DNCB (1 %, topically, administered on days 0 and 
3), with the response still exhibiting the characteristic plateau of 
scratching. Scratching directly following each antagonist was reduced. 
C; Combined mepyramine and thioperamide (n=6) treatment eliminated 
scratching directly following antagonist and also eliminated the 
characteristic plateau of scratching response usually evoked by DNCB. 
Arrows indicate DNCB treatment. Solid line shows antagonist treatment. 
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7.4 Discussion 
The evidence from the current study indicates that itch can be investigated in mice 
using chronically induced skin conditions, as well as the previously described acute 
models. This finding opens up new possibilities into the investigation of pruritus. 
Using acute models of experimentally induced scratching behaviour is of benefit in 
determining the pruritogenic properties of putative mediators of itch. However, such 
an approach is of more limited use when applied to specific pruritic conditions in 
man. For instance, there is no evidence in the 1iterature to support the suggestion that 
any clinical chronic pruritic condition is due solely to increased dermal 
concentrations of any one mediator. Such chronic conditions are invariably due to 
changes in skin pathophysiology, and as such are likely to be the consequence of a 
range of endogenous mediators acting directly or indirectly on sensory nerves. 
Clinically, chronic pruritic conditions are therefore more difficult to understand and 
treat effectively. The development of chronic skin conditions, that cause itch, are 
therefore more likely to resemble the pathophysiology of certain chronic clinical 
pruritic conditions in man. The investigation of such models is of potentially greater 
benefit for the development of antipruritic compounds than are acutely induced 
models of scratching. 
This study indicates that DNCB, applied topically, twice to the back of the neck of 
female BalbC mice, caused increased scratching over the course of approximately 17 
days. The scratching provided a plateau of relatively consistent scratching over the 
period from day 1 0 to 17, over which time scratching remained consistently above a 
mean level of 5 bouts per ten-minute observation period. This scratching was also 
accompanied by a skin reaction, over the same timescale, consisting of hair loss, 
dryness and blistering of the skin. Treatment with ethanol (vehicle for DNCB), 
induced no skin response or behavioural changes. This evidence supports the 
previous literature implicating DNCB as a contact sensitiser in mice, inducing 
scratching over a period of hours and days, not minutes as is the case with the 
mediators discussed in previous chapters (Laidlaw eta!., 2002). 
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Due to variability in scratching obtained in different animals, no statistically 
significant evidence was generated to prove that DNCB induced increased 
scratching; for this reason it is important to identify the trends indicated from the 
study, whilst not over interpreting the data obtained and drawing premature 
conclusions. One major factor in the variability from this study is the amount oftime 
for which each group of mice was observed. Each mouse was observed for only two 
ten-minute periods per day; this was in order to reduce the labour intensity of the 
process. Ideally, the mice would be observed over a longer, if not constant, time 
period. I suggest that due to the length of the study it is unreasonable to assume the 
mice scratched at a constant rate. It is likely that the mice had periods of reduced 
scratching throughout each day; possibly due to tiredness from excessive scratching 
or due to discomfort of the area, from either the skin condition itself or the increased 
scratching. To reduce the variability I think the most suitable approach would be to 
use the automated detector of scratching (see chapter 4). This would provi9e a 
constant recording of scratching and could reduce the variability generated from 
manually observing mice during 'inactive' periods of the day. Unfortunately, due to 
space restrictions within the animal facility such an approach was not possible during 
these studies. 
Studies usmg a three and four dose regtmen of DNCB also induced increased 
scratching responses. It was hoped that these increased doses would produce either a 
longer scratching response or that the plateau of scratching response would be 
higher, and therefore illustrate more clearly the pattern of response. The evidence 
from this study indicate that the three and four dose regimen evoke an elevated peak 
of scratching, around day 10, however this elevated peak diminishes within one or 
two days and from then on the pattern of response is very similar to that described 
for the two-dose protocol. As there was no clear elevation in the longer term level of 
scratching due to either the three or four dose regimen, further studies were 
conducted using the two-dose protocol as the standard chronic scratching state 
against which potential antipruritic drugs could be tested. 
134 
Chapter 7: Chronically induced scratching in mice 
Attempts to develop a model of chronic scratching were also made using the protease 
enzyme, papain, the P AR-2 receptor agonist, SLIGRL and also the pro-inflammatory 
agent, FCA (Freunds complete adjuvant, heat killed Mycobacterium tuberculosis). 
Proteases have been implicated as mediators of scratching since the 1950's (Shelley 
& Arthur, 1955) and their actions are described in more detail in chapter 6. One 
possible receptor site at which proteases act to induce itch is at the P AR-2 receptor 
(Macfarlane et al., 2001; Vergnolle et al., 200la). Both papain and SLIGRL have 
been shown to induce acute scratching behaviour (see chapter 6 for details) but 
results from the current study indicate that neither was capable of inducing a chronic 
itchy state equivalent to that evoked by DNCB. Both compounds continued to evoke 
scratching immediately following administration but neither drug produced an 
elevated long-term increase in scratching. As well as there being no increase in 
scratching there were also no other changes in skin condition (hair loss, scarification 
etc.) 
FCA is a pro-inflammatory agent commonly used in this laboratory for the induction 
of experimentally induced arthritis in both rats and mice (Gauldie et al., 2001; Grubb 
et al., 1991). FCA was administered intradermally to assess whether a pro-
inflammatory action would induce a chronic itch. From the results of this study there 
was no evidence to indicate that FCA was capable of evoking a scratch response in 
female BalbC mice. 
The present studies focused on the use of drugs to induce chronic scratching in 
standard laboratory strains of mice. However, there is one strain, NC/Nga mice, that 
exhibit a spontaneous scratching response, which is considered to be similar in 
pathophysiology to atopic dermatitis (Suto et al., 1999; Vestergaard et al., 2000). 
Models of spontaneous scratching conditions as well as drug-induced models are 
both of potential use in the further investigation into antipruritic drugs. In the future 
it may be possible to develop a wider range of spontaneously itchy mice by using 
gene technology to over or under express receptor or ligand genes. This approach is 
potentially of greater experimental use because there would be a known cause of the 
itch as opposed to the situation with the NC/Nga mouse, where the exact 
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pathophysiology of the condition is not yet fully established. Spontaneous scratching 
in NC/Nga mice is reported to be alleviated by the antipruritic cream, tacrolimus 
(Hiroi eta/., 1998). Tacrolimus is also described as being effective at relieving atopic 
dermatitis in man, and is now commercially available as an antipruritic (Cheer & 
Plosker, 2001). The action oftacrolimus is based on its ability to act as a lymphocyte 
T -cell stabilizer. It is thought that tacrolimus binds to an intracellular protein within 
the T -cell and inhibits the promoter region of a range of early pro-inflammatory 
mediators, such as interleukins (Pustisek et al., 2002). 
In this study the antipruritic effect of tacrolimus was investigated (over the course of 
6 days) in mice pre-treated with DNCB (2-treatment regimen). Tacrolimus (1 %) did 
not reduce the background level of scratching compared with DNCB-induced 
scratching, described previously. Indeed, the scratching induced appeared to be 
greater in magnitude due to tacrolimus with the behaviour of the mice also changing; 
showing signs of anxiety, discomfort and hyperactivity. This behavioural response 
may be due to the dose of tacrolimus used as some reports suggest that the drug can 
induce an irritant effect (Pustisek et al., 2002). From this study it is difficult to 
suggest whether there may have been any antipruritic effect of tacrolimus on mice 
treated with DNCB. The only evidence to support the antipruritic role of tacrolimus 
in this study comes from the frrst 4 days of tacrolimus administration, when a small 
but noticeable reduction in scratching could be seen, directly following tacrolimus 
treatment. Mice treated with tacrolimus vehicle showed no overt changes in 
behaviour following application of the cream. As we would expect from a vehicle 
drug, there were no changes in the level of scratching following administration of the 
cream. However, in the vehicle treated group there was an apparent reduction in the 
length of the plateau of scratching response compared to the pattern seen in DNCB 
treated mice receiving no antipruritic drug. This may indicate that the vehicle cream, 
although providing no immediate itch relief acts over the course of several days to 
reduce scratching, most probably due to moisturizing effects of the skin, reducing 
dryness and having a soothing effect. Further studies would be required using various 
concentrations of tacrolimus in order to determine whether the tacrolimus can reduce 
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the itch induced by DNCB, or whether DNCB induces its effects by a mechanism 
distinct from T -cell activation. 
It has previously been shown that the histamine H1 receptor antagonist, mepyramine, 
and the histamine HJIH4 receptor antagonist, thioperamide, are capable of 
significantly reducing histamine induced scratching (see chapter 5). The antipruritic 
effects of mepyramine, thioperamide and the combination were investigated in 
DNCB pre-treated mice. Mepyramine and thioperamide were both administered in 
the doses previously shown to reduce scratching (20mgkg-1, see chapter 5). The 
results from the present study indicate that mepyrarnine and thioperamide 
(administered twice daily over days 6-11) reduce scratching immediately following 
their administration, however, they did not appear to reduce the background level of 
scratching, as measured by either peak scratching response or by duration of the 
plateau of scratching response, when compared to the control DNCB treated mice 
described previously. Interestingly, mice treated with the combination of 
mepyramine and thioperamide showed less background scratching during the 
treatment period; at no point did scratching reach a mean level of 5 bouts which was 
the level in control DNCB treated mice during the plateau phase. Scratching 
immediately following antagonist treatment was eliminated completely. This 
evidence suggests that a combination of histamine H 1 and H3/H4 receptor antagonists 
may provide an interesting new treatment of itch, both in animal models and also in 
human clinical conditions. 
The development of models of chronic scratching, such as those described in this 
chapter, provides another new possibility for the investigation of putative antipruritic 
drugs, which may in time lead to the development of drugs of use clinically in man. 
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8. 1 Introduction 
The previous investigations described within this thesis have focused on the 
development of behavioural models of scratching to determine the sensation of itch. 
The problem of such an approach is that the evidence generated is subjective in two 
ways; firstly, the level of scratching evoked may be recorded differently over 
successive experiments (this variation is hopefully reduced by the development of 
the automated detector of scratching); secondly, we can not be sure that the same 
peripheral stimulus in two mice would elicit the same behavioural response. It is 
highly feasible that the central processing of the itch stimulus would evoke a variety 
of behavioural responses, dependent upon the individual being investigated, just as 
some people appear to be more sensitive to a given painful stimulus than others. 
One technique, to reduce the variation generated by the central processing and 
subsequent behavioural response, is to attempt to record the activity of the peripheral 
afferent nerves innervating the murine skin, following an itch stimulus. The use of 
electrophysiological techniques allows the degree of response to be determined, 
independent of central processing. One electrophysiological study into itch in mice 
has previously been described in the literature. The study describes an increase in the 
number of action potentials, recorded from an exposed cutaneous nerve from the 
back of the neck, following intradermal administration of 5-HT (scratch evoking 
compound, as described in chapter 6 of this thesis) in two standard laboratory strains, 
ICR and ddY, of anaesthetised mice (Maekawa et al., 2000). Moreover, the pattern 
of neural firing identified mirrors that seen in behavioural studies, with the increase 
in response starting after 3-4 minutes and lasting up to about 20 minutes. The two 
strains responded differently to another pruritogen, histamine. Histamine evoked a 
similar pattern of neural response to 5-HT in ICR mice; however, no increase in 
neural response was identified in ddY mice. This result may be explained by the 
strain related differences evoked by histamine in mice, as previously discussed in 
chapter 3 (Inagaki et al., 1999). The authors proposed that the neural responses 
generated were, 'itch-associated responses of afferent nerves'. Further investigation 
139 
Chapter 8: Electrophysiological studies of pruritus 
of itch-associated responses in electrophysiological studies would allow us to Jearn 
more about the pruritogenic effects of putative 'itch evoking' drugs. 
Work in humans has been able to identify a population of 'itch specific C-fibres', 
located in human skin that respond selectively to histamine (Schmelz et al., 1997). 
The suggestion that there is a population of nerves that respond specifically to 
pruritogenic stimuli is supported by work in cats showing a population of 
spinothalamic tract neurons that also respond selectively to histamine (Andrew & 
Craig, 2001 ). To date, the electrophysiological work in mice does not indicate 
whether the itch-associated responses are C-fibre mediated (Maekawa et al., 2000), 
as described in man and cats. If the work in mice, suggesting a similar itch-specific 
nerve population to that seen in man and cats, can be further progressed, more could 
be revealed about the nature of the nerves and receptors which detect pruritogenic 
stimuli. 
Evidence indicating that there are a population of itch specific nerve fibres has not 
been presented in the literature until recent years. Prior to the studies described above 
the weight of evidence indicated that the sensations of itch and pain 'shared' the 
same nerve fibres. Evidence from recordings from human cutaneous nerves showed 
that pain and itch inducing drugs activated the same fibres (Handwerker et al., 1991). 
This suggestion was supported by evidence from micro-stimulation of cutaneous C-
fibres, in which it was not conclusively shown that it was possible to evoke a 
sensation of itch, rather than pain in human subjects (Torebjork & Ochoa, 1980). 
Further development of electrophysiological recordings from cutaneous nerves in 
mice would provide extra evidence as to whether there is a population of itch-
specific nerves. 
The aim of the current study was to attempt to develop an in vivo model of recording 
from peripheral afferent nerves innervating the skin at the back of the neck in mice, 
using electrophysiological techniques, and to use this model to further investigate 
putative itch evoking compounds, as previously identified from behavioural studies. 
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8.2 Materials & Methods 
The surgical and recording procedures for the neural studies described in this chapter 
were carried out as described in Chapter 2.3. Experiments in this study were 
conducted in 36 BalbC mice and 2 ICR mice. 
8.3 Results 
Spontaneous neural firing of cutaneous afferent nerves 
A spontaneous neural signal was identified in 33 of the 38 mice involved in the 
current study. The reason for the lack of signal in the remaining mice was due to the 
death ofthe mice prior to, or during, the surgical procedure. The level of spontaneous 
firing identified was highly variable. This may have been because of activation of the 
nerves due to the surgical procedure in some mice. For this reason, most results 
expressed in this section are based on the duration of the increased firing response 
and the latency of the peak response, rather than the absolute level of firing induced. 
Increased neural firing following the administration of a range of drugs (i.d., see 
below for details of response to specific compounds) was identified in 13 of the 28 
mice, in which drugs were administered. 
Peripheral afferent neural responses to histamine 
Increased neural firing was evoked in eight of the 24 mice in which histamine (in the 
range 10-1000p.g, i.d.) was administered. A typical histamine evoked neural response 
is shown in figure 8.1. The duration ofhistamine evoked firing was 833±209 seconds 
(mean±sem, n=11). The latency of peak firing response was 348±118 seconds 
(mean±sem, n=ll). Saline did not evoke an increase in action potential firing, as 
shown in figure 8.2 
Histamine did not evoke increased neural firing in afferent nerves innervating the 
knee joint in mice, unpublished observations from within the laboratory. 
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Figure 8.1 Typical increase in neural activity following histamine 
(1000.ug, i.d.). Upper trace shows impulses per second, lower trace 
shows raw neural output. Injection ·indicated by *, also showing injection 
artifact. Black line indicates 100 seconds. Example of action potential 
recorded is shown below trace. Neural response peaks at 588 sees and 
has a duration of 1578 sees. 
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Figure 8.2 Typical neural activity following saline (i.d.). Upper trace 
shows impulses per second, lower trace shows raw neural output. 
Injection indicated by 's', also showing injection artifact. Black line 
indicates 100 seconds. Example of action potential recorded is shown 
below trace. 
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Peripheral afferent neural responses to capsaicin 
Increased neural firing was evoked in three of the seven mice in which capsaicin 
(0.3-lOp.g, i.d.) was administered. A typical capsaicin evoked neural response is 
shown in figure 8.3. The duration of capsaicin evoked firing was 87±21 seconds 
(mean±sem, n=5), significantly lower than that evoked by histamine, described 
above (P<0.05, Mann-Whitney test). The latency of peak firing response to capsaicin 
was 18±5 seconds (mean±sem, n=5), again, significantly less than that evoked by 
histamine (P<0.05, Mann-Whitney test). 
Increased neural firing was also identified in one of two mice receiving anandamide 
(VR1 receptor agonist, 1 OOOp.g, i.d.). Neural firing in response to anandamide had a 
latency close in nature to that evoked by capsaicin, 41 seconds (see figure 8.4). The 
duration of response was, however, greater than we might expect from a typical 
capsaicin response, 388 seconds, but still lower than that evoked by histamine. 
Peripheral afferent neural responses to 5-HT 
Increased neural firing was evoked in six ofthe 11 mice in which 5-HT (1-10p.g, i.d.) 
was administered. A typical 5-HT evoked neural response is shown in figure 8.5. The 
duration of 5-HT evoked firing was 830±162 seconds (mean±sem, n=9), not 
significantly different from that evoked by histamine (P>0.05, Mann-Whitney test). 
The latency of peak firing response to 5-HT was 342±74 seconds (mean±sem, n=9), 
again, not significantly different to that evoked by histamine (P<0.05, Mann-Whitney 
test). 
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Figure 8.3 Typical increase in neural activity following capsaicin (0.3pg, 
i.d.). Upper trace shows impulses per second, lower trace shows raw 
neural output. Injection indicated by 'c', also showing injection artifact. 
Black line indicates 100 seconds. Example of action potential recorded 
is shown below trace. Neural response peaks at 14 sees and has a 
duration of 48 sees. 
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Figure 8.4 Typical increase in neural activity following anandamide 
(1 mg, i.d.). Upper trace shows impulses per second, lower trace shows 
raw neural output. Injection indicated by 'a', also showing injection 
artifact. Black line indicates 100 seconds. Example of action potential 
recorded is shown below trace. Neural response peaks at 41 sees and 
has a duration of 388 sees. 
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Figure 8.5 Typical increase in neural activity following 5-HT (1 OJig, i.d.). 
Upper trace shows impulses per second , lower trace shows raw neural 
output. Injection indicated by '5', also showing injection artifact. Black 
line indicates 100 seconds. Example of action potential recorded is 
shown below trace. Neural response peaks at 8 sees and has a 
duration of 233 sees. 
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Peripheral afferent neural responses to clobenpropit, histamine H4 
receptor agonist 
Increased neural firing was evoked in two of the seven mice in which clobenpropit 
(3ug, i.d.) was administered. A typical clobenpropit evoked neural response is shown 
in figure 8.6. The duration of clobenpropit evoked firing was 828±11 seconds 
(mean±sem, n=2), similar to that identified in mice receiving histamine. The latency 
of peak firing response was 520±292 seconds (mean±sem, n=2), again, similar to that 
observed following histamine. 
Afferent nerve units respond to pruritogenic and algogenic stimuli 
The five afferent nerve units in which capsaicin (algogenic stimuli) increased neural 
firing also responded to pruritogenic stimuli. All five of the capsaicin sensitive units 
also responded positively to 5-HT. Two of the capsaicin sensitive units were also 
histamine sensitive. 
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Figure 8.6 Typical increase in neural activity following clobenpropit 
(3,ug, i.d.). Upper trace shows impulses per second, lower trace shows 
raw neural output. Injection indicated by '*' , also showing injection 
artifact Black line indicates 100 seconds. Example of action potential 
recorded is shown below trace. Neural response peaks at 228 sees and 
has a duration of 817 sees. 
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8.4 Discussion 
The studies described within this section of the thesis indicate that it is possible to 
make in vivo electrophysiological recordings from peripheral afferent nerves 
innervating the skin. This recording technique provides the possibility to investigate 
itch in mice, without the need for subjective behavioural studies on scratching. 
The current study has found that putative pruritogenic drugs, when administered 
intradermally, evoke increased neural activity in afferent cutaneous nerves. 
Histamine, 5-HT and clobenpropit (histamine H4 receptor agonist) all evoked an 
i~crease in the number of action potentials recorded. Responses to each drug had a 
delayed onset, peaking at 6-8 minutes post injection and having a duration of 12-14 
minutes. This time course of response is similar to that observed with scratching 
evoked by these compounds. This evidence indicates that the neural activity evoked 
is comparable with the scratching behaviour induced in mice, as described in the 
earlier chapters of this thesis. The findings of the present study are comparable with 
the existing literature in mice, indicating that histamine and 5-HT induce a time 
pattern of neural firing, similar to that identified in scratching (Maekawa et al., 
2000). Previous work within the laboratory has indicated that in electrophysiological 
investigations (Gauldie et a!., 2001) of rat and mouse nerves innervating the knee 
joint, histamine evokes no increase in neural activity, unpublished observations. 
Therefore, the histamine-evoked responses identified from cutaneous nerves suggest 
that such responses are specifically localised to the skin, as would be expected if itch 
responses were being investigated. 
Capsaicin and anandamide (VRl receptor agonist) both evoked a pattern of neural 
response distinct to that induced by 'pruritogenic' drugs. The neural response to both 
capsaicin and anandamide was a short burst of firing, lasting only seconds of a few 
minutes, and the response peaked within several seconds. This burst of neural 
activity is similar to that found in similar recordings made from rat and mouse nerves 
innervating the knee joint (Gauldie et al., 2001). 
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The difference in pattern of neural activity evoked by 'algogenic' and 'pruritogenic' 
compounds indicates that there may be a distinction in the sensory perception 
mechanisms of the two conditions. Work in humans and cats have indicated that 
there appear to be independent population of C-fibre nerves that can be described as 
'itch specific' (Andrew & Craig, 2001; Schmelz et a/., 1997). Findings from the 
present study in mice have not been able to confirm that there are distinct 
populations of itch and nociceptive fibres. The current study indicates that although 
there is a distinct pattern of response to pruritogenic stimuli, the individual units 
carrying the signal appear to be responsive to both sets of stimulus. 
The current investigation indicates that it is possible to study the neural activity of 
pruritogens in a murine model. Further investigations would be required to determine 
more about the exact nature of a pruritogenic response in comparison with a 
nociceptive response. It is plausible to further develop this technique to determine the 
character profile of the nerve fibres being studied, as work in humans and cats 
suggests that the sensation of itch in these species is carried by C-fibres (Andrew & 
Craig, 2001; Schmelz et al., 1997). Studies using other pruritogenic stimuli will be 
required to determine whether the nature of the response to histamine and 5-HT is 
identified in response to aU pruritogens. 
Although the current study has provided an insight into the nature of pruritogenic 
versus algogenic neural responses, this work was predominantly a series of pilot 
studies in which to develop cutaneous recording techniques. Various problems were 
encountered in this study which further development of the techniques described may 
reduce. The main problem of the current study was the noise encountered in many of 
the recordings; this meant identifying a drug-evoked response was not possible. 
Developing an in vitro recording technique may reduce much of the noise found 
using the current in vivo procedure, as much of the noise appeared to be due to 
interference of heartbeat and breathing. Such an approach would also alleviate the 
need for a more complex anaesthetic and surgical procedure. 
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In summary, the current study has shown that in vivo electrophysiological recordings 
of cutaneous afferent nerves are possible and that the effects of pruritogenic stimuli 
on such nerves can be investigated. The distinct pattern of neural response to 
pruritogenic and algogenic drugs enables further investigation of itch in mice, 
without the need for subjective behavioural studies. Such an approach opens up a 
new possibility for the investigation of new mediators of itch, and their mechanism 
of action in mice. 
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Chapter 9: General discussion 
9. 1 Acutely-induced scratching in mice 
The primary aim of the studies contained within this thesis were designed to test the 
hypothesis that the 'induction of scratching in mice is a useful and robust model of 
itch, which can be used to provide a guide to pruritic and antipruritic drugs for 
testing in humans'. The first half of this question was predominantly answered in 
chapter 3 of this thesis, in which a basic model of acutely induced scratching in mice 
was developed. 
The model developed in this thesis established that scratching could be evoked in 
mice using intradermal administration of histamine into the back of the neck. This 
fmding supported previous literature that scratching behaviour could be induced and 
quantified using 'known pruritogens' in mice (Inagaki et al., 1999; Kuraishi et al., 
1995). The model was developed around the use of mice due to the possibility of 
using genetically engineered animals in the future, either over or under-expressing 
receptors or ligands implicated in pilot studies. The development of the model 
incorporated other possible variables that may have affected the reproducibility of 
scratching responses. Such variables that were investigated included; strain of 
mouse, sex of mouse, volume of injected drug and the vehicle in which the drug was 
administered. The studies described within this thesis should ensure that any 
scratching evoked could be repeated consistently, within the boundaries of natural 
biological variability. 
The findings of this thesis suggest that scratching in mice is a response to an itchy 
and not painful stimulus. Some authors have proposed that such animal models of 
scratching may not directly correlate to the sensation of itch and are therefore floored 
when results are interpreted with human clinical conditions in mind (De Castro-Costa 
et al., 1987; McMahon & Koltzenburg, 1992). However, the findings of this thesis 
suggest that a significantly lower level of scratching is evoked when a painful 
stimulus is administered and that the pattern of scratching response is different to that 
evoked by an itchy stimulus. I believe it is fair to conclude that mice respond by 
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scratching when presented wjth an itchy stimulus and that by measuring a scratching 
response in mice we can be confident of defining the sensation as itch. 
Histamine evoked scratching .in BalbC mice was investigated in further detail to 
determine the role of the specific histamine receptor subtypes in itch. The fmdings of 
these studies indicate that there is an apparent role for histamine H1 receptors and 
also the newly described histamine H4 receptor. Although there is previous evidence 
indicating a role for the histamine H1 receptor in itch in mice (lnagaki et al., 1999; 
Sugimoto et al. , 1998) and man (Greaves & Davies, 1982), the evidence presented 
within this thesis is the first to implicate a role for the histamine H4 receptor. 
Studies contained within this thesis also illustrated that 5-HT elicited scratching in 
mice. 5-HT is recognised as a pruritogen in man (Fjellner & Hagerrnark, 1979) and 
mice (Andoh & Kuraishi , 1998). The current studies indicated that 5-HT evoked 
scratching in mice is mediated via the 5-HT2 and not the 5-HT3 receptor subtype. 
The current studies also investigated the pruritogenic role of P AR-2, previously 
implicated in itch in man (Steinhoff et al., 2003). The protease, papain, and the PAR-
2 specific agonist, SLIGRL, were both shown to evoke scratching in mice. 
Future Directions 
I believe that the model of acutely induced scratching in mice is a valid and robust 
method for quantifying the sensation of itch in mice, and as such is a useful basis for 
determining putative mediators worthy of investigation in human subjects. Although 
the model itself is reproducible and effective, there are still various areas in which 
further investigation may be beneficial. 
A novel mechanism of histamine induced scratching involving the histamine H4 
receptor has been described within this thesis. However, with the drugs commercially 
available at the time of research, it is not possible to conclude for certain that 
histamine evoked scratching is solely histamine H1 and H4 receptor mediated. The 
lack of specificity of some agonists and antagonists leaves some degree of doubt over 
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these findings, particularly in relation to the role of the histamine H3 versus H4 
receptor. In the future, investigations using drugs of known activity at each of the 
receptor subtypes would further clarify the precise role of each of the receptor 
subtypes. 
One of the major aims of this thesis was to attempt to confirm that any novel 
pruritogenic drugs identified in mice were also pruritogenic in hwnan subjects. The 
major area of interest from this thesis would be to investigate the role of specific 
histamine H4 receptor agonists and antagonists in humans. Unfortunately, due to time 
constraints and also the lack of commercially available and ethically approved 
histamine H4 receptor specific drugs, this was not possible within this thesis. 
However, I believe that future investigation into the role of histamine H4 receptors in 
itch may provide a new technique in the treatment of itch in man. 
The murine model of scratching developed would be equally effective at determining 
the pruritogenic effects of various other drugs administered. The pruritogenic effects 
of 5-HT and P AR-2 agonists have been investigated within this thesis; however, 1 
believe that further investigation into the receptor mechanism by which these drugs 
operate may provide novel evidence upon which to develop investigations in human 
subjects. Further putative mediators not covered by this thesis due to time constraints 
should also be considered for future investigation. These mediators were described in 
detail in chapter 1 of this thesis and even the current literature is unlikely to provide a 
comprehensive description of aU the mediators involved in the sensation of itch and 
new mediators are likely to be described in the literature in the future. 
9.2 Automated detection of scratching in mice 
One of the specific aims of the studies contained within this thesis was to 'devise and 
develop an automated mechanism for the detection of scratching in mice'. The 
studies described within chapter 4 of this thesis explain the development of a scratch 
detector based on the rhythmical beating characteristic of the hind paw during 
scratching. This characteristic formed the basis of the only two automated detectors 
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of scratching in mice, previously described in the literature (Elliott et al., 2000; 
lnagaki et al., 2003). Both of the models currently existing in the literature involved 
placing metallic components in or around the hind paw of the mice and placing the 
mice in cages, surrounded by metallic coils to detect changes in electrical current. 
Changes in electrical current exhibiting the beating pattern of scratching were 
identified as scratching. The main purpose of the detector described within this thesis 
was to identify scratching using a relatively simple and non-invasive procedure. 
Although the two models described in the literature appear capable of detecting 
scratching, they involve prior treatment to the mice involved, something that is not 
necessary with our model. The model developed in these studies is based on the 
detection of force change in the cage using a sensitive force transducer. Rhythmical 
changes in force, at a frequency similar to that observed for scratching, are identified 
as scratching. 
As well as detecting the number of bouts of scratching (as can be identified by the 
human eye), the automated detector can also be used to determine the exact number 
of scratch movements and the mean number of scratch movements per bout. This 
capability may be of great benefit if some pruritic drugs were to induce the same 
number of bouts, but with a greater number of overall scratch movements, than other 
pruritogens. 
The automated detector is currently designed to record four mice at one time but 
could feasibly be multiplied up to record many more mice at once. The limiting 
factor in such a set-up would be the number of computers available to record and 
process the data. Realistically, it is not plausible to visually measure scratching in 
any more than four mice at any one time, and ideally in no more than two. Therefore, 
as well as recording additional information, the detector can also significantly reduce 
the labour intensity associated with the measurement of scratching. 
Although I feel confident that the results generated by the automated detector are a 
true reflection of scratching in mice, the major area of inaccuracy concerns the 
detection of 'noise' associated with grooming behaviour. Grooming behaviour was 
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generally identified at a lower frequency than scratching and therefore the detector 
has built in filters to remove the majority of the background noise. However, despite 
these precautions, it was still evident that the majority of the detectors inaccuracy 
was as a result of grooming behaviour. 
Future Directions 
Further development of the detector is still required in order to gain a more accurate 
reflection of scratching behaviour in mice. It was never envisaged that the detector 
would be 100% accurate, however, I believe that further development may produce 
more accurate results. Despite any inaccuracies of the detector, it has proved to be a 
very useful tool, capable of saving a large amount of time in the recording of 
scratching behaviour. 
The automated detector may also prove to be of far greater benefit in the detection of 
chronically induced scratching in mice. To date the detector has only been used for 
periods of up to twenty minutes. Visual analysis of scratching is feasible over this 
time-period; however, scratching evoked over a period of hours or days cannot be 
measured in this way. Visual measurement of such data requires video recording 
equipment and subsequent analysis, or measuring the mice for only part of the 
scratching period, leading to a loss of data during times when the mice are not 
observed. Using the automated detector would allow detection of scratching over 
longer time periods, the length of which would only be determined by the computer 
power available for recording. 
The automated detector is currently designed to measure repetitive behaviour in 
mice, of a frequency associated with scratching. Further development would enable 
the detector to analyse additional repetitive movements (e.g. grooming) or repetitive 
behaviour in other small animals, such as rats or guinea pigs. Such studies of 
scratching in other species may provide a greater indication of the pruritogenic 
effects of the drugs examined in mice. The development of the current model was 
based on the induction of scratching in mice. This was primarily due to the 
possibility in the future of genetically engineering mice with up-regulated or knocked 
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out receptors or ligands, implicated to play a role in scratching. However, further 
development of genetic engineering in rats, opens up the possibility of such 
investigations in this species. Therefore, it may prove to be of benefit, in the future, 
to have an automated detection system capable of operating in both mice and rats. 
9.3 Chronically-induced scratching in mice 
One of the aims of the studies described within this thesis was to examine the effects 
of putative mediators of scratching mice. This was primarily achieved by 
administration of such compounds into the skin of mice, and the subsequent 
measurement of acutely evoked scratching. This model is suitable for dete~ining 
the effect of 'itch inducing' drugs but less suitable for examining the effect of 'itch 
relieving' drugs. The best model for examining itch-relieving drugs is to have a 
model in which the mice already scratch. One such strain of mice exists where 
scratching occurs spontaneously (Suto et al., 1999; V estergaard et al., 2000). The 
next option is to induce a chronic state of scratching in mice, using drugs, which 
elicits a long term scratching response. 
DNCB was shown in this study to evoke a scratching response in mice over a period 
of 25 days, when administered topically in a two, three or four dose regimen. 
Attempts to induce a consistent and chronic state of scratching were not possible 
using other compounds tested (FCA, papain or the P AR-2 receptor specific agonist 
papain). 
The chronic scratching induced by DNCB was considered significant enough to be 
able to examine the itch reducing properties of tacrolimus, a recently released itch 
alleviating drug in man (Cheer & Plosker, 2001). However, Tacrolimus showed no 
significant reduction in DNCB induced scratching in mice. The scratch reducing 
effects of histamine Ht and H3/H4 receptor antagonists were also studied, following 
the results gained in acute scratching studies. Both mepyramine (histamine H 1 
receptor antagonist) and thioperamide (histamine H3/H4 receptor antagonist) had a 
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scratch reducing effect on DNCB treated mice. Interestingly, this effect was even 
more significant when the two antagonists were administered in combination. 
Future Directions 
The DNCB model used in these studies provides a useful indication of potential itch 
relieving compounds. However, natural variability in scratching responses between 
mice did not allow data of statistical significance to be gained in these studies. For 
this reason one of two possibilities could be implemented in future investigations; 
more mice could be studied in order to reduce variability, or, mice could be observed 
for a greater amount of time. In the current studies, mice were observed for two ten-
minute periods per day, and it may be possible that for various reasons some mice 
were not scratching as anticipated at various recording times, for instance, due to 
tiredness or discomfort. This approach was taken to reduce the labour intensity of the 
experiment, however, one resolution would be to observe the mice constantly. Using 
the automated detection system it would be feasible to measure scratching over much 
longer periods of time. The result of such an approach would be reduce any variation 
in the times mice do or do not scratch. Now that the automated detector is validated, 
it would prove beneficial to focus its use on chronic rather than acute scratching 
studies. 
9.4 Electrophysio/ogical studies in mice 
The electrophysiological studies contained within this thesis confirm it is possible to 
record cutaneous afferent nerve activity, and that pruritogenic stimuli evoke an 
increase in neural activity distinct from that evoked by algogenic stimuli. This 
finding is comparable to the one other study of itch evoked neural activity in mice 
(Maekawa et a!., 2000). Unlike work in humans (Schmelz et al., 1997) and cats 
(Andrew & Craig, 2001), the current studies were unable to confirm the presence of 
a distinct population of itch sensitive nerves. However, although individual units in 
mice appear to respond to algogenic and pruritogenic stimuli, the pattern of 
responses are distinct in their time course. 
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Future Directions 
Further refinement of the electrophysiological techniques used in this study would 
allow a more comprehensive investigation into the character of neural responses to 
pruritogenic stimuli. The most useful development would be to use an in vitro 
recording system, by removing a patch of skin with the cutaneous nerve attached. 
Such an approach would remove all efferent neural activity and would also eliminate 
the predominant source of noise within the system, heartbeat and respiration. This 
more refined recording technique may allow a greater characterisation of the nerves 
transmitting the itch signal, specifically; to what stimuli do the nerves respond (e.g., 
mechano-stimuli, thermo-stimuli). This greater characterisation of the nerves may 
enable a more directed approach to blocking the itch stimulus, both in murine models 
and eventually in human clinical itch disorders. 
9.5 General conclusions 
The results described in this thesis contribute to our overall knowledge concerning 
scratching, and itch, in mice. The results indicate that this model of scratching in 
mice provides a sound basis in which to investigate itch, and provides the possibility 
for novel anti-pruritic compounds in man to be studied. Further to this, an automated 
detector of scratching in mice has been developed which is capable of gaining more 
information about the exact nature of the scratching and also significantly reducing 
the labour intensity otherwise associated with such studies. 
A novel mechanism of histamine mediated scratching in mice has been discovered, 
implicating a role for the recently discovered histamine H4 receptor in itch. If similar 
results were to be repeated in human subjects this may open up new possibilities in 
potential treatments of clinical pruritic disorders in man. 
Results also showed that in vivo electrophysiological studies from peripheral, 
cutaneous afferent nerves could be made in mice. Recordings showed that specific 
patterns of response could be elicited from nerves following administration of 
pruritic compounds. Such results allow further investigation into the mechanism and 
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neural pathway of the itch sensation in mice, and of potential new endogenous 
mediators. Such an approach would allow us to learn more about the sensation of itch 
in clinical pruritic disorders in man, and may lead to the discovery of novel and more 
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Anandamide 347.5 Tocris PBS 
Bradykinin 
Arg-Pro-Pro-Gly-Phe-Ser-Pro-




305.4 Sigma PBS 
nonenamide 
Cimetidine 252.3 Tocris PBS 
Cinanserin Cinanserin hydrochloride 381.4 Tocris PBS 
N -( 4-chlorobenzyl-S-[3-4( 5)-






Dimaprit dimethylaminopropyl)isothiourea 234.2 Tocris PBS 
dihydrochloride 
DNCB 1-chloro-2,4-dinitrobenzene 202.6 Sigma Ethanol 










Sigma 212.7 PBS 
hydrochloride 
lmetit lmetit dihydrobromide 332.1 Tocris PBS 
Mepyramine Mepyramine maleate 401.5 Tocris PBS 
Papain Papain crude Sigma PBS 
SLIGRL Ser-Leu-Ile-Gly-Arg-Leu-NH2 656.82 Tocris PBS 
Substance P 1347.6 Sigma PBS 
Terfenadine 471.7 Sigma PBS 
185 
N-cyclohexyl-4-(imidazol-4-yl)-












(from porcine pancreas) 1:250 
BABE 
units/mg 




0.2M Na2HP04. 12H20 in saline 






Appendix II - Publications 
187 
British Journal of Pharmacology (2004) 142, 374-380 © 2004 Nature Publ ishing Group All rights reserved 0007-1188/04 $30.00 • 
www.nature.com/bjp 
Involvement of histamine H 4 and H 1 receptors in scratching 
induced by histamine receptor agonists in BalbC mice 
'J.K. Bell, *·'D.S. McQueen & 2J .L. Rees 
1 Division of Neuroscience. College of Medicine. University of Edinburgh. Edinburgh, EH8 9JZ and 2Department of Dermatology, 
University of Edinburgh. Edinburgh. EH3 9YW 
The role of histamine H 1• H1• H,, and H.1 receptors in acute itch induced by histamine was 
investigated in female Ba lbC mice. Scratching was induced by int radermal injections of pruritogen 
in to the back of the neck and "itch' assessed by quan tifying the scratching evoked. 
2 Histamine (0.03- 80 Jtmol). histamine-triOuoromethyl-toluidine (HTMT. H 1 agonist. 0.002-
2 jltnol), clobenpropit (H. agonis t. H.1 antagonist. 0.002- 0.6 ~tmol ) and to a lesser extent imetit (H)/ 
H. agonist, 0.03- 3 Jtmol) all induced dose-dependent scratching. Dimaprit ~ H ~ agonist. 0.04-40 JllllOI) 
did not cause scratching. 
3 Mepyramine (H 1 antagonist, 20mg kg 
1
• i.p.) reduced scratching evoked by histamine and HT MT. 
but not that caused by H, or H. agonists. Thioperamide (H3/H. antagonist. 20 mg kg 1• i.p.) reduced 
scratching induced by histamine. H,~ and H. agonists, bu t not that caused by HTMT. The non-sedating 
H 1 antagonist. terfenadine. a lso significantly reduced the scratching induced by the H 1 ngonist, HTMT. 
Cimetidinc (H~ antagonist. 20 mg kg 1, i.p.) did not affect his tam ine-induced ~cra tching. 
4 These results indicate that activat ion of histamine H. receptors causes itch in mice, in addition to 
the previously recognised ro le for H 1 receptors in evoki ng itch. Histamine H. receptor antagon ists 
therefore merit investigation as ttnt ipruritic agents. 
British Journa/4 PlwmltlcO!ogy (2004) 142, 374-380. doi: 10.1038{sj.bjp.0705754 
Keywords: Itch; pruritus; histamine; mouse: H1 receptor; H 1 receptor: H4 receptor 
Abbreviations: HTMT. histamine-trilluoromcthyl- toluidinc: 1-1 1• histamine HI receptor; 1-11. histamine H2 receptor: H1, histamine 
H3 receptor; HJ. histamine H4 receptor: i.d .. int radermal; i.p., intraperitoneal: PBS, phosphate buffered saline 
Introduction 
Itch (pruritus) is commonly defined in humans as an 
unpleasant sensation of the superficia l layers of the skin 
(Shelley & Arthur. 1957) provoking the desire to scratch 
(Ekblom. 1995). It is a common clinical condition that ca n be 
associated with cutaneous (e.g. atopic eczema, contact 
dermatitis) or systemic (e.g. chronic renal failure) disease. Itch 
is difficult to study objectively in man and there arc curren tly 
few reliable animal models of itch . 
Histamine has long been recognised as a mediator of itch in 
humans (Lewis. 1927). Although traditional 1-1 1 receptor 
antagonists arc effective at reducing histamine-induced itch 
(1-lagcrmark e1 at .. 1979) and are widely used c li nically for 
treating pru ritus (Greaves, 1997). they are not ciTc~:tivc 
antipruritics in many clinical cond itions. such as atopic eC7ema 
(Yosipovitch et a/ .. 2003). It has been claimed that the 
effectiveness of H 1 receptor antagon ists in relieving itch re~ults 
from central seda tion rather than peripheral act ions on sensory 
nerves. in condi tions where histamine is not considered to b..: 
the primary mediator (Savin. 1980: Krause & Shuster. 19ll3; 
Savin N a/ .. 1986). Histam ine 1-1 ~ receptor antagonists are also 
used c li nically for treating itch (Monroe eta/ .. 198 1: Ring <'I a/ .. 
1999), but their ability to inhibit itching is not conclusive 
(Hagennark el a/ .. 1979: Davies & Greaves. 1980). Overall the 
*Autho r fo r correspondence: E-mail: D.S.McQuccntct cd.ac.uk 
Advance online publ ication: 5 April 2004 
evidence suggests that mechanisms other than those involving 
1-1 1/H1 receptors a re involved in itch. 
In murine st udies. itch is estimated by measuring the 
scratching elicited by itch-provoking agen ts (Kuraishi N a/ .. 
1995). Although some reports have questioned the role o f 
histamine as a pruritogen in mice (Kuraishi et at .. 1995), others 
have shown that histamine 1-1 1 receptor antagonists are 
effective at reducing histami ne-induced scratching (Sugimoto 
l'l a/ .. 1998) in this species. J n studies involving mice, it is 
necessa ry to appreciate that difference in strain can markedly 
inlluence scratching rcspon ·es to drugs ( lnagaki ('/a/ .. 2001). 
Concerns have been raised that scra tching in an ima l models o f 
itch may reflect pain rather than pruritus (McMahon & 
Koltzenburg, 1992), but c,·idencc shows that pain and itch do 
promote different behavioural responses in mice (Kuraish i 
e1 ul .. 1995: Laidlaw et a/ .. ::!002). 
The present s tudy wa undertaken to investigate the role of 
H 1• 1-1 1. H, and H. receptors in histamine-induced itch in BalbC 
mice based on the quantification of acutely induced scratching. 
Methods 
Animals 
All experiments were performed under U.K. Home Ol'licc 
n.:gulations. Female BalbC mice (Charles River, Margate. 
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Kent. U.K .), 10-weeks old. were used in the experimen ts. Mice 
weighed 18- 26 g and were housed under controlled light 
(07:00-19:00 h) and temperature (22°C) with food and wa ter 
available ad /ibi1um. Each mouse was used for only one 
experiment. 
Materials 
Histamine diphosphate (Sigma, Poole. U.K . MW = 307) was 
dissolved in saline (0.9% wv 1 aqueous NaCI solution) . 
Histamine- trinuoromethyl- toluidine dima leate (HTMT; H 1 
receptor agonis t, MW = 615), d imaprit dihydrochloride (H 2 
agonist, MW = 234), imelit dihydrobromide (dual H 3 and H4 
agonist, M W = 332), clobenpropit dihydrobrom ide (H4 ago-
nist and H 3 antagonist, MW = 471 ), mepyramine maleate 
(sedating H 1 antagonist, MW = 40 I), terfenadine (nonsedating 
H 1 antagonist. MW = 472). cimetidine (H2 antagonist, 
MW = 252) and thioperamide maleate (H., and H 4 antagonist. 
MW = 4 13) (all Tocris, Avonmouth, U.K . unless specified) 
were dissolved in phosphate-buffered sali ne (PBS. pH = 7.4) . 
All drugs were injected in a volume of I 00 111. 
Procedure 
The itch-inducing properties of histamine and H1. H2. 1-1 3 and 
H. agonists were studied by administer ing the drugs intrader-
ma lly (i.d. ) into the back of the neck via a 26 G needle . Drugs 
were administered at 1-h intervals. Inject ion of PBS was used 
as a control. T he injection site was chosen as it is only 
accessible by the animal's hind paws and therefore scratching 
behaviour can be separa tely identi fied from grooming, which is 
perfo rmed by the forelimbs. 
In experiments involving antagonists. scratching was in-
duced by a mid-range dose of histamine, which was repea ted 
30 and again 90 min after treatment wi th e ither an H 1, H 2 or 
1-13 antagonist (20 mg kg 1, i.p.). This dose of antagonis t was 
selected on the basis or its effectiveness in reducing scra tching 
induced by H ., H 2 or H3 antagonists. 
The e ffects of antagonists on receptor-selective agonist-
induced scratching were studied in separate groups of mice, as 
desensitisa tion to the agonists precluded repeated dosing. The 
response to agonist was reco rded 30 min after antagonis t 
trea tment and compared to responses obtained from vehicle 
(saline)-t reated mice. The dose of agonist was selected on the 
basis of its abi lity to elicit scra tching in each mouse stud ied, 
and with the aim of eliciting approx imately 50% of maximum 
scratching response. 
M easurement of itch 
Mice were filmed with a video camera (Vista. NCO 132) and 
the signal recorded on a VC R (Panasonic, NV-HD640). 'Itch' 
was measured by counti ng the number of 'bouts' of scratching 
in the 20-m in period immediately following injection o r 
histamine o r select ive H1. H2, H 3 o r H4 agonist. A bout o f 
scratching was defined as three o r more individual rapid 
scratch movements wit h the hind paws to the area around the 
injection site (i.e. the back of the neck). 
Stalislica/ ana~rsis 
All data were ana lysed using GraphPad Prism (v3.02) 
software. Log dose - response curves were plotted using the 
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nonlinear regression (sigmoidal dose - response) function. The 
mean 'apparent' ED 50 was calculated from the pooled data and 
was the dose required to eljcit half the apparent maximal 
response. Nonparametric statis tical analysis was used and the 
null hypothesis was rejected at P<0.05. 
The effects of antagonists on histamine-induced scratching 
were analysed using the Wilcoxon matched pairs test. 
comparing the response to a dose of histamine preantagonist 
with the response to the same dose 30 min after antagonist. A 
second postantagonist response to the dose of histamine was 
also recorded 90 min after antagon ist, to give an indication of 
the antagonist 's duration. The effect of antagonist on agonist-




His tamine evoked dose-dependent scratching in all the mice 
studied, as summarised in F igure I. Scratching was not 
obtained at lower doses (up to 0.8 Jlmol). but was consistently 
observed with higher doses, reaching a maximum at 26 pmol 
histamine. Above this dose there was no further increase, and 
often a decrease, in scratching. Histamine-induced scratching 
reached a maxjmum of 73 ± 12 bouts (mean± s.e.m.). with a 
mean apparent ED50 of 5.8 J.lmol. 
Scratching induced by phospha te-buffered saline served as a 
control (5± I bouts of scratching. 11 = 12). 
A pa inful stimulus (9 M HCl, 0. 1 ml, i.d. n = 4) did not 
induce scratching (0±0 bouts) and was associa ted with 
behaviour not seen with histamine (vocalisation upon injection 
and ' hunching' a fter the injection). 
Role of histamine H, recep1ors in histamine agonist-
induced scratching 
The selective histamine H 1 receptor agonist, HTMT, evoked 
dose-dependent scratching in all six mice studied (Figure 2a). 
Maximal scratching was 133 ± 17 bouts. with a mean apparent 





~ E 75 
111 C1l 
t; ~ 






I ''"""I . I ...... , ' '"""I 'iiiiiiiJ ' I iiiiiij 
10• 10~ 104 10 4 10~ 10 ~ 
Histamine (mol, i.d.) 
Figure I Pooled d:na for his tamine-induced scra tching in female 
BalbC mice during the 20-min post injection period (11 = 4-8). 
His tamine caused dose-dependent scratching. Dashed line represents 
the mean level of scra tching induced by PBS. which served as a 
control (5 ± I bouts of scratching. 11 = 12). 
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Hi tamine-induced scratching (8 Jtmol. i.d.) wa:, ignificantl) 
reduced follo,,ingmepyramine(~Omgkg 1 i.p.: P<0.05.n =6. 
Figure 3a). Saline (0.9% '' ' 1 aqueou~ ':aCI solution). used a~ 
a control for the antagoni t , did no t significantly reduce 
histamine-induced scratching (? > 0.05. n = 5. Figure 3b). 
HTM T -induced scratching (0.2,mwl i .d.) was significantly 
reduced in mice pretreated with mepyraminc (20 mg kg 1 i.p.) 
in comparison with vehicle-treated mice (P <0.05, Figure 3c). 
Lower dose~ of mepyramine ( I I 0 mg kg 1) did not signili· 
cantly reduce HTMT-induced scratching. 
HTMT-induced scratching (0.2/tmol i.d.) wa also signifi-
cant!) reduced by pretreatment '' ith the nonsedating histamine 
H 1 receptor antagonist. terfcnadine (~0 mg kg 
1 i.p.) a:, 
compared with vel1icle-treated mice (P<0.05. Figure 3d). 
Lower doses of terfenadine ( 1- I 0 mg kg 1) did not significantly 
reduce HTMT-induced scratching (P>O.OSJ but there was 
variability wi th responses. and the trend indicated that the 
an tiscra tch effect o f terfenadinc was dose related. 
Role of histamine H1 receptors in hiswmine 
agonist-induced scratching 
Dimaprit. a histamine H 2 receptor agonist. did not induce 
dose-dependent scratching in mice (0.04-40 pmol. n = 3, 
Figure 2d). The H2 antagonist cimetidine (20 mg kg 
1 i.p.) 
did not significantly reduce hi tamine-induced scratching 
( P> 0.05. 11 = 6: data not shown). 
Role of histamine H3 receptors in histamine 
agonist-induced scratching 
lmetit, a histamine H 3 and H. receptor agonist. induced dose-
dependent scratching in all six mice studied (Figure 2c). The 
maximal scratching was 69±23 bouts. with a mean apparent 
ED 50 for imetit or 0.9 Jtmol. 
Scratching induced by histamine (3 pmol i.d.) was signifi-
can tly reduced after treatment with the H1/ H. antagonist 
thioperamide (20 mg kg- 1 i.p.: P < O.OS, n = 6, Figure 4a). 
Saline vehicle (i.p.) did not signi fi cant ly reduce histamine-
induced scratcl1ing (P> 0.05, 11 = 6. Figure 4b). 
lmetit-induced scratching (3 pmol i.d.) was significantly 
reduced in mice pretreated with thioperamide (20 mg kg 1 
i.p.) in comparison with vehicle-treated animals (P<0.05. 
Figure 4c). Lower doses of thioperamidc ( 1- I 0 mg kg 1) reduce 
the mean level or imetit-induced scratching. but due to 
variability in responses. the diiTerence between means (l'ersus 
saline) was not statistically significant (?>0.05) (Figure 5). 
Role of Mstamine H4 receptors in histamine agonisl· 
induced scratching 
Clobenpropit, an H., agonist and H3 antagonist. induced dose-
dependent scratching in all 10 mice studied (Figure 2b). The 
maximal level of scratching was 144 ± 20 bout , with a mean 
apparent EDso for clobenpropit or 0.05/tmol. 
Clobenpropit-induced scratching (0.06/tmol. i.d.) was sig-
nificantly lower in mice pretreated with the highest doses or 
thiopentmide used ( 10 and 20mgkg 1, i.p.) when compared to 
veh icle-trea ted mice (P<0.05. Figu re 6). 
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Figure 2 Pooled data illustrat ing scratching induced by (a) HTMT 
(H 1 receptor agonist, 11 = 6), (b) clobenpropit (H., agonist. H, 
antagonist. 11 = 10), (c) imetit (H, H, agonist, 11 = 6) and (d) dimaprit 
(H~ agonist. 11 = 3) during the 20 min postinjection. HTMT. 
clobcnpropit. and to a lesser extent imetit. caused dose-related 
)Cratching. whereas dimaprit had no .:!Teet (dashed line illustrates 
PBS-induced scratching). 
1-11 versus HJ{ H.s recep1or im•olremelll i11 itch 
The H 1 agonist. HTMT (0.2Jm1ol. i.d.). induced scratching 
that was not s ignificantly reduced by the H3/ H4 receptor 
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Figure 3 (a) Mepyramine (20 mg kg 1 i.p.) signilicant ly reduced scratching induced by histamine (8Jnnol, i.d.) in female Ba lbC mice. 30 min 
after treatment with the antagonist versus pretreatment value (* P<0.05. Wilcoxon matched pairs test. 11 = 6). (b) Saline vehicle did not 
signilicantly reduce scra tching induced by histamine (P> 0.05, Wilcoxon matched pairs test. 11 = 5). (c) Mcpyramine (20 mgkg- ' i.p.) 
pretreated mice showed a signilicant ly lower scratching response to HTMT (0.2J.tmOI i.d.) in comparison wi th vehic le-treated an imals 
(*P<0.05. Mann- Whitney test, n = 6 in each g roup). Mepyramine at lower doses (1. 3 or IOmgkg ')did not significant ly reduce HTMT-
induced scratching (?>0.05. Mann Whi tney test.11 = 6 in each group). (d) Tcrfenadinc significant ly reduced scratching induced by HTMT 
(0.2tunol i.d.) in a dose-dependent manner (tcrfenadine 20 mg kg- • versus contro l, * P < 0.05. Mann- Whitney test. 11 = 6 in each group) 
(V = vehicle for antagonist. Dashed line il lustrates PBS-induced scratching). 
antagon ist, thioperamide (20 mg kg- •. Figure 6a. P > 0.05 
versus vehicle), whereas it was by the H 1 receptor antagonists. 
terfenadine and mepyraminc (as described above). 
The H., agonist, clobenpropil (0.06Jtmol i.d.). induced 
scratc hing Lhat was not significantly red uced by e ithe r 
mepyramine (sedat ing). or terfenadine (nonsedating) H 1 
receptor antagonists (20 mg kg 1• Figure 6b, P > 0.05 "ersus 
vehicle), whereas it was by the H~/H4 receptor antagonist 
thioperamide (see above). 
Discussion 
Results from this study indicate the involvement of histamine 
H 4 receptors in the scratching (i tch) evoked by histamine. in 
mice. The lack of effectiveness of classical H 1 receptor 
antihistamines in a lleviating many chronic prurit ic conditions 
(Greaves, 1997) led to the focus of research for antipruritic 
drugs being shifted from histamine to ot her putative media-
tors. The present study suggests that histamine can generate 
itching in mice via H4 and possibly H 3 receptors. 
We confirmed that acu tely adm inistered his tamine induces 
dose-dependent scratching when injected intradermally in 
BalbC mice (lnagaki eta! .. 2001). as it does in humans (Keele 
& Armstrong. 1964). I 1 has previously been shown in mice tha t 
the dose of h istamine required to induce scratching behaviour 
in this species is substan tia lly higher (approximate ly I 00 times) 
than that which evokes itch in humans (Kura ishi et at .• 1995; 
Maekawa et a/ .. 2000; lnagaki et a/., 2001). This probably 
reflects species differences in the properties of histamine 
receptors, as has been shown to be the case for mice and 
man (Liu eta/., 2001), but caution is needed when interpreting 
results from functiona l studies undertaken in mouse o r man. 
The 1-1 1 antagonist, mepyramine, reduced histamine-induced 
scratching, as previously established in mice (Sugimoto et a!. , 
1998) and humans (Hagermark et a!., 1979). Some authors 
have suggested this may. at least in part. be due to the sedating 
properties of H 1 a ntagonists rather than a direct peripheral 
action a t pruritoceptors (Krause & Shuster, 1983). We have 
shown that i.d. injection of the histamine H 1 receptor agonist 
HTMT induces acute scra tching in mice, strongly suggesting 
the involvement of peripheral H 1 receptors in itch. This act ion 
of HTMT was mediated ria H 1 receptors because mepyramine 
reduced agonist induced scratching. We also showed tha t a 
nonseda ting H 1 receptor antagonist , terfenadine, signi ficantl y 
reduced 1-ITMT-induced scratching, thus suggesting that 
sedation is not responsible fo r the red uction in scratching 
observed following H 1 receptor antagonists. 
Fu rther studies investigating the mechanism of histam ine-
induced scratching in other strains of mouse and in other 
species. including humans. wou ld be desirable. In preliminary 
Sllldies using IC R mice, we found tha t they were mo re sensi tive 
by a factor of approxima tely 30 to histamine, in comparison 
with BalbC mice. Variabi lity in individual responses meant 
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Figure 4 (a) Thioperamide (20 mg kg- • i.p.) s ignificant ly reduced 
scratching induced by histamine (3 ttmol, * P <0.05. Wilcoxon 
matched pairs test. 11 = 6). (b) Saline vehicle d id not significantly 
reduce scratching induced by histamine (P> 0.05. Wilcoxon 
matched pairs test. 11 = 6). (c) Thioperamide (20 mg kg- • i.p.) 
pretreated mice showed a s ignificantly lower scratching response 
to imeti t (3 ttmol, i.d.) in comparison wi th vehicle treated a nima ls 
(* P<0.05. Mann- Whitney test. 11 = 5 in each group). Thioperamide 
at lower doses ( 1, 3 or IOmgkg- 1) did no t significantly reduce 
imet it-induced scratching (P>0.05 , Mann- Whitney tes t. 11 = 4 in 
each group) (V = vehicle for antagonist. Dashed line illus trates PBS· 
induced scratching). 
that we were unable to obtain clear evidence from the ICR 
strain concerning the effects of agonists a nd a ntagonists 
selective for di fferent histam ine receptor subtypes. 
We found no evidence for involvement of H2 receptors in the 
scratching evoked by histamine in the mice studied. The H2 
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Figure 5 Thioperamide (20 and 10 mg kg- 1 i.p.) pretreated mice 
showed a significantly lower scratching response to clobenpropit 
(0.06Jtmol, i.d.) in comparicon with vebide-tre:\te.;l ·~nim" l ~ 
(* P <0.05, Mann- Whitney test. 11 = 6 in each group). Thioperamide 
a t lower doses (I. or 3 mg kg 1) did not significantly reduce 
imetitinduced scra tching (P> 0.05, Mann- W hitney test. 11 = 6 in 
each group) (V = vehicle fo r antagonist. Dashed line illustrates PBS 
induced scratching). 
receptor agonist , dimaprit, did not evoke scratchjng, and the 
H2 receptor antagonist, cimetidine, had no significant effect on 
histamine-induced scratching. Th is is consistent wi th evidence 
in the literat ure: a lthough a combination of H 1 and H2 
histamine antagonists is sometimes used clinically for treating 
itch (Drake era/. , 1994; Ringer a/., 1999). H2 receptors a re not 
thought to be crucial in histamine-evoked itch (Hagermark 
e1 a/ .. 1979; Davies & Greaves, 1980). 
The discovery of histamine H3 (Haaksma e1 a!., 1990) and, 
more recently, H4 (Oda eta/. , 2000) receptors, has implications 
for histamine as a mediator of itch (Repka-Ramirez, 2003). T he 
tissue distribution of both receptor subtypes ind icates a 
potential role for them in the periphery: the H3 receptor afTects 
histamine-mediated axonal transport in mouse dorsal root 
ganglia (Amano er a/., 200 l ), whereas the H4 receptor is 
associa ted with immune responses, is preferentially expressed 
on leukocytes (Oda et a/., 2000), a nd plays a role in mast cell 
chemotaxis (Hofstra e1 a/., 2003). We found that the dual H3 
and H4 receptor antagonist thioperamide significantly reduced 
histamine-induced scratching in mice. The nonselective HJ and 
H4 receptor agonist , imetit, evoked scratching that was red uced 
by thioperamide. In order to differentiate between histamine H3 
and H,. mechanisms, we used clobenpropit, which is an H3 
antagonist but an H4 agonist (Oda er a/., 2000). Clobenpropjt 
induced dose-dependent scratching in mice. which was 
antagonised by thioperarnide, a finding that implicates a 
peripheral H4 receptor in scratching induced by i.d. histamine. 
We conclude that distinct H 1 and H4 receptor mechanisms a re 
responsible for itching evoked by exogenous histamine, and this 
is supported by data showing that scra tchi.ng i.nduced by H, 
agonist was not significan !ly reduced by the H3JH., antagonist. 
Also, scratching evoked by a n H4 agonist was not significantly 
reduced by sedating o r nonseda6ng H 1 receptor a ntagonists. 
Although our data strongly suggests a role for H 1 and H. 
receptors in histamine-mediated scratching, we were unable to 
determine whether .H3 receptors play a role. This is because 
imetit, thioperam.ide and clobenpropit act at multiple hista-
mine receptor subtypes. The H3/H. receptor agonist imetit 
induced less scratching than the H 1 and H 4 agonists. wbjch 
could be because imetit has a low affinity for the murine H. 
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Figure 6 (a) Thioperamide (20 mg kg - • i.p.) did not significantly reduce HTMT-induced scratching (0.2Jimol i.d.) in comparison lO vehicle 
treated m ice (? >0.05, M a nn- Whitney test. n = 6 in each group). whereas the H 1 antagonis t, terfenadine (20 mg kg- • i.p.) did reduce HTMT-
induced scratching (* P<0.05. Mann- Whitney tes t. 11 = 6 in each group). (b) Mcpyramine and terfenadine. sedat ing and no nsedating H 1 
receptor antagonists. respectively (20 mg kg- • i.p.) d id not significantly reduce c lobenpropi t-induced scratching (0.06 tnnol i.d.) in comparison 
to vehicle-treated mice (P> 0 .05. Mann- W h itney tes t. n = 6 in each group), whereas the H.v• antagonist, thiopcramide (20 mg kg- • i.p.) did 
reduce clobenpropi t-induced scrmching (* P <0.05. Mann- Whitney test. 11 = 6 in each group). D ashed line illustrates PBS-induced scra tc hing. 
receptor. o r it may be due to a combined H~ and H. action. It 
has recen tly been repon ed that mepyramine binds to the H4 
receptor: which may expla in why H 1 antihistamines can relieve 
itch in some clinical cond it ions. even if H 1 receptors a re not 
involved ( guyen et a/. , 2001). Further studies us ing drugs 
with g rea ter selectivity for histamine receptor subtypes. 
particularly selective H4 agonists a nd antagonists a re required 
to dist ing uish between an H3 and/o r a n H. mecha nism. but 
based on the use of current ly ava ilable drugs. we conclude that 
H. as well as H 1 recepto rs con tribute to itch evoked by 
histamine in mice. 
We ca nnot be certa in that the responses to histamine 
receptor agonists that we observed result from direct actions 
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